

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

BioScience Trends

14, 72-73

DOI: [10.5582/bst.2020.01047](https://doi.org/10.5582/bst.2020.01047)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8+ T effector levels in Han Chinese pulmonary TB patients. <i>Microbes and Infection</i> , 2020, 22, 119-126.	1.0	10
2	Overview of coronavirus disease 2019: Treatment updates and advances. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 805-808.	0.6	10
3	Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem Cells (AD-MSCs), Drugs, and Vaccines in Inhibiting COVID-19 Disease. , 2020, 11, 1191.		46
4	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. <i>Frontiers in Medicine</i> , 2020, 7, 546.	1.2	5
5	Respiratory Microbial Co-infection With SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2020, 11, 2079.	1.5	41
6	Gut Microbiota Dysbiosisâ€“Immune Hyperresponseâ€“Inflammation Triad in Coronavirus Disease 2019 (COVID-19): Impact of Pharmacological and Nutraceutical Approaches. <i>Microorganisms</i> , 2020, 8, 1514.	1.6	52
7	Emergence and molecular mechanisms of SARS-CoV-2 and HIV to target host cells and potential therapeutics. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104583.	1.0	11
8	Drug Weaponry to Fight Against SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 204.	1.6	2
9	Effects of SARS-CoV-2 and its functional receptor ACE2 on the cardiovascular system. <i>Herz</i> , 2020, 45, 659-662.	0.4	4
11	Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19). <i>International Journal of Biological Sciences</i> , 2020, 16, 2906-2923.	2.6	33
12	2019-nCoV: a worldwide concern and facts. <i>VirusDisease</i> , 2020, 31, 424-431.	1.0	3
14	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 763-773.	0.8	19
15	First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2. <i>New Microbes and New Infections</i> , 2020, 38, 100759.	0.8	2
16	Strategies for Targeting SARS CoV-2: Small Molecule Inhibitorsâ€“The Current Status. <i>Frontiers in Immunology</i> , 2020, 11, 552925.	2.2	38
17	Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. <i>European Journal of Pharmacology</i> , 2020, 887, 173561.	1.7	14
18	Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. <i>Phytomedicine</i> , 2020, 79, 153333.	2.3	46
19	Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101873.	1.5	75
20	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trialsâ€“ Diabetes and Metabolic Syndrome: <i>Clinical Research and Reviews</i> , 2020, 14, 1673-1680.	1.8	40

#	ARTICLE	IF	CITATIONS
21	Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2094729.	1.2	10
22	Chloroquine against malaria, cancers and viral diseases. <i>Drug Discovery Today</i> , 2020, 25, 2012-2022.	3.2	61
23	<p>ACEIs and ARBs and Their Correlation with COVID-19: A Review</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3217-3224.	1.1	23
24	Curcumin (a constituent of turmeric): New treatment option against COVID-19. <i>Food Science and Nutrition</i> , 2020, 8, 5215-5227.	1.5	97
25	The use of copper to help prevent transmission of SARS-coronavirus and influenza viruses. A general review. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115176.	0.8	73
26	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. <i>Genes and Diseases</i> , 2021, 8, 385-400.	1.5	60
27	Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019. <i>Life Sciences</i> , 2020, 262, 118496.	2.0	8
28	Leukotrienes, a potential target for Covid-19. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020, 161, 102174.	1.0	12
29	Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. <i>Toxicology and Applied Pharmacology</i> , 2020, 406, 115237.	1.3	15
30	Early Research on COVID-19: A Bibliometric Analysis. <i>Innovation(China)</i> , 2020, 1, 100027.	5.2	34
31	Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in". <i>Frontiers in Immunology</i> , 2020, 11, 2132.	2.2	96
32	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. <i>European Journal of Pharmacology</i> , 2020, 887, 173568.	1.7	3
33	Therapeutic options for the management of severe COVID-19: A rheumatology perspective. <i>Reumatología Clínica (English Edition)</i> , 2020, 17, 431-436.	0.2	4
34	A review on coronavirus survivability on material's surfaces: present research scenarios, technologies and future directions. <i>Surface Engineering</i> , 2020, 36, 1226-1239.	1.1	14
35	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. <i>Nature Communications</i> , 2020, 11, 5214.	5.8	179
36	Molecular basis of COVID-19 pathogenesis. <i>Russian Chemical Reviews</i> , 2020, 89, 858-878.	2.5	16
37	A comprehensive review about SARS-CoV-2. <i>Future Virology</i> , 2020, 15, 625-648.	0.9	61
38	Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers. <i>Infectious Diseases: Research and Treatment</i> , 2020, 13, 117863372096293.	0.7	36

#	ARTICLE	IF	CITATIONS
39	Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic. PLoS ONE, 2020, 15, e0240123.	1.1	75
40	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	13.9	1,013
41	Fractures in Patients With COVID-19 Infection: Early Prognosis and Management. A Case Series of 20 Patients in a Single Institution in Lombardy, Northern Italy. Journal of Orthopaedic Trauma, 2020, 34, e389-e397.	0.7	10
42	Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors. Mediators of Inflammation, 2020, 2020, 1-7.	1.4	49
43	Current treatment of COVID-19 in renal patients: hope or hype?. Internal and Emergency Medicine, 2020, 15, 1389-1398.	1.0	9
44	Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19). IJC Heart and Vasculature, 2020, 30, 100638.	0.6	15
45	CURRENT THERAPEUTIC OPTIONS FOR CORONAVIRUS DISEASE-2019 – A PHARMACOLOGICAL REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 2020, , 42-50.	0.3	2
46	Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. Plant Foods for Human Nutrition, 2020, 75, 458-466.	1.4	34
48	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. Clinical Infectious Diseases, 2021, 73, e4073-e4081.	2.9	219
49	Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. Pharmacotherapy, 2020, 40, 1072-1081.	1.2	10
50	Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 β -ketoamide derivative and Pentagastrin: An in-silico drug discovery approach. Journal of Molecular Graphics and Modelling, 2020, 101, 107730.	1.3	21
51	The impact of COVID-19 pandemic on cardiac surgery in Israel. Journal of Cardiothoracic Surgery, 2020, 15, 294.	0.4	18
52	A possible application of hinokitiol as a natural zinc ionophore and anti-infective agent for the prevention and treatment of COVID-19 and viral infections. Medical Hypotheses, 2020, 145, 110333.	0.8	25
53	Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 463-484.	0.4	8
54	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology, 2020, 225, 152008.	0.8	65
55	Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. Informatics in Medicine Unlocked, 2020, 21, 100446.	1.9	21
56	Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines. Trends in Immunology, 2020, 41, 1083-1099.	2.9	154
57	Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?. Heliyon, 2020, 6, e04900.	1.4	10

#	ARTICLE	IF	CITATIONS
58	Mesenchymal stem cell research progress for the treatment of COVID-19. Journal of International Medical Research, 2020, 48, 030006052095506.	0.4	5
59	SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management. Microorganisms, 2020, 8, 1468.	1.6	9
60	A multimodal deep learning-based drug repurposing approach for treatment of COVID-19. Molecular Diversity, 2021, 25, 1717-1730.	2.1	44
61	TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19. Arabian Journal of Chemistry, 2020, 13, 8069-8079.	2.3	14
62	Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomedicine and Pharmacotherapy, 2020, 131, 110668.	2.5	98
63	Viroinformatics approach to explore the inhibitory mechanism of existing drugs repurposed to fight against COVID-19. European Journal of Pharmacology, 2020, 885, 173496.	1.7	13
64	Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. International Journal of Infectious Diseases, 2020, 101, 107-120.	1.5	9
65	Can neuromodulation support the fight against the COVID19 pandemic? Transcutaneous non-invasive vagal nerve stimulation as a potential targeted treatment of fulminant acute respiratory distress syndrome. Medical Hypotheses, 2020, 143, 110093.	0.8	7
66	Drug-induced â€”Torsade de Pointesâ€” in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.3	4
67	An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. Journal of Infection and Public Health, 2020, 13, 1405-1414.	1.9	38
68	Agentes terapÃ©uticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relaciÃ³n con la mortalidad. Medicina ClÃ©nica, 2020, 155, 375-381.	0.3	5
69	De la querelle du quinquina Ã la querelle de lâ€™hydroxychloroquine, ou comment notre systÃ¨me de protection du mÃ©dicament est mis Ã lâ€™Ã©preuve: une analyse historique, scientifique et juridique. Medecine Et Droit, 2020, 2020, 96-101.	0.1	0
70	<i>In-silico</i> drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. Journal of Biomolecular Structure and Dynamics, 2021, 39, 5756-5767.	2.0	48
71	Inhibiting fusion with cellular membrane system: therapeutic options to prevent severe acute respiratory syndrome coronavirus-2 infection. American Journal of Physiology - Cell Physiology, 2020, 319, C500-C509.	2.1	9
72	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. Frontiers in Public Health, 2020, 8, 384.	1.3	13
73	Myocardial Injury in COVID-19â€”Can We Successfully Target Inflammation?â€”Reply. JAMA Cardiology, 2020, 5, 1070.	3.0	18
74	Micro and nanoscale technologies in oral drug delivery. Advanced Drug Delivery Reviews, 2020, 157, 37-62.	6.6	123
75	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cellular Signalling, 2020, 74, 109721.	1.7	105

#	ARTICLE	IF	CITATIONS
76	Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?. Pathology Research and Practice, 2020, 216, 153086.	1.0	33
77	A Randomized Clinical Trial of the Efficacy and Safety of Interferon β -1a in Treatment of Severe COVID-19. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	255
78	Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress, 2020, 4, 66-75.	1.4	271
79	SARS-COV-2 in Ophthalmology: Current Evidence and Standards for Clinical Practice. Acta Medica Portuguesa, 2020, 33, 593-600.	0.2	9
80	Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. Frontiers in Immunology, 2020, 11, 1439.	2.2	27
81	Immunoglobulin fragment F(ab ϵ TM) ₂ against RBD potently neutralizes SARS-CoV-2 in vitro. Antiviral Research, 2020, 182, 104868.	1.9	48
82	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?. International Journal of Antimicrobial Agents, 2020, 56, 106056.	1.1	29
83	Association between COVID-19 and cardiovascular disease. IJC Heart and Vasculature, 2020, 29, 100583.	0.6	24
84	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. Life Sciences, 2020, 257, 118058.	2.0	11
85	Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. Molecular Neurobiology, 2020, 57, 4106-4116.	1.9	38
86	Degradation of hydroxychloroquine by electrochemical advanced oxidation processes. Chemical Engineering Journal, 2020, 402, 126279.	6.6	70
87	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates, 2020, 53, 100719.	6.5	110
88	Guidance for the management of adult patients with coronavirus disease 2019. Chinese Medical Journal, 2020, 133, 1575-1594.	0.9	20
89	Advances in the possible treatment of COVID-19: A review.. European Journal of Pharmacology, 2020, 883, 173372.	1.7	50
90	Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. European Journal of Pharmacology, 2020, 883, 173375.	1.7	91
91	Matrix metalloproteinase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis. Life Sciences, 2020, 257, 118096.	2.0	45
92	Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL ^{pro}). Journal of Biomolecular Structure and Dynamics, 2021, 39, 5735-5755.	2.0	45
93	Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study. Journal of Biomolecular Structure and Dynamics, 2021, 39, 5792-5798.	2.0	24

#	ARTICLE	IF	CITATIONS
94	The epidemiology and therapeutic options for the COVID-19. Precision Clinical Medicine, 2020, 3, 71-84.	1.3	17
95	Convalescent Plasma Coupled With Medications for the Treatment of a Severe COVID-19 Patient: Drugs Analysis and Pharmaceutical Care Based on the Newly Established Guidelines for COVID-19 Remedy. Frontiers in Pharmacology, 2020, 11, 966.	1.6	7
96	Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. International Journal of Molecular Sciences, 2020, 21, 4972.	1.8	24
97	A new threat from an old enemy: Re-emergence of coronavirus (Review). International Journal of Molecular Medicine, 2020, 45, 1631-1643.	1.8	175
98	Clinical presentation and management of COVID-19. Medical Journal of Australia, 2020, 213, 134-139.	0.8	52
99	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. International Journal of Antimicrobial Agents, 2020, 56, 106101.	1.1	83
100	The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. Life Sciences, 2020, 257, 118097.	2.0	65
101	Safety perspectives on presently considered drugs for the treatment of COVID-19. British Journal of Pharmacology, 2020, 177, 4353-4374.	2.7	17
102	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. Clinical Pharmacology and Therapeutics, 2020, 108, 1135-1149.	2.3	25
103	Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 872-881.	1.1	10
104	Volatile molecules for COVID-19: A possible pharmacological strategy?. Drug Development Research, 2020, 81, 950-968.	1.4	14
105	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. Pathogens, 2020, 9, 546.	1.2	31
106	QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. Journal of Interventional Cardiac Electrophysiology, 2020, 59, 337-345.	0.6	24
107	The "president's drug". Netherlands Heart Journal, 2020, 28, 363-365.	0.3	1
108	Differential Diagnosis and Hospital Emergency Management for Fastlane Treatment of Central Nervous System Infection Under the COVID-19 Epidemic in Changsha, China. Frontiers in Neurology, 2020, 11, 555202.	1.1	4
109	A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020, 2020, 1-9.	0.7	49
110	Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin. Frontiers in Physiology, 2020, 11, 587709.	1.3	17
111	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. International Journal of Molecular Sciences, 2020, 21, 8141.	1.8	4

#	ARTICLE	IF	CITATIONS
112	Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 3071-3081.	2.0	20
113	Convalescent Plasma Therapy: An Effective Therapeutic Option to Treat COVID-19? A Narrative Review. <i>International Journal of Clinical Transfusion Medicine</i> , 2020, Volume 8, 7-21.	0.8	4
114	SARS-CoV-2 Proteins Induce IFNG in Th1 Lymphocytes Generated from CD4+ Cells from Healthy, Unexposed Polish Donors. <i>Vaccines</i> , 2020, 8, 673.	2.1	14
115	High-content screening of Thai medicinal plants reveals <i>Boesenbergia rotunda</i> extract and its component Panduratin A as anti-SARS-CoV-2 agents. <i>Scientific Reports</i> , 2020, 10, 19963.	1.6	97
116	Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. <i>Journal of Thoracic Disease</i> , 2020, 12, 6054-6069.	0.6	14
117	Physical Exercise as a Multimodal Tool for COVID-19: Could It Be Used as a Preventive Strategy?. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8496.	1.2	47
118	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. <i>Cell Reports Medicine</i> , 2020, 1, 100146.	3.3	24
119	Emerging diagnostic tools for detection of COVID-19 and perspective. <i>Biomedical Microdevices</i> , 2020, 22, 83.	1.4	40
120	Knowing more about chloroquine/hydroxychloroquine in COVID-19 patients. <i>Future Microbiology</i> , 2020, 15, 1523-1526.	1.0	3
121	Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. <i>Colombian Association of Rheumatology. ReumatologÃa ClÃnica (English Edition)</i> , 2020, 16, 437-446.	0.2	3
122	The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic. <i>Future Microbiology</i> , 2020, 15, 1571-1582.	1.0	11
123	Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 242-247.	0.5	3
124	Milestones in Personalized Medicine: From the Ancient Time to Nowadays—the Provocation of COVID-19. <i>Frontiers in Genetics</i> , 2020, 11, 569175.	1.1	17
125	Addressing the Challenges in dental practice during Covid-19: A review. <i>Orthodontic Journal of Nepal</i> , 2020, 9, 17-20.	0.0	1
126	Status of Novel Coronavirus Disease 2019 (COVID-19) and Animal Production. <i>Frontiers in Veterinary Science</i> , 2020, 7, 586919.	0.9	12
128	Chloroquine and hydroxychloroquine “ safety profile of potential COVID-19 drugs from the rheumatologist’s perspective. <i>Annals of Agricultural and Environmental Medicine</i> , 2021, 28, 122-126.	0.5	2
129	Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1). <i>Annals of Internal Medicine</i> , 2020, 173, 137-142.	2.0	26
130	Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. <i>Journal of Infection and Public Health</i> , 2020, 13, 1856-1861.	1.9	44

#	ARTICLE	IF	CITATIONS
131	SARS coronavirus 2: from genome to infectome. <i>Respiratory Research</i> , 2020, 21, 318.	1.4	62
132	MANAGEMENT OF DIABETES WITH COVID-19: A REVIEW. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 1-6.	0.3	7
133	Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 375-381.	0.1	1
134	FDA efficiency for approval process of COVID-19 therapeutics. <i>Infectious Agents and Cancer</i> , 2020, 15, 73.	1.2	8
135	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 606393.	1.6	21
136	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. <i>Frontiers in Medicine</i> , 2020, 7, 581521.	1.2	42
137	Pharmacy services during COVID-19 pandemic: experience from a tertiary care teaching hospital in Pakistan. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 74.	1.1	10
138	The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis. <i>European Journal of Pharmacology</i> , 2020, 888, 173487.	1.7	8
139	Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. <i>RMD Open</i> , 2020, 6, e001323.	1.8	2
140	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. <i>Methods in Pharmacology and Toxicology</i> , 2020, , 329-431.	0.1	4
141	Phytogenic Products and Phytochemicals as a Candidate Strategy to Improve Tolerance to Coronavirus. <i>Frontiers in Veterinary Science</i> , 2020, 7, 573159.	0.9	61
142	COVID-19: Therapeutics and interventions currently under consideration. <i>Disease-a-Month</i> , 2020, 66, 101058.	0.4	21
143	COVID-19 and immunological regulations “ from basic and translational aspects to clinical implications. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 795-807.	0.4	45
144	Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E689-E708.	1.8	51
145	30-Year-Old Woman With Cough, Dyspnea, and Anosmia. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1775-1779.	1.4	0
146	Ultrarapid diagnosis, microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1601-1603.	1.3	52
147	What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. <i>European Journal of Pharmacology</i> , 2020, 887, 173467.	1.7	16
148	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. <i>International Immunopharmacology</i> , 2020, 88, 106885.	1.7	30

#	ARTICLE	IF	CITATIONS
149	Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study. <i>Life Sciences</i> , 2020, 258, 118205.	2.0	69
150	COVID-19: Pharmacology and kinetics of viral clearance. <i>Pharmacological Research</i> , 2020, 161, 105114.	3.1	17
151	Resolution of coronavirus disease 2019 (COVID-19). <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1201-1211.	2.0	115
152	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 957-975.	1.3	6
153	Role for antimalarials in the management of COVID-19. <i>Current Opinion in Rheumatology</i> , 2020, 32, 449-457.	2.0	7
154	Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019. <i>Cardiology in Review</i> , 2020, 28, 266-271.	0.6	12
155	Rheumatology Drugs and COVID-19. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020, 20, 1-3.	0.4	0
156	Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of IK(M) or IK(DR) and in the Stimulation of IMEP. <i>Frontiers in Pharmacology</i> , 2020, 11, 1091.	1.6	22
157	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 188.	1.7	24
158	Screening of potential drug for Alzheimer's disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 7065-7079.	2.0	12
159	Drugs against SARS-CoV-2: What do we know about their mode of action?. <i>Reviews in Medical Virology</i> , 2020, 30, 1-10.	3.9	30
160	Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery. <i>Medicinal Chemistry Research</i> , 2020, 29, 1777-1791.	1.1	34
161	Potential strategies for combating COVID-19. <i>Archives of Virology</i> , 2020, 165, 2419-2438.	0.9	12
162	Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 715-723.	0.6	20
163	Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2020, 9, 56.	1.2	19
164	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro. <i>Frontiers in Microbiology</i> , 2020, 11, 1704.	1.5	18
165	GSK3 modulation in acute lung injury, myocarditis and polycystic kidney disease-related aneurysm. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118798.	1.9	6
166	OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath. <i>European Journal of Pharmacology</i> , 2020, 884, 173381.	1.7	17

#	ARTICLE	IF	CITATIONS
167	Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review. Biological Procedures Online, 2020, 22, 15.	1.4	22
168	<p>A Review on Currently Available Potential Therapeutic Options for COVID-19</p>. International Journal of General Medicine, 2020, Volume 13, 443-467.	0.8	15
169	Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?. Nutrition, 2020, 79-80, 110948.	1.1	65
170	Development and Implementation of a COVID-19 Disease Response Protocol at a Large Academic Medical Center. Disaster Medicine and Public Health Preparedness, 2020, 14, 792-795.	0.7	1
171	Human SARS-CoV-2 has evolved to reduce CG dinucleotide in its open reading frames. Scientific Reports, 2020, 10, 12331.	1.6	39
172	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. Clinical Infectious Diseases, 2021, 73, e4166-e4174.	2.9	135
173	Global Efforts towards Potential Therapeutic Options for COVID-19. , 2020, 12, .		0
174	COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis. International Journal of Molecular Sciences, 2020, 21, 5145.	1.8	18
175	Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. American Journal of Emergency Medicine, 2020, 38, 2209-2217.	0.7	50
176	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochemical Pharmacology, 2020, 180, 114169.	2.0	26
177	Potential repurposed SARS-CoV-2 (COVID-19) infection drugs. RSC Advances, 2020, 10, 26895-26916.	1.7	40
178	Kidney transplant recipients infected by COVID-19: Review of the initial published experience. Transplant Infectious Disease, 2020, 22, e13426.	0.7	12
179	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1971-1980.	2.9	51
180	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. Current Pharmacology Reports, 2020, 6, 228-240.	1.5	17
181	Management of multiple myeloma during COVID-19 pandemic. Leukemia Research Reports, 2020, 14, 100212.	0.2	2
182	COVID-19: A Multidisciplinary Review. Frontiers in Public Health, 2020, 8, 383.	1.3	208
183	Diagnostic Performance of Serological Assays in the Detection of SARS-CoV-2: A Review. Applied Sciences (Switzerland), 2020, 10, 4506.	1.3	3
184	The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2. International Journal of Pharmaceutics, 2020, 588, 119689.	2.6	46

#	ARTICLE	IF	CITATIONS
185	COVID-19 therapeutics: how to sow confusion and break public trust during international public health emergencies. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 47.	1.1	18
186	Estimation of COVID-19 spread curves integrating global data and borrowing information. <i>PLoS ONE</i> , 2020, 15, e0236860.	1.1	57
187	Public Trust and Compliance with the Precautionary Measures Against COVID-19 Employed by Authorities in Saudi Arabia. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 753-760.	1.2	72
188	Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19. <i>Nanomedicine</i> , 2020, 15, 2085-2102.	1.7	60
189	Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review. <i>Clinical Rheumatology</i> , 2020, 39, 2803-2810.	1.0	33
190	In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106119.	1.1	35
191	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3001-3013.	2.0	21
192	Recomendaciones sobre el manejo de pacientes adultos con enfermedades reumáticas en el contexto de la infección por SARS-CoV-2/COVID-19. <i>Asociación Colombiana de Reumatología Clínica</i> , 2020, 16, 437-446.	0.2	9
193	Acute lymphoblastic leukemia onset in a 3-year-old child with COVID-19. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28423.	0.8	14
194	Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. <i>Computational Biology and Chemistry</i> , 2020, 88, 107351.	1.1	57
195	Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1357-1362.	0.7	12
196	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. <i>Infectious Diseases and Therapy</i> , 2020, 9, 561-572.	1.8	23
197	Follow-up and Management of Kidney Transplant Recipients During the COVID-19 Lockdown: The Experience of an Italian Transplant Center, Including Two Cases of COVID-19 Pneumonia. <i>Transplantation Proceedings</i> , 2020, 52, 2614-2619.	0.3	7
198	Diagnostic and Treatment Strategies for COVID-19. <i>AAPS PharmSciTech</i> , 2020, 21, 222.	1.5	31
199	Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management. <i>Journal of Translational Internal Medicine</i> , 2020, 8, 9-19.	1.0	105
200	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1991.	2.2	124
201	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. <i>Arthritis and Rheumatology</i> , 2020, 72, e1-e12.	2.9	64
202	Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. <i>Bangladesh Journal of Medical Science</i> , 0, , .	0.1	13

#	ARTICLE	IF	CITATIONS
203	Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. <i>Life Sciences</i> , 2020, 258, 118202.	2.0	43
204	Chloroquine in fighting COVID-19: good, bad, or both?. <i>Autophagy</i> , 2020, 16, 2273-2275.	4.3	15
205	Coronaviruses disease 2019 (COVID-19): Causative agent, mental health concerns, and potential management options. <i>Journal of Infection and Public Health</i> , 2020, 13, 1840-1844.	1.9	34
206	Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. <i>Drug Discovery Today</i> , 2020, 25, 1822-1838.	3.2	13
207	COVID-19: Clinical aspects and therapeutics responses. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1004-1008.	1.2	39
208	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. <i>Life</i> , 2020, 10, 146.	1.1	6
209	Cardiovascular manifestation and treatment in COVID-19. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 704-709.	0.6	29
210	Cardiac arrhythmias in patients with COVID-19. <i>Journal of Arrhythmia</i> , 2020, 36, 827-836.	0.5	70
211	Application of Geospatial Technologies in the COVID-19 Fight of Ghana. , 2020, 5, 193-204.		52
212	Antimalarials as Antivirals for COVID-19: Believe it or Not!. <i>American Journal of the Medical Sciences</i> , 2020, 360, 618-630.	0.4	20
213	Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach. <i>Genomics</i> , 2020, 112, 4486-4504.	1.3	26
214	The Impact of Covid-19 on Rural Areas Students of Pakistan: Moderating Role of HEC Policy and Internet Service. <i>Asian Journal of Contemporary Education</i> , 2020, 4, 69-79.	0.5	9
215	<p><p>Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine</p></p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 531-542.	0.4	9
216	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. <i>Cellular Immunology</i> , 2020, 358, 104240.	1.4	6
217	SARS-CoV-2 epidemic calculation in Italy by SEIR compartmental models. <i>Applied Computing and Informatics</i> , 2020, ahead-of-print, .	3.7	8
218	Compare the epidemiological and clinical features of imported and local COVID-19 cases in Hainan, China. <i>Infectious Diseases of Poverty</i> , 2020, 9, 143.	1.5	12
219	<p><p>Cytokine Response in SARS-CoV-2 Infection in the Elderly</p></p>. <i>Journal of Inflammation Research</i> , 2020, Volume 13, 737-747.	1.6	39
220	<p><p>Current Options in the Treatment of COVID-19: A Review</p></p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 1999-2010.	1.2	8

#	ARTICLE	IF	CITATIONS
221	Race to arsenal COVID-19 therapeutics: Current alarming status and future directions. <i>Chemico-Biological Interactions</i> , 2020, 332, 109298.	1.7	7
222	PHARMACOLOGICAL TREATMENTS OF COVID-19 – A REVIEW. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 16-22.	0.3	4
223	Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 587866.	1.8	14
224	What is the novel coronavirus disease 2019 (COVID-19) that paralyze the world?. <i>Reviews in Medical Microbiology</i> , 2020, 31, 234-241.	0.4	2
225	Citation Network Analysis of the Novel Coronavirus Disease 2019 (COVID-19). <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7690.	1.2	22
226	The impact of COVID-19 pandemic on malaria elimination. <i>Parasite Epidemiology and Control</i> , 2020, 11, e00187.	0.6	43
227	A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. <i>Journal of Translational Medicine</i> , 2020, 18, 390.	1.8	64
228	COVID-19 Pneumonia in Patients with Chronic Myocarditis (Recurrent Infectious Immune): Specifics of the Diseases Course, the Role of Basic Therapy (Part 1). <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 550-556.	0.3	1
229	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 562264.	2.2	8
230	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. <i>Journal of Proteome Research</i> , 2020, 19, 4291-4315.	1.8	68
231	COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia. <i>Case Reports in Infectious Diseases</i> , 2020, 2020, 1-4.	0.2	3
232	<p>Glycopeptides as Potential Interventions for COVID-19</p>. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 107-114.	3.0	3
233	Early epidemiological indicators, outcomes, and interventions of COVID-19 pandemic: A systematic review. <i>Journal of Global Health</i> , 2020, 10, 020506.	1.2	40
234	Hydroxychloroquine for coronavirus: how not to repurpose a drug during a pandemic. <i>Internal Medicine Journal</i> , 2020, 50, 1307-1310.	0.5	2
235	Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rationale. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110694.	2.5	13
236	Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye. <i>Journal of Ophthalmology</i> , 2020, 2020, 1-9.	0.6	96
237	Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial. <i>Trials</i> , 2020, 21, 748.	0.7	5
238	Hydroxychloroquine and Chloroquine in COVID-19. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 224-228.	0.5	5

#	ARTICLE	IF	CITATIONS
240	COVID-19: an update on diagnostic and therapeutic approaches. <i>BMB Reports</i> , 2020, 53, 191-205.	1.1	72
241	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1777-1789.	0.3	51
242	SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 40.	1.7	93
243	Progress in the diagnosis and treatment of COVID-19 and the role of surgeons in the front line of the pandemic. <i>Surgery Today</i> , 2020, 50, 1544-1548.	0.7	1
244	Stability Indicating LC Method Development for Hydroxychloroquine Sulfate Impurities as Available for Treatment of COVID-19 and Evaluation of Risk Assessment Prior to Method Validation by Quality by Design Approach. <i>Chromatographia</i> , 2020, 83, 1269-1281.	0.7	21
245	Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. <i>Molecules</i> , 2020, 25, 3980.	1.7	80
246	Zinc(II)â€™The Overlooked Å%minence Grise of Chloroquineâ€™s Fight against COVID-19?. <i>Pharmaceuticals</i> , 2020, 13, 228.	1.7	21
247	Kinetic Monte Carlo model for the COVID-19 epidemic: Impact of mobility restriction on a COVID-19 outbreak. <i>Physical Review E</i> , 2020, 102, 032133.	0.8	15
248	The pandemic COVID-19: a tale of viremia, cellular oxidation and immune dysfunction. <i>Pan African Medical Journal</i> , 2020, 36, 188.	0.3	8
249	Intensive care for seriously ill patients affected by novel coronavirus sars - CoV â€™ 2: Experience of the Crema Hospital, Italy. <i>American Journal of Emergency Medicine</i> , 2021, 45, 156-161.	0.7	14
250	Xuebijing injection in the treatment of COVID-19: a retrospective case-control study. <i>Annals of Palliative Medicine</i> , 2020, 9, 3235-3248.	0.5	36
251	Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines. <i>Frontiers in Immunology</i> , 2020, 11, 2159.	2.2	10
252	Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6845.	1.2	4
254	Therapeutic Effectiveness of Interferon-Î±2b Against COVID-19: The Cuban Experience. <i>Journal of Interferon and Cytokine Research</i> , 2020, 40, 438-442.	0.5	36
255	Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. <i>Italian Journal of Pediatrics</i> , 2020, 46, 139.	1.0	47
256	Denovo designing, retrosynthetic analysis, and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2. <i>Biology Open</i> , 2020, 9, .	0.6	9
257	Lessons from past epidemics and pandemics and a way forward for pregnant women, midwives and nurses during COVID-19 and beyond: A meta-synthesis. <i>Midwifery</i> , 2020, 90, 102821.	1.0	45
258	Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1377-1386.	2.8	25

#	ARTICLE	IF	CITATIONS
259	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. <i>Europace</i> , 2020, 22, 1855-1863.	0.7	28
260	Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 239-243.	0.9	16
261	A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. <i>SLAS Discovery</i> , 2020, 25, 1108-1122.	1.4	25
262	Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1761-1766.	0.3	21
263	Traditional Chinese Medicine as Potential Therapy for COVID-19. <i>The American Journal of Chinese Medicine</i> , 2020, 48, 1263-1277.	1.5	11
264	Rheumatological aspects of pathogenesis and treatment of COVID-19 infection. <i>Reumatologia</i> , 2020, 58, 231-235.	0.5	1
265	Investigation on the impacts of COVID-19 quarantine on society and environment: Preventive measures and supportive technologies. <i>3 Biotech</i> , 2020, 10, 393.	1.1	28
266	Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 599-609.	0.4	5
267	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 143.	1.1	35
268	The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. <i>Processes</i> , 2020, 8, 937.	1.3	23
269	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13205-13227.	2.9	40
270	Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1346-1353.	0.4	18
271	Therapeutic Options for the Treatment of Coronavirus Disease (COVID-19). <i>Critical Care Nursing Quarterly</i> , 2020, 43, 349-368.	0.4	3
273	A Review of the Dermatological Manifestations of Coronavirus Disease 2019 (COVID-19). <i>Dermatology Research and Practice</i> , 2020, 2020, 1-9.	0.3	28
274	<p>COVID-19 (Coronavirus Disease 2019): A New Coronavirus Disease</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2819-2828.	1.1	43
275	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. <i>Frontiers in Microbiology</i> , 2020, 11, 1818.	1.5	81
276	Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic Targets. <i>Frontiers in Microbiology</i> , 2020, 11, 1821.	1.5	59
277	Is Nanotechnology Helping in the Fight Against COVID-19?. <i>Frontiers in Nanotechnology</i> , 2020, 2, .	2.4	27

#	ARTICLE	IF	CITATIONS
278	Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB) Tj ETQq0 009gBT /Ozrlock 10	0.9	27
279	COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management. <i>Frontiers in Pharmacology</i> , 2020, 11, 563478.	1.6	45
280	Artificial intelligence, drug repurposing and peer review. <i>Nature Biotechnology</i> , 2020, 38, 1127-1131.	9.4	56
281	Systems Pharmacology and Verification of ShenFuHuang Formula in Zebrafish Model Reveal Multi-Scale Treatment Strategy for Septic Syndrome in COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 584057.	1.6	12
282	Smoking and COVID-19: Adding Fuel to the Flame. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6581.	1.8	76
283	Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of patients with COVID-19 combined with diabetes mellitus. <i>Medicine (United States)</i> , 2020, 99, e22031.	0.4	2
284	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. <i>Frontiers in Pharmacology</i> , 2020, 11, 582025.	1.6	14
285	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. <i>Shock</i> , 2020, 54, 416-437.	1.0	41
286	Quantitative Fundus Autofluorescence in Systemic Chloroquine/Hydroxychloroquine Therapy. <i>Translational Vision Science and Technology</i> , 2020, 9, 42.	1.1	13
287	Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltration with nafamostat mesylate. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 1319-1323.	0.8	10
289	Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. <i>Genes and Environment</i> , 2020, 42, 25.	0.9	11
290	Methods of Synthesis of Remdesivir, Favipiravir, Hydroxychloroquine, and Chloroquine: Four Small Molecules Repurposed for Clinical Trials during the Covid-19 Pandemic. <i>Synthesis</i> , 2020, 52, 3735-3750.	1.2	16
291	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008686.	2.1	16
292	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. <i>Frontiers in Pharmacology</i> , 2020, 11, 1205.	1.6	143
293	Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 812-816.	0.6	14
294	COVID-19 Pandemic: A Case for Phytomedicines. <i>Natural Product Communications</i> , 2020, 15, 1934578X2094508.	0.2	22
295	Coronavirus disease 2019 and cardiovascular implications. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 725-732.	0.6	21
296	COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact. <i>Current Pharmacology Reports</i> , 2020, 6, 212-227.	1.5	31

#	ARTICLE	IF	CITATIONS
297	COVID-19 Therapeutic Options Under Investigation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1196.	1.6	65
298	COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. <i>Inflammopharmacology</i> , 2020, 28, 1153-1161.	1.9	144
299	Antiviral Activity of Ivermectin Against SARS-CoV-2: An Old-Fashioned Dog with a New Trick? A Literature Review. <i>Scientia Pharmaceutica</i> , 2020, 88, 36.	0.7	20
300	Treatment Options for COVID-19: A Review. <i>Frontiers in Medicine</i> , 2020, 7, 480.	1.2	75
301	Pharmacological treatments of COVID-19. <i>Pharmacological Reports</i> , 2020, 72, 1446-1478.	1.5	35
302	Antitussive nospapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 101-116.	2.0	40
303	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612094751.	1.1	11
304	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. <i>Microorganisms</i> , 2020, 8, 1250.	1.6	90
305	Antiviral Potential of Nanoparticles? Can Nanoparticles Fight Against Coronaviruses?. <i>Nanomaterials</i> , 2020, 10, 1645.	1.9	162
306	Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. <i>BMC Infectious Diseases</i> , 2020, 20, 954.	1.3	125
307	COVID-19 pandemic: How close are we for an effective therapy?. <i>Journal of Biomedical Sciences</i> , 2020, 7, 1-3.	0.5	5
308	Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments. <i>Frontiers in Pharmacology</i> , 2020, 11, 595888.	1.6	44
309	Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review. <i>Hematology Reports</i> , 2020, 12, 8630.	0.3	4
310	Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. <i>Frontiers in Physiology</i> , 2020, 11, 611275.	1.3	17
311	Taming the Autophagy as a Strategy for Treating COVID-19. <i>Cells</i> , 2020, 9, 2679.	1.8	52
312	Network Pharmacology Integrated Molecular Docking Reveals the Anti-COVID-19 Mechanism of Xingnaojing Injection. <i>Natural Product Communications</i> , 2020, 15, 1934578X2097802.	0.2	1
313	Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives. <i>Frontiers in Pharmacology</i> , 2020, 11, 606097.	1.6	17
314	Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 603037.	1.6	29

#	ARTICLE	IF	CITATIONS
315	Hydroxychloroquine as Prophylaxis for COVID-19: A Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 605185.	1.6	10
316	A review of Corona Virus Disease 2019 (COVID-19). <i>IOP Conference Series: Earth and Environmental Science</i> , 2020, 615, 012015.	0.2	0
317	Liver transplant immunosuppression during the COVID-19 pandemic. <i>Gastroenterology & Hepatology (English Edition)</i> , 2020, 43, 457-463.	0.0	3
318	HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. <i>Heliyon</i> , 2020, 6, e05672.	1.4	118
319	It is time to drop hydroxychloroquine from our COVID-19 armamentarium. <i>Medical Hypotheses</i> , 2020, 144, 110198.	0.8	7
320	Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. <i>Colombian Association of Rheumatology. Revista Colombiana De Reumatología (English Edition)</i> , 2020, 27, 230-241.	0.1	3
321	An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 877-888.	2.0	184
322	Fighting Strategies Against the Novel Coronavirus Pandemic: Impact on Global Economy. <i>Frontiers in Public Health</i> , 2020, 8, 606129.	1.3	18
323	Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. <i>Scientific Reports</i> , 2020, 10, 19199.	1.6	14
324	An Updated Understanding of the Current Emerging Respiratory Infection: COVID-19. <i>BioMed Research International</i> , 2020, 2020, 1-15.	0.9	2
325	Hypoxia: A key feature of COVID-19 launching activation of HIF-1 and cytokine storm. <i>Journal of Inflammation</i> , 2020, 17, 33.	1.5	105
326	COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8155.	1.2	63
327	A case-study to examine doctors' intentions to use IoT healthcare devices in Iraq during COVID-19 pandemic. <i>International Journal of Pervasive Computing and Communications</i> , 2022, 18, 527-547.	1.1	31
328	In-line treatments and clinical initiatives to fight against COVID-19 outbreak. <i>Respiratory Medicine</i> , 2022, 191, 106192.	1.3	15
329	Immunotherapeutics for Covid-19 and post vaccination surveillance. <i>3 Biotech</i> , 2020, 10, 527.	1.1	17
330	Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs. <i>Computers in Biology and Medicine</i> , 2020, 126, 104054.	3.9	30
331	Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV. <i>Medical Hypotheses</i> , 2020, 144, 110293.	0.8	4
332	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. <i>Academic Emergency Medicine</i> , 2020, 27, 493-504.	0.8	104

#	ARTICLE	IF	CITATIONS
333	Cardiovascular manifestations and treatment considerations in COVID-19. <i>Heart</i> , 2020, 106, 1132-1141.	1.2	296
334	Mental health treatment online during the COVID-19 outbreak. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 783-784.	1.8	18
335	Sports Health During the SARS-Cov-2 Pandemic. <i>Sports Medicine</i> , 2020, 50, 1413-1416.	3.1	28
336	Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. <i>Autoimmunity Reviews</i> , 2020, 19, 102567.	2.5	521
337	Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. <i>Autoimmunity Reviews</i> , 2020, 19, 102570.	2.5	30
338	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2020, 157, 104872.	3.1	81
339	Medical treatment options for COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 209-214.	0.4	39
340	New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 410.	1.8	96
341	Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China. <i>Journal of Medical Virology</i> , 2020, 92, 2055-2066.	2.5	68
342	Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 569-572.	0.2	8
343	The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. <i>FASEB Journal</i> , 2020, 34, 7253-7264.	0.2	83
344	The changing landscape of SARS-CoV-2: Implications for the maternal-infant dyad. <i>Journal of Neonatal-Perinatal Medicine</i> , 2020, 13, 293-305.	0.4	4
345	COVID-19 Pandemic: Prevention and Protection Measures to Be Adopted at the Workplace. <i>Sustainability</i> , 2020, 12, 3603.	1.6	183
346	Ethical and Sensible Dissemination of Information During the COVID-19 Pandemic. <i>American Journal of Bioethics</i> , 2020, 20, W4-W6.	0.5	4
347	Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial" by Gautret et al. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1758390.	0.8	9
348	COVID-19 as an Acute Inflammatory Disease. <i>Journal of Immunology</i> , 2020, 205, 12-19.	0.4	133
349	The Evolution of Computational Chemistry Along with Coronaviruses. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1339-1341.	1.0	0
350	Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?. <i>Frontiers in Public Health</i> , 2020, 8, 185.	1.3	8

#	ARTICLE	IF	CITATIONS
351	A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1137-1152.	1.4	37
352	COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. GeroScience, 2020, 42, 1021-1049.	2.1	115
353	COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?. American Journal of Ophthalmology, 2020, 216, A1-A2.	1.7	25
354	Covid-19 Pandemic and Current Medical Interventions. Archives of Medical Research, 2020, 51, 473-481.	1.5	11
355	Hydroxychloroquine hitting the headlinesâ€”retinal considerations. Eye, 2020, 34, 1158-1160.	1.1	7
356	Cardiac Arrhythmias in COVID-19 Infection. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008719.	2.1	104
357	Prevention and treatment of COVIDâ€“19 disease by controlled modulation of innate immunity. European Journal of Immunology, 2020, 50, 932-938.	1.6	59
358	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. Military Medical Research, 2020, 7, 22.	1.9	57
359	COVID-19 and Cancer: a Comprehensive Review. Current Oncology Reports, 2020, 22, 53.	1.8	220
360	Knowledgeâ€“based structural models of SARSâ€“CoVâ€“2 proteins and their complexes with potential drugs. FEBS Letters, 2020, 594, 1960-1973.	1.3	21
361	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Canadian Journal of Anaesthesia, 2020, 67, 1201-1211.	0.7	19
362	Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes and Infection, 2020, 22, 231-235.	1.0	44
363	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Medicine and Infectious Disease, 2020, 35, 101735.	1.5	94
364	Novel coronavirus 2019 (COVID-19). Medicine (United States), 2020, 99, e20207.	0.4	44
365	Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options. American Journal of Transplantation, 2020, 20, 2916-2922.	2.6	41
366	Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARSâ€“CoVâ€“2 (COVIDâ€“19) pandemic emergency: A quick review for a quick consultation. Dermatologic Therapy, 2020, 33, e13537.	0.8	4
367	Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?. Molecular Medicine, 2020, 26, 42.	1.9	176
368	SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment. Frontiers in Medicine, 2020, 7, 184.	1.2	27

#	ARTICLE	IF	CITATIONS
369	Coronavirus Pandemicâ€”Therapy and Vaccines. <i>Biomedicines</i> , 2020, 8, 109.	1.4	42
370	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020, 19, 102574.	2.5	32
371	Severe COVID-19 infection in pregnancy requiring intubation without preterm delivery: A case report. <i>Case Reports in Women's Health</i> , 2020, 27, e00217.	0.2	31
372	Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019. <i>Heart Rhythm</i> , 2020, 17, 1417-1422.	0.3	37
373	Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106012.	1.1	216
374	COVID-19: Wait for a novel drug or act with the age old drug â€” Do we have a choice?. <i>Journal of Infection and Public Health</i> , 2020, 13, 899-900.	1.9	3
375	A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. <i>Life Sciences</i> , 2020, 254, 117775.	2.0	35
376	Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants. <i>Clinical Infectious Diseases</i> , 2020, 71, 2265-2268.	2.9	9
377	Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	134
378	Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. <i>Annals of Pharmacotherapy</i> , 2020, 54, 827-831.	0.9	16
379	Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3330.	1.8	98
380	Anti-rheumatic in SARS-CoV-2: benefit or risk?. <i>Italian Journal of Medicine</i> , 0, , .	0.2	14
381	Involvement of the Nervous System in SARS-CoV-2 Infection. <i>Neurotoxicity Research</i> , 2020, 38, 1-7.	1.3	96
382	Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. <i>Cytokine and Growth Factor Reviews</i> , 2020, 53, 43-52.	3.2	77
383	The challenges of urgent radical sigmoid colorectal cancer resection in a COVID-19 patient: A case report. <i>International Journal of Surgery Case Reports</i> , 2020, 71, 147-150.	0.2	3
384	Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. <i>Medical Hypotheses</i> , 2020, 142, 109783.	0.8	41
385	Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?. <i>Medical Hypotheses</i> , 2020, 142, 109815.	0.8	131
387	â€œOff-labelâ€”use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. <i>Therapie</i> , 2020, 75, 371-379.	0.6	97

#	ARTICLE	IF	CITATIONS
388	Drug repurposing against COVID-19: focus on anticancer agents. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 86.	3.5	57
389	Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. <i>Clinical Rheumatology</i> , 2020, 39, 2085-2094.	1.0	599
390	Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. <i>Life Sciences</i> , 2020, 256, 117883.	2.0	114
391	Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2965-2967.	2.9	4
392	The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-COV-2 and other enveloped viruses hijacking the endocytic pathway. <i>Biochimie</i> , 2020, 179, 237-246.	1.3	25
393	Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An insight from MD-simulation studies. <i>Journal of Molecular Structure</i> , 2020, 1219, 128595.	1.8	64
394	Current Perspective of Antiviral Strategies against COVID-19. <i>ACS Infectious Diseases</i> , 2020, 6, 1624-1634.	1.8	51
395	Dr. Favalli, et al reply. <i>Journal of Rheumatology</i> , 2020, 47, 1592-1592.	1.0	4
396	Cancer and COVID-19: Unmasking their ties. <i>Cancer Treatment Reviews</i> , 2020, 88, 102041.	3.4	82
397	COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase. <i>Frontiers in Immunology</i> , 2020, 11, 1196.	2.2	10
398	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. <i>Viruses</i> , 2020, 12, 526.	1.5	197
399	COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. <i>Therapeutic Delivery</i> , 2020, 11, 245-268.	1.2	113
400	Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. <i>Diabetologia</i> , 2020, 63, 1440-1452.	2.9	121
401	Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. <i>BMJ</i> , The, 2020, 369, m1849.	3.0	811
402	Interferon- β Treatment for COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1061.	2.2	314
403	Emerging pharmacotherapies for COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2020, 128, 110267.	2.5	70
404	Surgical Management of Patients With COVID-19 Infection. Recommendations of the Spanish Association of Surgeons. <i>Cirug�a Espa�ola (English Edition)</i> , 2020, 98, 251-259.	0.1	27
405	�Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.� <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 589-596.	1.8	95

#	ARTICLE	IF	CITATIONS
406	Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106020.	1.1	87
407	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. <i>MSphere</i> , 2020, 5, .	1.3	66
408	Research Progress of Drug Treatment in Novel Coronavirus Pneumonia. <i>AAPS PharmSciTech</i> , 2020, 21, 130.	1.5	6
409	High-Value Plant Species Used for the Treatment of "Fever" by the Karen Hill Tribe People. <i>Antibiotics</i> , 2020, 9, 220.	1.5	11
410	Current evidence for directed and supportive investigational therapies against COVID-19. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2020, 26, 45.	0.3	1
411	Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 174-180.	2.1	39
412	Counting the cost of COVID-19. <i>International Journal of Information Technology (Singapore)</i> , 2020, 12, 311-317.	1.8	78
413	COVID-19: an unexpected indication for anti-rheumatic therapies?. <i>Rheumatology</i> , 2020, 59, 1200-1203.	0.9	10
414	COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. <i>Clinical Rheumatology</i> , 2020, 39, 2069-2075.	1.0	29
415	A review of potential treatments to date in COVID-19 patients according to the stage of the disease. <i>Current Research in Translational Medicine</i> , 2020, 68, 93-104.	1.2	18
417	Coronavirus Disease 2019 and the Pediatric Gastroenterologist. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 70, 720-726.	0.9	16
418	Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. <i>Dermatologic Therapy</i> , 2020, 33, e13686.	0.8	9
419	Liver injury in COVID-19: The current evidence. <i>United European Gastroenterology Journal</i> , 2020, 8, 509-519.	1.6	182
420	A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). <i>Pharmacological Research</i> , 2020, 158, 104929.	3.1	95
421	Molecular docking reveals the potential of <i>Salvadora persica</i> flavonoids to inhibit COVID-19 virus main protease. <i>RSC Advances</i> , 2020, 10, 19570-19575.	1.7	96
422	Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008688.	2.1	17
423	The impact of the COVID-19 infection in dentistry. <i>Experimental Biology and Medicine</i> , 2020, 245, 940-944.	1.1	41
424	Potential specific therapies in COVID-19. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662092685.	1.0	18

#	ARTICLE	IF	CITATIONS
425	Treatment algorithm for COVID-19: a multidisciplinary point of view. <i>Clinical Rheumatology</i> , 2020, 39, 2077-2084.	1.0	38
426	Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. <i>Medical Hypotheses</i> , 2020, 143, 109851.	0.8	53
427	The Impact of the COVID-19 Pandemic on Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 452-455.	0.6	272
428	Molecular Targets in the Chemotherapy of Coronavirus Infection. <i>Biochemistry (Moscow)</i> , 2020, 85, 523-530.	0.7	10
429	Repurposed Drugs Against COVID-19: Safety Concerns and Stockout. <i>Hospital Pharmacy</i> , 2020, 55, 218-219.	0.4	7
430	Fighting the Host Reaction to SARS-CoV-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs. <i>Frontiers in Immunology</i> , 2020, 11, 1201.	2.2	15
431	COVID-19: Emergence, Spread, Possible Treatments, and Global Burden. <i>Frontiers in Public Health</i> , 2020, 8, 216.	1.3	168
432	Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review. <i>Frontiers in Public Health</i> , 2020, 8, 252.	1.3	48
434	Conversion of Quinine Derivatives into Biologically Active Ionic Liquids: Advantages, Multifunctionality, and Perspectives. <i>ACS Sustainable Chemistry and Engineering</i> , 2020, 8, 9263-9267.	3.2	12
435	Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 796-803.	1.5	9
436	Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?. <i>Autophagy</i> , 2020, 16, 2267-2270.	4.3	18
437	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. <i>Autophagy</i> , 2020, 16, 2260-2266.	4.3	54
438	Ethical rationale for better coordination of clinical research on COVID-19. <i>Research Ethics</i> , 2020, 16, 1-10.	0.8	6
439	Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. <i>AAPS Journal</i> , 2020, 22, 86.	2.2	23
440	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12256-12274.	2.9	183
441	Possible therapeutic agents for COVID-19: a comprehensive review. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1005-1020.	2.0	24
442	Extensive hard palate hyperpigmentation associated with chloroquine use. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2325-2327.	1.1	15
443	COVID-19 Drug Treatment in China. <i>Current Pharmacology Reports</i> , 2020, 6, 146-154.	1.5	14

#	ARTICLE	IF	CITATIONS
444	Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 98, 166-175.	1.5	30
445	Tackling SARS-CoV-2: proposed targets and repurposed drugs. <i>Future Medicinal Chemistry</i> , 2020, 12, 1579-1601.	1.1	46
446	Current and future therapeutical approaches for COVID-19. <i>Drug Discovery Today</i> , 2020, 25, 1545-1552.	3.2	15
447	Cardiac effects and toxicity of chloroquine: a short update. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106057.	1.1	45
448	Three-dimensional printing in the fight against novel virus COVID-19: Technology helping society during an infectious disease pandemic. <i>Technology in Society</i> , 2020, 62, 101305.	4.8	76
449	The Effect of Anti-COVID-19 Policies on the Evolution of the Disease: A Complex Network Analysis of the Successful Case of Greece. <i>Physics</i> , 2020, 2, 325-339.	0.5	26
450	Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?. , 2020, 214, 107618.		213
451	Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1761677.	0.7	26
452	Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1144-1153.	1.5	24
453	Risk of using hydroxychloroquine as a treatment of COVID-19. <i>International Journal of Risk and Safety in Medicine</i> , 2020, 31, 111-116.	0.3	27
454	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. <i>Pathogens</i> , 2020, 9, 426.	1.2	47
455	Emergence of novel coronavirus and progress toward treatment and vaccine. <i>Reviews in Medical Virology</i> , 2020, 30, e2116.	3.9	8
456	Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?. <i>Clinical Rheumatology</i> , 2020, 39, 2461-2465.	1.0	35
457	COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 59, 329-336.	0.6	163
458	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 23-25.	0.1	3
459	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. <i>Postgraduate Medicine</i> , 2020, 132, 604-613.	0.9	24
460	Clinical update on COVID-19 in pregnancy: A review article. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1235-1245.	0.6	92
461	Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19. <i>SLAS Discovery</i> , 2020, 25, 1171-1173.	1.4	21

#	ARTICLE	IF	CITATIONS
462	A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2631-2636.	2.5	23
463	Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106044.	1.1	56
464	Potential therapeutic agents against COVID-19: What we know so far. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 534-536.	0.6	153
465	Treatment of COVID 19â€”Repurposing drugs commonly used in dermatology. <i>Dermatologic Therapy</i> , 2020, 33, e13829.	0.8	7
466	Inmunosupresi3n en el trasplante hep3tico en la era covid-19. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2020, 43, 457-463.	0.2	17
467	Literature-based review of the drugs used for the treatment of COVID-19. <i>Current Medicine Research and Practice</i> , 2020, 10, 100-109.	0.1	32
468	COVID-19 in the Cancer Patient. <i>Anesthesia and Analgesia</i> , 2020, 131, 16-23.	1.1	45
469	Antimicrobial Photodynamic Therapy in the Control of COVID-19. <i>Antibiotics</i> , 2020, 9, 320.	1.5	81
470	Vaccine development and therapeutic design for 2019â€”nCoV/SARSâ€”CoVâ€”2: Challenges and chances. <i>Journal of Cellular Physiology</i> , 2020, 235, 9098-9109.	2.0	53
471	Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital. <i>Clinical Infectious Diseases</i> , 2021, 73, e4064-e4072.	2.9	38
472	Knowledge and Information Sources About COVID-19 Among University Students in Jordan: A Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2020, 8, 254.	1.3	130
473	Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. <i>In Vivo</i> , 2020, 34, 1597-1602.	0.6	53
474	COVID-19: from epidemiology to treatment. <i>European Heart Journal</i> , 2020, 41, 2092-2112.	1.0	67
475	From Wuhan to COVID-19 Pandemic: An Up-to-Date Review of Its Pathogenesis, Potential Therapeutics, and Recent Advances. <i>Microorganisms</i> , 2020, 8, 850.	1.6	5
476	The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. <i>Clinical Rheumatology</i> , 2020, 39, 2043-2047.	1.0	27
477	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106054.	1.1	410
478	Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 976-984.	2.3	30
479	Why Your Patientsâ€™ Believing Hydroxychloroquine and Chloroquine Are 90% Effective for COVIDâ€™19 Is 100% Dangerous. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 949-953.	1.0	1

#	ARTICLE	IF	CITATIONS
480	Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165878.	1.8	770
481	Cytokine storm induced by SARS-CoV-2. <i>Clinica Chimica Acta</i> , 2020, 509, 280-287.	0.5	405
482	A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 125, 170-178.	2.4	24
483	Reaction Cycles of Halogen Species in the Immune Defense: Implications for Human Health and Diseases and the Pathology and Treatment of COVID-19. <i>Cells</i> , 2020, 9, 1461.	1.8	12
484	The first case of COVID-19 pneumonia in a hemodialysis patient in Japan. <i>CEN Case Reports</i> , 2020, 9, 404-408.	0.5	3
485	Relationship between ABO blood group distribution and clinical characteristics in patients with COVID-19. <i>Clinica Chimica Acta</i> , 2020, 509, 220-223.	0.5	218
486	Potentially repurposing adamantanes for COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 531-532.	2.5	32
487	Treatment of COVID-19: old tricks for new challenges. <i>Critical Care</i> , 2020, 24, 91.	2.5	232
488	National Institute for the Infectious Diseases & L. Spallanzani & IRCCS. Recommendations for COVID-19 Clinical Management. <i>Gastroenterology Insights</i> , 2020, 12, 8543.	0.7	139
489	COVID-19 infection and rheumatoid arthritis: Faraway, so close!. <i>Autoimmunity Reviews</i> , 2020, 19, 102523.	2.5	353
490	Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105945.	1.1	189
491	Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105948.	1.1	804
492	Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2352-2371.	1.2	1,557
493	A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. <i>Journal of Critical Care</i> , 2020, 57, 279-283.	1.0	842
494	New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105938.	1.1	842
495	Of chloroquine and COVID-19. <i>Antiviral Research</i> , 2020, 177, 104762.	1.9	468
496	The Novel Coronavirus 2019 epidemic and kidneys. <i>Kidney International</i> , 2020, 97, 824-828.	2.6	502
497	COVID-19 and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1648-1655.	1.6	1,398

#	ARTICLE	IF	CITATIONS
498	SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. <i>International Journal of Biological Sciences</i> , 2020, 16, 1678-1685.	2.6	751
499	The Emerging Pandemic of Coronavirus and the Urgent Need for Public Health Leadership. <i>American Journal of Medicine</i> , 2020, 133, 648-650.	0.6	23
500	Are my patients with rheumatic diseases at higher risk of COVID-19?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 839-840.	0.5	71
501	Novel Coronavirus: What Neuroradiologists as Citizens of the World Need to Know. <i>American Journal of Neuroradiology</i> , 2020, 41, 552-554.	1.2	25
502	Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. <i>International Journal of Biological Sciences</i> , 2020, 16, 1724-1731.	2.6	351
503	Insights from nanomedicine into chloroquine efficacy against COVID-19. <i>Nature Nanotechnology</i> , 2020, 15, 247-249.	15.6	250
504	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa105.	0.4	255
505	COVID-19: Knowns, Unknowns, and Questions. <i>MSphere</i> , 2020, 5, .	1.3	124
506	Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 521-531.	0.7	893
507	Potential Effects of Coronaviruses on the Cardiovascular System. <i>JAMA Cardiology</i> , 2020, 5, 831.	3.0	1,469
508	Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 241-246.	1.8	357
509	SARS-CoV-2: What do we know so far?. <i>Acta Physiologica</i> , 2020, 229, e13470.	1.8	23
510	Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). <i>JAMA Cardiology</i> , 2020, 5, 819.	3.0	1,465
511	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). <i>Intensive Care Medicine</i> , 2020, 46, 854-887.	3.9	1,536
512	COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?. <i>American Journal of Ophthalmology</i> , 2020, 213, A3-A4.	1.7	34
513	Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 740-746.	2.5	257
514	Covid-19: what treatments are being investigated?. <i>BMJ, The</i> , 2020, 368, m1252.	3.0	79
515	Emerging prophylaxis strategies against COVID-19. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	62

#	ARTICLE	IF	CITATIONS
516	Chloroquine in COVID-19: the evidence. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	17
517	Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. <i>Rheumatology International</i> , 2020, 40, 825-826.	1.5	33
518	Thoughts on COVID-19 and autoimmune diseases. <i>Lupus Science and Medicine</i> , 2020, 7, e000396.	1.1	31
519	The New Challenge of Geriatrics: Saving Frail Older People from the SARS-COV-2 Pandemic Infection,. <i>Journal of Nutrition, Health and Aging</i> , 2020, 24, 466-470.	1.5	94
520	To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 666-667.	0.5	44
521	Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19). <i>Aging Medicine (Milton (N S W))</i> , 2020, 3, 98-101.	0.9	13
522	COVID-19 virus and children: What do we know?. <i>Archives De Pediatrie</i> , 2020, 27, 117-118.	0.4	59
523	Manejo quir�rgico de pacientes con infecci3n por COVID-19. Recomendaciones de la Asociaci3n Espa�ola de Cirujanos. <i>Cirug�a Espa�ola</i> , 2020, 98, 251-259.	0.1	109
524	Insight into 2019 novel coronavirus " An updated interim review and lessons from SARS-CoV and MERS-CoV. <i>International Journal of Infectious Diseases</i> , 2020, 94, 119-124.	1.5	337
525	Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. <i>Journal of Autoimmunity</i> , 2020, 109, 102442.	3.0	104
526	<scp>COVID</scp>19 and Older Adults: What We Know. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 926-929.	1.3	729
527	Chloroquine and hydroxychloroquine in covid-19. <i>BMJ, The</i> , 2020, 369, m1432.	3.0	297
528	Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. <i>World Journal of Pediatrics</i> , 2020, 16, 271-274.	0.8	50
529	Angiotensin receptor blockers as tentative SARS-CoV2 therapeutics. <i>Drug Development Research</i> , 2020, 81, 537-540.	1.4	636
530	Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105932.	1.1	724
531	Current pharmacological treatments for SARS-COV-2: A narrative review. <i>European Journal of Pharmacology</i> , 2020, 882, 173328.	1.7	35
532	Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. <i>International Journal of Clinical Practice</i> , 2020, 74, e13600.	0.8	31
533	Coronavirus disease 2019: Knowledge, attitude, and practice of pregnant women in a tertiary hospital in Abakaliki, southeast Nigeria. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 197-202.	1.0	44

#	ARTICLE	IF	CITATIONS
534	Recomendaciones de la Sociedad Española de Cirugía Cardiovascular y Endovascular ante la pandemia de COVID-19. En representación de la Sociedad Española de Cirugía Cardiovascular y Endovascular (SECCE). <i>Cirugía Cardiovascular</i> , 2020, 27, 86-92.	0.1	2
535	The strategy for controlling COVID-19 in Kurdistan Regional Government (KRG)/Iraq: Identification, epidemiology, transmission, treatment, and recovery. <i>International Journal of Surgery Open</i> , 2020, 25, 41-46.	0.2	14
536	Novel Coronavirus (nCoV): a Bitter Old Enemy in a New Avatar. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1083-1088.	0.3	3
537	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 97, 396-403.	1.5	445
538	Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 285-299.	1.5	46
539	Natural history of COVID-19 and current knowledge on treatment therapeutic options. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110493.	2.5	118
540	Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. <i>European Urology Focus</i> , 2020, 6, 1028-1031.	1.6	5
541	Potential benefits of combination of <i>Nigella sativa</i> and Zn supplements to treat COVID-19. <i>Journal of Herbal Medicine</i> , 2020, 23, 100382.	1.0	46
542	Hydroxychloroquine and COVID-19 – A narrative review. <i>Indian Journal of Tuberculosis</i> , 2020, 67, S147-S154.	0.3	8
543	Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update. <i>Journal of Digestive Endoscopy</i> , 2020, 11, 69-72.	0.1	3
544	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches – Insights into Chemical Structure – Biological Activity and Toxicological Screening. <i>Journal of Clinical Medicine</i> , 2020, 9, 2084.	1.0	38
545	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. <i>European Journal of Pharmacology</i> , 2020, 883, 173348.	1.7	55
546	Pandemic COVID-19: Current status and challenges of antiviral therapies. <i>Genes and Diseases</i> , 2020, 7, 502-519.	1.5	11
547	Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. <i>Future Medicinal Chemistry</i> , 2020, 12, 1565-1578.	1.1	22
548	Is hydroxychloroquine beneficial for COVID-19 patients?. <i>Cell Death and Disease</i> , 2020, 11, 512.	2.7	82
549	Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine – from HIV-1 infection to COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1119-1133.	2.0	23
550	Progress in the Research and Development of Anti-COVID-19 Drugs. <i>Frontiers in Public Health</i> , 2020, 8, 365.	1.3	21
551	Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4782.	1.8	68

#	ARTICLE	IF	CITATIONS
552	Chloroquine: A Potential Drug in the COVID-19 Scenario. , 2020, 5, 399-410.		10
553	Drug-drug and drug-solvent interaction studies of Chloroquine phosphate, Acefylline piperazine and Gentamicin sulfate in polymeric systems. Arabian Journal of Chemistry, 2020, 13, 6221-6235.	2.3	5
554	Efficient degradation of chloroquine drug by electro-Fenton oxidation: Effects of operating conditions and degradation mechanism. Chemosphere, 2020, 260, 127558.	4.2	92
555	Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. Psychosomatics, 2020, 61, 597-606.	2.5	24
556	Living evidence in response to controversies about the use of antimalarials in COVID-19. Revista Espanola De Cardiologia (English Ed), 2020, 73, 693-694.	0.4	0
557	Coronavirus Disease 2019“COVID-19. Clinical Microbiology Reviews, 2020, 33, .	5.7	767
558	Network Pharmacology Integrated Molecular Docking Reveals the Anti-COVID-19 Mechanism of Qing-Fei-Da-Yuan Granules. Natural Product Communications, 2020, 15, 1934578X2093421.	0.2	10
559	A Review of the Current State of Management and Post-Recovery Rehabilitation of COVID-19. Critical Reviews in Physical and Rehabilitation Medicine, 2020, 32, 97-109.	0.1	0
560	Pharmacotherapeutics Advice in Guidelines for COVID-19. Frontiers in Pharmacology, 2020, 11, 950.	1.6	6
561	Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19. Ethics, Medicine and Public Health, 2020, 14, 100547.	0.5	4
562	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Medicine and Infectious Disease, 2020, 36, 101791.	1.5	209
563	Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. Virus Research, 2020, 286, 198073.	1.1	35
564	Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19. Frontiers in Pharmacology, 2020, 11, 854.	1.6	17
565	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. Journal of Clinical Medicine, 2020, 9, 1944.	1.0	36
566	Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach. Computers in Biology and Medicine, 2020, 122, 103848.	3.9	44
567	Spatial modeling, risk mapping, change detection, and outbreak trend analysis of coronavirus (COVID-19) in Iran (days between February 19 and June 14, 2020). International Journal of Infectious Diseases, 2020, 98, 90-108.	1.5	94
568	Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?. Evidence-Based Dentistry, 2020, 21, 64-65.	0.3	10
569	SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. Vaccines, 2020, 8, 335.	2.1	43

#	ARTICLE	IF	CITATIONS
570	Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19. <i>Journal of Evidence-based Integrative Medicine</i> , 2020, 25, 2515690X2093252.	1.4	0
571	Current therapies under investigation for COVID-19: potential COVID-19 treatments. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 483-489.	0.7	6
572	Effects of Nanoparticles on Viral Infection – A Review. <i>Nano</i> , 2020, 15, 2030003.	0.5	5
573	Minimum costs to manufacture new treatments for COVID-19. <i>Journal of Virus Eradication</i> , 2020, 6, 61-69.	0.3	63
574	Water matrices as potential source of SARS-CoV-2 transmission – An overview from environmental perspective. <i>Case Studies in Chemical and Environmental Engineering</i> , 2020, 2, 100023.	2.9	21
575	Tackling the cytokine storm in COVID-19, challenges and hopes. <i>Life Sciences</i> , 2020, 257, 118054.	2.0	64
576	Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges. <i>Drug Discovery Today</i> , 2020, 25, 1786-1792.	3.2	6
577	Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective. <i>International Journal of Biological Macromolecules</i> , 2020, 163, 1-8.	3.6	72
578	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	1.3	57
579	COVID-19: Progress in diagnostics, therapy and vaccination. <i>Theranostics</i> , 2020, 10, 7821-7835.	4.6	121
580	Outbreak of COVID-19: An emerging global pandemic threat. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110499.	2.5	48
581	Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. <i>Heart Rhythm</i> , 2020, 17, 1480-1486.	0.3	22
582	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106078.	1.1	37
583	Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms. <i>Medical Hypotheses</i> , 2020, 144, 110033.	0.8	38
584	On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. <i>Nanomaterials</i> , 2020, 10, 852.	1.9	102
585	Treatment of SARS-CoV-2: How far have we reached?. <i>Drug Discoveries and Therapeutics</i> , 2020, 14, 67-72.	0.6	38
586	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. <i>Arthritis and Rheumatology</i> , 2020, 72, 1241-1251.	2.9	142
587	Clinical and transmission dynamics characteristics of 406 children with coronavirus disease 2019 in China: A review. <i>Journal of Infection</i> , 2020, 81, e11-e15.	1.7	67

#	ARTICLE	IF	CITATIONS
588	Natural product-derived phytochemicals as potential agents against coronaviruses: A review. <i>Virus Research</i> , 2020, 284, 197989.	1.1	337
589	COVID-19 diagnosis and management: a comprehensive review. <i>Journal of Internal Medicine</i> , 2020, 288, 192-206.	2.7	924
590	Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. <i>Viruses</i> , 2020, 12, 486.	1.5	94
591	Treatment Considerations for COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1454-1466.	1.4	79
592	Rethinking the role of hydroxychloroquine in the treatment of COVID-19. <i>FASEB Journal</i> , 2020, 34, 6027-6037.	0.2	110
593	Is the type of diabetes treatment relevant to outcome of COVID-19?. <i>Journal of Diabetes</i> , 2020, 12, 486-487.	0.8	5
594	Increasing the Signal-to-Noise Ratio: COVID-19 Clinical Synopsis for Outpatient Providers. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272092295.	1.0	5
595	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. <i>Pathogens</i> , 2020, 9, 331.	1.2	198
596	COVID-19: Therapeutics and Their Toxicities. <i>Journal of Medical Toxicology</i> , 2020, 16, 284-294.	0.8	82
597	Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19. <i>Drug Discovery Today</i> , 2020, 25, 1121-1123.	3.2	30
598	Candidate drugs against SARS-CoV-2 and COVID-19. <i>Pharmacological Research</i> , 2020, 157, 104859.	3.1	426
599	Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 1021.	2.2	147
600	Repurposing therapeutic agents and herbal medicines to defeat viral nemesis. <i>Drug Development Research</i> , 2020, 81, 641-642.	1.4	3
601	COVID-19: A review of therapeutics under investigation. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 231-237.	0.4	29
602	COVID-19: The Uninvited Guest in the Intensive Care Unit – Implications for Pharmacotherapy. <i>Pharmacotherapy</i> , 2020, 40, 382-386.	1.2	8
603	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. <i>Pharmacotherapy</i> , 2020, 40, 416-437.	1.2	166
604	Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. <i>Reviews in Medical Virology</i> , 2020, 30, e2107.	3.9	179
606	Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. <i>Clinical Rheumatology</i> , 2020, 39, 2055-2062.	1.0	215

#	ARTICLE	IF	CITATIONS
607	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. <i>Lancet Respiratory Medicine</i> , 2020, 8, 506-517.	5.2	1,177
609	Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. <i>Canadian Journal of Cardiology</i> , 2020, 36, 948-951.	0.8	100
610	COVID-19 and diabetes: Knowledge in progress. <i>Diabetes Research and Clinical Practice</i> , 2020, 162, 108142.	1.1	519
611	Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 251-254.	1.8	102
612	An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. <i>Heart Rhythm Case Reports</i> , 2020, 6, 244-248.	0.2	61
613	The epidemiology, diagnosis and treatment of COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105955.	1.1	672
614	Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105960.	1.1	460
615	Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105964.	1.1	9
616	Drug repositioning is an alternative for the treatment of coronavirus COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105969.	1.1	100
617	Chloroquine as a prophylactic agent against COVID-19?. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105980.	1.1	30
618	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , 2020, 2, 100113.	2.6	378
619	The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. <i>Journal of Infection</i> , 2020, 80, 607-613.	1.7	2,231
620	Chloroquine and COVID-19, where do we stand?. <i>Médecine Et Maladies Infectieuses</i> , 2020, 50, 229-230.	5.1	14
621	Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain. <i>Travel Medicine and Infectious Disease</i> , 2020, 35, 101653.	1.5	80
622	Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. <i>Travel Medicine and Infectious Disease</i> , 2020, 34, 101663.	1.5	605
623	A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. <i>Travel Medicine and Infectious Disease</i> , 2020, 35, 101664.	1.5	63
625	Neurologic Manifestations of Severe Respiratory Viral Contagions. , 2020, 2, e0107.		51
626	Fact Versus Science Fiction: Fighting Coronavirus Disease 2019 Requires the Wisdom to Know the Difference. , 2020, 2, e0108.		18

#	ARTICLE	IF	CITATIONS
627	A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 613-619.	0.9	106
628	Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. <i>Clinical and Translational Science</i> , 2020, 13, 642-645.	1.5	37
629	Updated Approaches against SARS-CoV-2. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	198
630	Geographical Accessibility to Glucose-6-Phosphate Dioxygenase Deficiency Point-of-Care Testing for Antenatal Care in Ghana. <i>Diagnostics</i> , 2020, 10, 229.	1.3	17
631	Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 1131.	1.0	112
632	COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help. <i>Molecules</i> , 2020, 25, 1834.	1.7	37
633	COVID-19: A Brief Overview of the Discovery Clinical Trial. <i>Pharmaceuticals</i> , 2020, 13, 65.	1.7	30
634	Antiviral treatment of COVID-19. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 611-619.	0.4	214
635	COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 620-632.	0.4	351
636	Novel coronavirus disease (COVID-19) in children. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 592-603.	0.4	144
637	Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. <i>BioScience Trends</i> , 2020, 14, 139-143.	1.1	35
638	Cloroquina y sus derivados en el manejo de la COVID-19: una revisión sistemática exploratoria. <i>Biomedica</i> , 2020, 40, 80-95.	0.3	4
639	Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. <i>JAMA Network Open</i> , 2020, 3, e208857.	2.8	842
640	Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019. <i>JAMA Network Open</i> , 2020, 3, e209035.	2.8	49
641	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <i>The Cochrane Library</i> , 0, , .	1.5	18
642	Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 791-797.	2.3	80
644	Current pharmacological treatments for COVID-19: What's next?. <i>British Journal of Pharmacology</i> , 2020, 177, 4813-4824.	2.7	210
645	COVID-19 Drug Discovery Using Intensive Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2839.	1.8	55

#	ARTICLE	IF	CITATIONS
646	Is GSK3 β a molecular target of chloroquine treatment against COVID-19?. <i>Drug Discoveries and Therapeutics</i> , 2020, 14, 107-108.	0.6	10
647	Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India?. <i>Journal of Medical Virology</i> , 2020, 92, 1391-1393.	2.5	6
648	Strong policies control the spread of COVID-19 in China. <i>Journal of Medical Virology</i> , 2020, 92, 1980-1987.	2.5	14
649	Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1216-1227.	5.7	40
650	Uso de antipalúdicos en el tratamiento del COVID-19: ¿una ventana de oportunidad?. <i>Medicina Clínica</i> , 2020, 155, 23-25.	0.3	5
651	Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Chloroquine, and antiviral agents. <i>Medical Hypotheses</i> , 2020, 140, 109777.	0.8	69
652	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2020, 19, 16.	1.7	36
653	Origin, Potential Therapeutic Targets and Treatment for Coronavirus Disease (COVID-19). <i>Pathogens</i> , 2020, 9, 307.	1.2	62
654	Inpatient Care of Patients with COVID-19: A Guide for Hospitalists. <i>American Journal of Medicine</i> , 2020, 133, 1019-1024.	0.6	16
655	5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection. <i>Medical Hypotheses</i> , 2020, 142, 109754.	0.8	9
656	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1824-1836.	3.8	1,940
657	Novel Coronavirus 2019 (2019-nCoV) Infection: Part I - Preparedness and Management in the Pediatric Intensive Care Unit in Resource-limited Settings. <i>Indian Pediatrics</i> , 2020, 57, 324-334.	0.2	17
658	Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e147-e160.	2.0	37
659	COVID-19: Immunology and treatment options. <i>Clinical Immunology</i> , 2020, 215, 108448.	1.4	485
660	In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. <i>Microbial Pathogenesis</i> , 2020, 145, 104228.	1.3	246
661	Response to and Recovery from the COVID-19 Pandemic: What Will It Take?. <i>Psychiatry (New York)</i> , 2020, 83, 143-148.	0.3	2
662	Anesthesia and COVID-19: What We Should Know and What We Should Do. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2020, 24, 127-137.	0.4	37
663	SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis. <i>IDCases</i> , 2020, 20, e00778.	0.4	8

#	ARTICLE	IF	CITATIONS
664	Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India. <i>Science of the Total Environment</i> , 2020, 728, 138914.	3.9	179
665	Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 510-513.	0.6	1
666	COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. <i>Journal of Clinical Epidemiology</i> , 2020, 123, 120-126.	2.4	130
667	Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 192.	1.2	0
668	Sc(OTf) ₃ -Mediated One-Pot Synthesis of 2,3-Disubstituted Quinolines from Anilines and Epoxides. <i>Journal of Organic Chemistry</i> , 2020, 85, 6741-6746.	1.7	18
669	Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?. <i>Nanomaterials</i> , 2020, 10, 802.	1.9	194
670	Drug Development and Medicinal Chemistry Efforts toward SARS-CoV-2 Coronavirus and COVID-19 Therapeutics. <i>ChemMedChem</i> , 2020, 15, 907-932.	1.6	229
671	The prevention and management of the coronavirus disease 2019 (COVID-19) outbreak in radiology departments in epidemic areas. <i>Japanese Journal of Radiology</i> , 2020, 38, 483-488.	1.0	11
672	Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105982.	1.1	204
673	Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6558-6570.	1.6	86
674	COVID-19 in otolaryngologist practice: a review of current knowledge. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 1885-1897.	0.8	145
675	Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. <i>Clinical Pharmacokinetics</i> , 2020, 59, 659-669.	1.6	50
676	Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. <i>Lancet Respiratory Medicine</i> , 2020, 8, 539-541.	5.2	97
677	Areas of academic research with the impact of COVID-19. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1524-1526.	0.7	147
678	Pharmacotherapy in COVID-19; A narrative review for emergency providers. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1488-1493.	0.7	79
679	Current status of potential therapeutic candidates for the COVID-19 crisis. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 59-73.	2.0	239
680	Renin-angiotensin system at the heart of COVID-19 pandemic. <i>Biochimie</i> , 2020, 174, 30-33.	1.3	103
681	Management and Treatment of COVID-19: The Chinese Experience. <i>Canadian Journal of Cardiology</i> , 2020, 36, 915-930.	0.8	147

#	ARTICLE	IF	CITATIONS
682	Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105988.	1.1	61
683	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. <i>Journal of Autoimmunity</i> , 2020, 111, 102468.	3.0	103
684	Old and new antirheumatic drugs for the treatment of COVID-19. <i>Joint Bone Spine</i> , 2020, 87, 195-197.	0.8	24
685	Current epidemiological and clinical features of COVID-19; a global perspective from China. <i>Journal of Infection</i> , 2020, 81, 1-9.	1.7	285
686	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. <i>Infection, Genetics and Evolution</i> , 2020, 83, 104327.	1.0	248
687	All about COVID-19 in brief. <i>New Microbes and New Infections</i> , 2020, 35, 100678.	0.8	56
688	Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. <i>New Microbes and New Infections</i> , 2020, 35, 100680.	0.8	18
689	Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 1-10.	2.0	365
690	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa130.	0.4	160
691	Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 737-739.	0.5	37
692	Does hydroxychloroquine prevent the transmission of COVID-19?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e60-e60.	0.5	3
693	Hydroxychloroquine and COVID-19. <i>Postgraduate Medical Journal</i> , 2020, 96, 550-555.	0.9	134
694	COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. <i>Pediatric Rheumatology</i> , 2020, 18, 35.	0.9	35
695	COVID-19 and neuromuscular disorders. <i>Neurology</i> , 2020, 94, 959-969.	1.5	233
696	Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. <i>Cmaj</i> , 2020, 192, E450-E453.	0.9	175
697	Prediction of Number of Cases of 2019 Novel Coronavirus (COVID-19) Using Social Media Search Index. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2365.	1.2	151
698	Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , 2020, 47, 783-786.	1.0	19
699	Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). <i>BioScience Trends</i> , 2020, 14, 156-158.	1.1	41

#	ARTICLE	IF	CITATIONS
700	Does hydroxychloroquine combat COVID-19? A timeline of evidence. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e33-e34.	0.6	24
701	Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 363-382.	4.0	311
702	To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e8-e8.	0.5	6
703	SARS-CoV-2 outbreak: How can pharmacists help?. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 480-482.	1.5	73
704	The impact of coronavirus infectious disease 19 (COVID-19) on oral health. <i>Oral Diseases</i> , 2021, 27, 703-706.	1.5	103
705	Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. <i>Clinical Toxicology</i> , 2021, 59, 70-71.	0.8	29
706	Coronavirus Disease (COVID-19): A primer for emergency physicians. <i>American Journal of Emergency Medicine</i> , 2021, 44, 220-229.	0.7	201
707	Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021, 35, 1860-1865.	0.6	40
708	Pandemic preparedness of community pharmacies for COVID-19. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1888-1896.	1.5	56
709	Clearance of chloroquine and hydroxychloroquine by the Seraph® 100 Microbinda Affinity Blood Filter – a device approved for the treatment of COVID-19 patients. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 237-241.	0.4	9
710	Structural Basis of SARS-CoV-2 and SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 465-493.	4.2	36
711	COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. <i>Pharmacie Hospitalier Et Clinicien</i> , 2021, 56, 3-11.	0.3	16
712	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 755-759.	2.5	31
713	Response to: Correspondence on Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine by Nikpour et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e34-e34.	0.5	29
714	Response to: Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey by PIAÿ et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e53-e53.	0.5	0
715	Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 4-23.	4.3	46
716	Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection. <i>Microbial Pathogenesis</i> , 2021, 152, 104554.	1.3	88
717	Effect of pre-existing diseases on COVID-19 infection and role of new sensors and biomaterials for its detection and treatment. <i>Medical Devices & Sensors</i> , 2021, 4, e10140.	2.7	5

#	ARTICLE	IF	CITATIONS
718	An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. <i>International Journal of Clinical Practice</i> , 2021, 75, e13825.	0.8	6
719	A district-level susceptibility and vulnerability assessment of the COVID-19 pandemic's footprint in India. <i>Spatial and Spatio-temporal Epidemiology</i> , 2021, 36, 100390.	0.9	25
720	Cytokine storm syndrome in coronavirus disease 2019: A narrative review. <i>Journal of Internal Medicine</i> , 2021, 289, 147-161.	2.7	177
721	Los antimaláricos (cloroquina e hidroxicloroquina) en la pandemia COVID-19. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 156-158.	0.0	0
722	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. <i>International Reviews of Immunology</i> , 2021, 40, 5-53.	1.5	20
723	Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. <i>Drug Development Research</i> , 2021, 82, 86-96.	1.4	49
724	SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge. <i>Measurement: Journal of the International Measurement Confederation</i> , 2021, 168, 108335.	2.5	35
725	Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research. <i>Briefings in Bioinformatics</i> , 2021, 22, 882-895.	3.2	28
726	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. <i>Vascular</i> , 2021, 29, 220-227.	0.4	1
727	Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus disease: COVID-19. <i>Drug Development Research</i> , 2021, 82, 12-26.	1.4	15
728	Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH). <i>Medicina Intensiva</i> , 2021, 45, 104-121.	0.4	18
729	Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 102640.	0.6	23
730	Clinical trial protocols of repurposed prophylaxis for COVID-19: A review. <i>Infectious Diseases Now</i> , 2021, 51, 7-13.	0.7	5
731	What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. <i>European Journal of Ophthalmology</i> , 2021, 31, 291-303.	0.7	0
732	Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 30-42.	1.3	109
733	Assessment and characterisation of post-COVID-19 manifestations. <i>International Journal of Clinical Practice</i> , 2021, 75, e13746.	0.8	352
734	SARS-CoV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. <i>Cell Biochemistry and Function</i> , 2021, 39, 10-28.	1.4	13
735	Remdesivir and its antiviral activity against COVID-19: A systematic review. <i>Clinical Epidemiology and Global Health</i> , 2021, 9, 123-127.	0.9	143

#	ARTICLE	IF	CITATIONS
736	Targeting pivotal inflammatory pathways in COVID-19: A mechanistic review. <i>European Journal of Pharmacology</i> , 2021, 890, 173620.	1.7	24
737	COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. <i>Postgraduate Medical Journal</i> , 2021, 97, 312-320.	0.9	444
738	Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 553-574.	1.4	33
739	Does IHU-MÃ©diterranÃ©e Infection influence Gilead Sciences' stock price?. <i>New Microbes and New Infections</i> , 2021, 39, 100711.	0.8	2
740	Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic. <i>European Journal of Pharmacology</i> , 2021, 890, 173643.	1.7	14
741	QTc prolongation among hydroxychloroquine sulphate-reated COVID-19 patients: An observational study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13767.	0.8	11
742	Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 102, 107769.	1.3	18
743	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. <i>Biochemical Pharmacology</i> , 2021, 183, 114296.	2.0	79
744	COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. <i>European Journal of Pharmacology</i> , 2021, 892, 173751.	1.7	201
745	Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. <i>Respiratory Medicine</i> , 2021, 176, 106239.	1.3	193
746	An automatic approach based on CNN architecture to detect Covid-19 disease from chest X-ray images. <i>Applied Intelligence</i> , 2021, 51, 2864-2889.	3.3	60
747	COVID-19 mortality risk factors in older people in a long-term care center. <i>European Geriatric Medicine</i> , 2021, 12, 601-607.	1.2	49
748	3D printing of nasopharyngeal swabs for COVID-19 diagnose: Past and current trends. <i>Materials Today: Proceedings</i> , 2021, 44, 1361-1368.	0.9	27
749	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. <i>Arthritis and Rheumatology</i> , 2021, 73, e1-e12.	2.9	201
750	COVID-19; current situation and recommended interventions. <i>International Journal of Clinical Practice</i> , 2021, 75, e13886.	0.8	18
751	Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. <i>International Journal of Clinical Practice</i> , 2021, 75, e13896.	0.8	10
752	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. <i>Medicinal Research Reviews</i> , 2021, 41, 1375-1426.	5.0	28
753	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111008.	2.5	40

#	ARTICLE	IF	CITATIONS
754	Stem cell therapy in coronavirus disease 2019: current evidence and future potential. <i>Cytotherapy</i> , 2021, 23, 471-482.	0.3	11
755	Development of an efficient, one-pot, multicomponent protocol for synthesis of 8-hydroxy-1,2-dihydroquinoline derivatives. <i>Journal of Heterocyclic Chemistry</i> , 2021, 58, 534-547.	1.4	2
756	Understanding the temporal evolution of COVID-19 research through machine learning and natural language processing. <i>Scientometrics</i> , 2021, 126, 725-739.	1.6	46
757	Evolutionary study of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emerging coronavirus: Phylogenetic analysis and literature review. <i>Veterinary Medicine and Science</i> , 2021, 7, 559-571.	0.6	23
758	SARS-CoV-2: a new dimension to our understanding of coronaviruses. <i>International Microbiology</i> , 2021, 24, 19-24.	1.1	25
759	Decoding the silent walk of COVID-19: Halting its spread using old bullets. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110891.	2.5	1
760	Global public health significances, healthcare perceptions of communities, treatments, prevention and control methods of COVID-19. <i>Human Antibodies</i> , 2021, 29, 129-137.	0.6	8
761	Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. <i>International Immunopharmacology</i> , 2021, 90, 107228.	1.7	24
762	Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. <i>Bioorganic Chemistry</i> , 2021, 106, 104490.	2.0	119
763	Management of Pregnancy during the COVID-19 Pandemic. <i>Global Challenges</i> , 2021, 5, 2000052.	1.8	11
764	Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 137-150.	1.2	39
765	Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study. <i>American Journal of Emergency Medicine</i> , 2021, 40, 41-46.	0.7	23
766	Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 611-617.	2.8	22
767	How artificial intelligence and machine learning can help healthcare systems respond to COVID-19. <i>Machine Learning</i> , 2021, 110, 1-14.	3.4	102
768	Autoimmune connective tissue diseases in the COVID-19 pandemic. <i>Clinics in Dermatology</i> , 2021, 39, 56-63.	0.8	8
769	Nitric oxide as a therapeutic option for COVID-19 treatment: a concise perspective. <i>New Journal of Chemistry</i> , 2021, 45, 1774-1784.	1.4	30
770	Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. <i>Medical Hypotheses</i> , 2021, 146, 110434.	0.8	0
771	Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 583-593.	0.8	2

#	ARTICLE	IF	CITATIONS
772	Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. <i>American Journal of Clinical Pathology</i> , 2021, 155, 793-801.	0.4	15
773	COVID-19. <i>Critical Care Nursing Quarterly</i> , 2021, 44, 128-137.	0.4	17
774	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2170-2185.	1.1	15
775	Commentary: Providing optimal care for cardiothoracic patients of the future requires expertise spanning barriers of time and specialization. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 1363-1364.	0.4	0
776	Repurposed Drugs, Molecular Vaccines, Immune Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. <i>Advanced Therapeutics</i> , 2021, 4, 2000172.	1.6	24
777	Recent progress of antiviral therapy for coronavirus disease 2019. <i>European Journal of Pharmacology</i> , 2021, 890, 173646.	1.7	32
778	Combating COVID-19: The role of drug repurposing and medicinal plants. <i>Journal of Infection and Public Health</i> , 2021, 14, 495-503.	1.9	43
779	Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic. <i>Journal of Neurology</i> , 2021, 268, 1580-1591.	1.8	34
780	Therapeutics for COVID-19: from computation to practices "where we are, where we are heading to. <i>Molecular Diversity</i> , 2021, 25, 625-659.	2.1	53
781	Pharmacy and Pharm.D students' knowledge and information needs about COVID-19. <i>International Journal of Clinical Practice</i> , 2021, 75, e13696.	0.8	10
782	Characteristics and outcomes of patients with COVID-19 admitted to ICU in a tertiary hospital in Stockholm, Sweden. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 76-81.	0.7	45
783	Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review. <i>CJC Open</i> , 2021, 3, 28-40.	0.7	7
784	Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 411-425.	1.3	48
785	COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 113-131.	1.7	16
786	Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients. <i>American Journal of Hospice and Palliative Medicine</i> , 2021, 38, 480-488.	0.8	0
787	Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. <i>International Ophthalmology</i> , 2021, 41, 719-725.	0.6	7
788	Potential small-molecule drugs as available weapons to fight novel coronavirus (<sc>2019-nCoV</sc>): A review. <i>Cell Biochemistry and Function</i> , 2021, 39, 4-9.	1.4	8
789	COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. <i>Medicinal Research Reviews</i> , 2021, 41, 5-28.	5.0	72

#	ARTICLE	IF	CITATIONS
790	Immune response and possible therapeutics in COVID-19. RSC Advances, 2021, 11, 960-977.	1.7	7
791	Association of blood groups on the risk of COVID 19 infection, morbidity and mortality. İstanbul Kuzey Klinikleri, 2021, 8, 298-305.	0.1	0
793	DETAILED VIEW ON REPURPOSED DRUGS, TRACKING OF VACCINES, AND BRIEF VIEW ON PROPHYLACTIC NANOMEDICINES AS AN ALTERNATIVE APPROACH AND PATIENT CARE FOR COVID-19. International Journal of Applied Pharmaceutics, 0, , 19-26.	0.3	2
794	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. Rheumatology International, 2021, 41, 257-273.	1.5	3
795	The strange case of hydroxychloroquine and COVID-19. European Journal of Preventive Cardiology, 2022, 28, 1873-1874.	0.8	1
796	CORONAVIRUS and COVID-19: A Systematic Review and Perspective. Current Drug Therapy, 2020, 15, 423-435.	0.2	2
797	The growth of COVID-19 in Spain. A view based on time-series forecasting methods. , 2021, , 643-660.		1
798	Shedding light on therapeutics in alopecia and their relevance to COVID-19. Clinics in Dermatology, 2021, 39, 76-83.	0.8	9
799	Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2096269.	1.2	20
800	SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. Journal of Biological Chemistry, 2021, 296, 100306.	1.6	316
801	Micronutrient zinc roles in adjunctive therapy for COVID-19 by enhancing patients immunoregulation and tolerance to the pathogen. Reviews in Medical Microbiology, 2021, Publish Ahead of Print, .	0.4	1
802	Causal Therapy of COVID-19: Critical Review and Prospects. Obshchaya Reanimatologiya, 2021, 16, 65-90.	0.2	8
803	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. Topics in Current Chemistry, 2021, 379, 4.	3.0	15
804	COVID-19 Spreading Prediction and Impact Analysis by Using Artificial Intelligence for Sustainable Global Health Assessment. Springer Proceedings in Earth and Environmental Sciences, 2021, , 375-386.	0.2	5
805	Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. Acta Biochimica Et Biophysica Sinica, 2021, 53, 273-282.	0.9	30
806	Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flare. PLoS ONE, 2021, 16, e0245274.	1.1	18
807	QTc Prolongation in COVID-19 Patients Using Chloroquine. Cardiovascular Toxicology, 2021, 21, 314-321.	1.1	5
808	Inflammatory pathways and potential therapies for COVID-19: A mini review. European Journal of Inflammation, 2021, 19, 205873922110029.	0.2	6

#	ARTICLE	IF	CITATIONS
809	Therapeutic options for COVID-19: a quick review. <i>Journal of Chemotherapy</i> , 2021, 33, 67-84.	0.7	10
810	Comparative Evaluation of the Treatment of COVID-19 with Multicriteria Decision-Making Techniques. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-11.	1.1	30
811	In vitro Dissolution Profile at Different Biological pH Conditions of Hydroxychloroquine Sulfate Tablets Is Available for the Treatment of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 613393.	1.6	18
812	An environmentally benign regioselective synthesis of 2-benzyl-4-arylquinoline derivatives using aryl amines, styrene oxides and aryl acetylenes. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 8772-8782.	1.5	4
813	Flipped classroom: How higher education institutions (HEIs) of Bangladesh could move forward during COVID-19 pandemic. <i>Social Sciences & Humanities Open</i> , 2021, 4, 100187.	1.3	21
814	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. <i>FASEB BioAdvances</i> , 2021, 3, 192-197.	1.3	2
815	2019-nCoV effects, transmission and preventive measures: an overview. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2023, 31, 27-35.	0.8	5
816	Effect of Weather on the Spread of COVID-19 Using Eigenspace Decomposition. <i>Computers, Materials and Continua</i> , 2021, 69, 3047-3063.	1.5	8
817	Potential Therapeutic Approaches for SARS CoV2 Infection. <i>SpringerBriefs in Applied Sciences and Technology</i> , 2021, , 71-114.	0.2	0
819	SARS-CoV-2 (COVID-19): Beginning to Understand a New Virus. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1321, 3-19.	0.8	10
820	A review on potential of natural products in the management of COVID-19. <i>RSC Advances</i> , 2021, 11, 16711-16735.	1.7	59
821	Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. <i>Indian Journal of Critical Care Medicine</i> , 2021, 25, 441-452.	0.3	2
822	Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19. <i>Current Microbiology</i> , 2021, 78, 435-448.	1.0	9
823	COVID-19 Pandemisinde Kullanılan İlaçlar, Etki Mekanizmaları ve Etklilikleri. <i>Osmangaz Journal of Medicine</i> , 0, 00, .	0.1	2
824	Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs. <i>Precision Clinical Medicine</i> , 2021, 4, 1-16.	1.3	66
825	Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing. <i>Gut Pathogens</i> , 2021, 13, 7.	1.6	17
826	When Music Changes, so Does the Dance. <i>Advances in Business Strategy and Competitive Advantage Book Series</i> , 2021, , 262-283.	0.2	0
827	Assessment of self-medication practices in the context of the COVID-19 outbreak in Togo. <i>BMC Public Health</i> , 2021, 21, 58.	1.2	78

#	ARTICLE	IF	CITATIONS
828	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
829	A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity. <i>Laryngoscope</i> , 2021, 131, 1626-1632.	1.1	20
830	Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. <i>International Journal of Biological Sciences</i> , 2021, 17, 1538-1546.	2.6	24
831	Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial. <i>Indian Journal of Medical Research</i> , 2021, 153, 151-158.	0.4	7
832	Treatment of COVID-19 by Combination Therapy with 5-fluorouracil, Ribonucleosides and Ribavirin: A Modified Strategy. , 2021, , 571-581.		0
833	Human Viruses: Infection, Prevention and Potential Target(s) for Therapy: A Comprehensive Review. , 2021, , 3-54.		0
834	Targeting protein-protein interaction interfaces in COVID-19 drug discovery. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2246-2255.	1.9	28
835	Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 1333-1343.	1.7	59
836	Single-Cell Gene Regulatory Network Analysis Reveals Potential Mechanisms of Action of Antimalarials Against SARS-CoV-2. <i>Lecture Notes in Computer Science</i> , 2021, , 88-94.	1.0	0
837	Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 2126.	0.3	6
838	Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach. <i>Informatics in Medicine Unlocked</i> , 2021, 26, 100745.	1.9	11
839	Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19). <i>3 Biotech</i> , 2021, 11, 89.	1.1	29
840	An optimal control model of COVID-19 pandemic: a comparative study of five countries. <i>Opsearch</i> , 2021, 58, 790.	1.1	7
841	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	20
842	Hyperpolarisation of weakly binding N-heterocycles using signal amplification by reversible exchange. <i>Chemical Science</i> , 2021, 12, 5910-5917.	3.7	10
843	Therapeutic and Vaccine Strategies for Stopping the COVID-19 Pandemic Based on Structural and Molecular Modeling Studies of Virus-Ganglioside Interactions. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 273.	0.1	0
844	Time-Dependent Distribution of Hydroxychloroquine in Cynomolgus Macaques Using Population Pharmacokinetic Modeling Method. <i>Frontiers in Pharmacology</i> , 2020, 11, 602880.	1.6	4
845	Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19. <i>Chemical Biology and Drug Design</i> , 2021, 97, 978-983.	1.5	7

#	ARTICLE	IF	CITATIONS
846	CORTICOSTEROIDS AND SECONDARY INFECTIONS: AN INSIGHT INTO CORONAVIRUS DISEASE-2019. Asian Journal of Pharmaceutical and Clinical Research, 0, , 36-47.	0.3	0
847	Crystal structure, Hirshfeld surface analysis, DFT and molecular docking investigation of 2-(2-oxo-1,3-oxazolidin-3-yl)ethyl 2-[2-(2-oxo-1,3-oxazolidin-3-yl)ethoxy]quinoline-4-carboxylate. Acta Crystallographica Section E: Crystallographic Communications, 2021, 77, 28-33.	0.2	0
848	Identification of potential antivirals against SARS-CoV-2 using virtual screening method. Informatics in Medicine Unlocked, 2021, 23, 100531.	1.9	17
850	Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents. Journal of Anaesthesiology Clinical Pharmacology, 2021, 37, 160.	0.2	6
851	Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses. Genetics and Molecular Biology, 2021, 44, e20200212.	0.6	11
852	SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. Frontiers in Physiology, 2020, 11, 605908.	1.3	89
853	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS Journal, 2021, 23, 14.	2.2	291
854	Time-trend analysis of medicine sales and shortages during COVID-19 outbreak: Data from community pharmacies. Research in Social and Administrative Pharmacy, 2021, 17, 1876-1881.	1.5	54
855	Therapeutic Development in COVID-19. Advances in Experimental Medicine and Biology, 2021, 1318, 435-448.	0.8	2
856	The Implications of COVID-19 to Ophthalmology. Advances in Experimental Medicine and Biology, 2021, 1318, 637-655.	0.8	8
857	Mapping the footprints of COVID-19 pandemic. Journal of Family Medicine and Primary Care, 2021, 10, 2467.	0.3	2
858	Personal Hygiene Concept, Knowledge, and Awareness Regarding COVID-19 among Bangladeshi People. Journal of Biosciences and Medicines, 2021, 09, 73-91.	0.1	0
859	COVID-19 in Qatar: Ways forward in public health and treatment. Qatar Medical Journal, 2021, 2020, 38.	0.2	2
860	Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York. BMJ Open, 2021, 11, e042965.	0.8	5
861	Therapeutic Strategies in the Management of COVID-19. Frontiers in Molecular Biosciences, 2020, 7, 636738.	1.6	10
862	Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS). Drugs - Real World Outcomes, 2021, 8, 131-140.	0.7	7
863	The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. Genetic Testing and Molecular Biomarkers, 2021, 25, 85-101.	0.3	6
864	Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19. Pathogens, 2021, 10, 217.	1.2	25

#	ARTICLE	IF	CITATIONS
865	Coronavirus disease 2019 (COVID-19) manifestations during pregnancy in all three trimesters: A case series. <i>International Journal of Reproductive BioMedicine</i> , 2021, 19, 191-204.	0.5	5
866	Targeting Lipid Rafts as a Strategy Against Coronavirus. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 618296.	1.8	43
867	SARS-CoV-2 infection in children. <i>Turkish Archives of Pediatrics</i> , 2021, 55, 95-102.	0.5	22
868	<scp>COVID</scp>â€19 and the generation of novel scientific knowledge: Research questions and study designs. <i>Journal of Evaluation in Clinical Practice</i> , 2021, 27, 694-707.	0.9	6
869	COVIDâ€19: Current knowledge in clinical features, immunological responses, and vaccine development. <i>FASEB Journal</i> , 2021, 35, e21409.	0.2	71
870	Intensive care management of patients with COVID-19: a practical approach. <i>Annals of Intensive Care</i> , 2021, 11, 36.	2.2	73
871	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. <i>Current Respiratory Medicine Reviews</i> , 2021, 16, 165-183.	0.1	0
872	COVID-19 and neurology perspective. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2021, 42, 69-75.	0.3	0
873	Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. <i>The Cochrane Library</i> , 2021, 2021, CD013587.	1.5	134
874	Clinical Characteristics and Remedy Profiles of Patients with COVID-19: A Retrospective Cohort Study. <i>Homeopathy</i> , 2021, 110, 086-093.	0.5	29
875	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeuticsâ€a review. <i>Archives of Microbiology</i> , 2021, 203, 2043-2057.	1.0	9
876	Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. <i>Frontiers in Immunology</i> , 2020, 11, 616595.	2.2	20
877	A New Index in the Follow-Up of Arrhythmia of Coronavirus Disease-2019 (COVID-19) Patients Receiving Hydroxychloroquine and Azithromycin Therapy; Index of Cardiac Electrophysiological Balance. <i>Cumhuriyet Medical Journal</i> , 0, , .	0.1	2
878	Psychosocial Impacts of the Coronavirus Disease (COVID-19) Pandemic in Zimbabwe: Citizensâ€™ Perspective. <i>Perspectives on Global Development and Technology</i> , 2021, 19, 565-583.	0.2	7
879	SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. <i>PLoS Computational Biology</i> , 2021, 17, e1008686.	1.5	72
880	Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study. <i>Turkish Thoracic Journal</i> , 2021, 22, 62-66.	0.2	6
881	Chloroquine-Induced Accumulation of Autophagosomes and Lipids in the Endothelium. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2401.	1.8	12
882	Recent Advances on Nanotechnology-Based Strategies for Prevention, Diagnosis, and Treatment of Coronavirus Infections. <i>Journal of Nanomaterials</i> , 2021, 2021, 1-20.	1.5	18

#	ARTICLE	IF	CITATIONS
883	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. Journal of Microbiology, Immunology and Infection, 2021, 54, 37-45.	1.5	5
884	Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating <sc>COVID</sc>â€19. International Journal of Quantum Chemistry, 2021, 121, e26617.	1.0	50
885	Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy. Journal of Biomolecular Structure and Dynamics, 2022, 40, 6477-6502.	2.0	10
886	Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro. Viruses, 2021, 13, 354.	1.5	113
887	Living with the virus: Infection and epidemiology of <sc>COVID</sc>â€19 in hotspot area of India. Journal of Public Affairs, 2021, 21, e2651.	1.7	6
888	A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic. Frontiers in Immunology, 2021, 12, 631139.	2.2	117
889	COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development. Current Clinical Microbiology Reports, 2021, 8, 152-166.	1.8	15
890	Clinical characteristics of hospitalized mild/moderate COVID-19 patients with a prolonged negative conversion time of SARS-CoV-2 nucleic acid detection. BMC Infectious Diseases, 2021, 21, 141.	1.3	12
891	A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. Frontiers in Pharmacology, 2020, 11, 590154.	1.6	8
892	Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. Viruses, 2021, 13, 329.	1.5	4
893	The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. PLoS ONE, 2021, 16, e0246190.	1.1	64
894	Traditional Chinese herbal medicine-potential therapeutic application for the treatment of COVID-19. Chinese Medicine, 2021, 16, 24.	1.6	21
896	Surge effects and survival to hospital discharge in critical care patients with COVID-19 during the early pandemic: a cohort study. Critical Care, 2021, 25, 70.	2.5	14
897	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. Frontiers in Pharmacology, 2021, 12, 576448.	1.6	11
898	Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study. Turkish Journal of Chemistry, 2021, 45, 35-41.	0.5	8
899	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). Current Pharmaceutical Design, 2021, 27, 115-126.	0.9	13
900	Multidrug treatment for COVID-19. Drug Discoveries and Therapeutics, 2021, 15, 39-41.	0.6	6
901	Rehabilitation, a necessity in hospitalized and discharged people infected with COVID-19: a narrative review. Physical Therapy Reviews, 2021, 26, 202-210.	0.3	3

#	ARTICLE	IF	CITATIONS
902	Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2. <i>Phytotherapy Research</i> , 2021, 35, 4258-4283.	2.8	36
903	An Overview of Drugs Used in COVID-19: A Pharmacotherapeutic Approach. <i>International Journal of Health Sciences and Pharmacy</i> , 0, , 34-54.	0.0	0
904	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113157.	2.6	35
905	In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2021, 10, 22.	1.2	5
906	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 172, 524-541.	3.6	123
907	Repositioning therapeutics for COVID-19: virtual screening of the potent synthetic and natural compounds as SARS-CoV-2 3CLpro inhibitors. <i>Journal of the Iranian Chemical Society</i> , 2021, 18, 2807-2827.	1.2	5
908	State-of-the-Art of Nanodiagnosics and Nanotherapeutics against SARS-CoV-2. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 14816-14843.	4.0	27
909	Recognition of plausible therapeutic agents to combat COVID-19: An omics data based combined approach. <i>Gene</i> , 2021, 771, 145368.	1.0	11
910	Dampak pandemi COVID-19 terhadap pendidikan tinggi di Kota Malang. <i>Jurnal Ekonomi, Bisnis Dan Pendidikan</i> , 2021, 1, 209-218.	0.0	0
912	Prediction of potential inhibitors of SARS-CoV-2 using 3D-QSAR, molecular docking modeling and ADMET properties. <i>Heliyon</i> , 2021, 7, e06603.	1.4	16
913	Individuals'™ conceptions of COVID-19 pandemic through metaphor analysis. <i>Current Psychology</i> , 2022, 41, 449-458.	1.7	18
914	A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment. <i>Computers in Biology and Medicine</i> , 2021, 130, 104186.	3.9	26
915	Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. <i>Journal of Infection and Public Health</i> , 2021, 14, 365-370.	1.9	14
916	Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial. <i>Cureus</i> , 2021, 13, e14186.	0.2	12
917	Revising the "Hyge Pipeline" Model in Scientific Communication. <i>Frontiers in Communication</i> , 2021, 6, .	0.6	3
918	Effectiveness and quality analysis of methods in studies for the treatment of COVID-19. <i>Research on Biomedical Engineering</i> , 0, , 1.	1.5	0
919	A mini review on the pathogenesis, diagnosis and treatment options for COVID-19. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	0
920	Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. <i>International Journal of Infectious Diseases</i> , 2021, 104, 7-14.	1.5	13

#	ARTICLE	IF	CITATIONS
921	Potentiality of <i>Moringa oleifera</i> against SARS-CoV-2: identified by a rational computer aided drug design method. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-18.	2.0	18
923	Eyes on coronavirus. <i>Stem Cell Research</i> , 2021, 51, 102200.	0.3	18
924	Could Nanotheranostics be the Answer to the Coronavirus Crisis?. <i>Global Challenges</i> , 2021, 5, 2000112.	1.8	6
925	Potential therapeutic and pharmacological strategies for SARS-CoV2. <i>Journal of Pharmaceutical Investigation</i> , 2021, 51, 281-296.	2.7	15
926	In the Age of Viral Pandemic, Can Ingredients Inspired by Human Milk and Infant Nutrition Be Repurposed to Support the Immune System?. <i>Nutrients</i> , 2021, 13, 870.	1.7	12
927	Survey of Twitter Viewpoint on Application of Drugs by VADER Sentiment Analysis among Distinct Countries. <i>International Journal of Management, Technology, and Social Science</i> , 0, , 110-127.	0.0	4
928	Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-17.	2.0	8
929	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 104-121.	0.1	11
930	BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1169-1184.	1.1	11
931	An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. <i>Viruses</i> , 2021, 13, 560.	1.5	15
932	A review of Cameroonian medicinal plants with potentials for the management of the COVID-19 pandemic. <i>Advances in Traditional Medicine</i> , 2023, 23, 59-84.	1.0	16
933	SiO ₂ -Ag Composite as a Highly Virucidal Material: A Roadmap that Rapidly Eliminates SARS-CoV-2. <i>Nanomaterials</i> , 2021, 11, 638.	1.9	41
934	Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice. <i>Scientific Reports</i> , 2021, 11, 6918.	1.6	7
935	A systematic review of the role of hypovitaminosis D in coronavirus disease-19 (COVID-19) infection and mortality: Is there a role of recommending high dose vitamin D supplementation?. <i>Human Nutrition and Metabolism</i> , 2021, 23, 200120.	0.8	0
936	Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19. <i>The Cochrane Library</i> , 2021, 3, ED000151.	1.5	6
937	Photodynamic Therapy: A Rational Approach Toward COVID-19 Management. <i>Journal of Exploratory Research in Pharmacology</i> , 2021, 000, 000-000.	0.2	4
938	Worldwide Survey of COVID-19-associated Arrhythmias. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009458.	2.1	127
939	SAveRUNNER: an R-based tool for drug repurposing. <i>BMC Bioinformatics</i> , 2021, 22, 150.	1.2	42

#	ARTICLE	IF	CITATIONS
940	Science under Covid-19's magnifying glass: Lessons from the first months of the chloroquine debate in the French press. <i>Journal of Sociology</i> , 2022, 58, 76-94.	0.9	7
941	A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2. <i>Current Drug Research Reviews</i> , 2021, 13, 203-221.	0.7	2
942	COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development. <i>Experimental Biology and Medicine</i> , 2021, 246, 1533-1540.	1.1	2
943	Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. <i>Pathogens and Global Health</i> , 2021, 115, 235-242.	1.0	51
944	Ethical Challenges Related to the Novel Coronavirus (COVID-19) Outbreak: Interviews With Professionals From Saudi Arabia. <i>Frontiers in Medicine</i> , 2021, 8, 620444.	1.2	6
945	TREATMENT MODALITIES OF THE COVID-19 PANDEMIC THROUGH REPURPOSED DRUGS AND STATUS OF VACCINES. <i>International Journal of Applied Pharmaceutics</i> , 0, , 48-58.	0.3	4
947	A Therapeutic Journey of Potential Drugs Against COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 1876-1894.	1.1	1
948	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. <i>Infectious Disease Reports</i> , 2021, 13, 259-284.	1.5	27
949	Cytokine Storm of COVID-19 and its Impact on Patients with and without Chronic Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	20
950	Association of built environment attributes with the spread of COVID-19 at its initial stage in China. <i>Sustainable Cities and Society</i> , 2021, 67, 102752.	5.1	66
951	Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. <i>Frontiers in Immunology</i> , 2021, 12, 589095.	2.2	102
952	The therapeutic effect and safety of the drugs for COVID-19. <i>Medicine (United States)</i> , 2021, 100, e25532.	0.4	3
953	Covid 19: Risk faktörleri, Tedavide Kullanılan İlaçlar ve İlaçın Oranları. <i>Van Sağlık Bilimleri Dergisi</i> , 0, , 98-105.	0.6	0
954	Antidepressants and Antipsychotic Agents as Repurposable Oncological Drug Candidates. <i>Current Medicinal Chemistry</i> , 2021, 28, 2137-2174.	1.2	10
955	Current diagnostic and therapeutic strategies for COVID-19. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 129-137.	2.4	11
956	COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer. <i>BioScience Trends</i> , 2021, 15, 64-73.	1.1	43
957	Characteristics and Risk Factors Associated With Mortality in a Multicenter Spanish Cohort of Patients With COVID-19 Pneumonia. <i>Archivos De Bronconeumologia</i> , 2021, 57, 34-41.	0.4	19
958	Simultaneous electrochemical detection of azithromycin and hydroxychloroquine based on VS2 QDs embedded N, S @graphene aerogel/cCNTs 3D nanostructure. <i>Microchemical Journal</i> , 2021, 163, 105925.	2.3	31

#	ARTICLE	IF	CITATIONS
959	Aspects About Science in the Context of Production and Communication of Knowledge of COVID-19. Science and Education, 2021, 30, 1075-1098.	1.7	13
960	Antimalarials (chloroquine and hydroxychloroquine) in the COVID-19 pandemic. Revista Colombiana De ReumatologĀa (English Edition), 2021, 28, 156-158.	0.1	0
961	Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state. BMJ Open, 2021, 11, e042549.	0.8	6
962	System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India. Expert Review of Anti-Infective Therapy, 2021, 19, 1331-1339.	2.0	3
963	COVID-19 prediction using AI analytics for South Korea. Applied Intelligence, 2021, 51, 8579-8597.	3.3	19
964	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. Therapeutics and Clinical Risk Management, 2021, Volume 17, 371-387.	0.9	50
965	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. International Journal of Molecular Sciences, 2021, 22, 4067.	1.8	27
966	Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis. Annals of Translational Medicine, 2021, 9, 524-524.	0.7	0
967	The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. Journal of Pharmacy Practice, 2022, 35, 971-978.	0.5	2
968	An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery. Current Topics in Medicinal Chemistry, 2021, 21, 571-596.	1.0	12
969	Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Topics in Current Chemistry, 2021, 379, 23.	3.0	6
970	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. Frontiers in Pharmacology, 2021, 12, 576093.	1.6	17
971	COVID-19: A Review on Epidemiology, Clinical Features and Possible Potential Drugs Based on Available Case Studies. Coronaviruses, 2021, 2, 299-312.	0.2	3
972	Therapeutic Agents for COVID-19: an Overview. Current Drug Therapy, 2021, 16, 22-44.	0.2	1
973	COVID 19 IN PREGNANT WOMEN - A RETROSPECTIVE COHORT STUDY. Samsun SaÄŸlĀk Bilimleri Dergisi, 2021, 6, 181-186.	0.3	2
974	In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. Journal of Taibah University Medical Sciences, 2021, 16, 162-176.	0.5	28
975	A Systematic Review on Various Therapeutic Options for Coronavirus Outbreak. Journal of Drug Delivery and Therapeutics, 2021, 11, 185-194.	0.2	0
976	An Overview of the Treatment Contributions Measured Globally for the COVID-19 Outbreak. Coronaviruses, 2021, 2, 198-203.	0.2	1

#	ARTICLE	IF	CITATIONS
977	Use of Natural Compounds as a Potential Therapeutic Agent Against COVID-19. Current Pharmaceutical Design, 2021, 27, 1144-1152.	0.9	13
978	Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. Viruses, 2021, 13, 647.	1.5	41
979	Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. Journal of Environmental and Public Health, 2021, 2021, 1-11.	0.4	24
980	Simulation Prediction and Control Strategy of COVID-19 Dynamic Contact Network in USA and Various States – Based on Effective Regeneration Number and Improved Discrete SEIQDHR Model. Journal of Physics: Conference Series, 2021, 1865, 042071.	0.3	1
981	SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. Frontiers in Pharmacology, 2021, 12, 638334.	1.6	14
982	Repurposing of approved drug molecules for viral infectious diseases: a molecular modelling approach. Journal of Biomolecular Structure and Dynamics, 2022, 40, 8056-8072.	2.0	7
984	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. Drug Metabolism and Personalized Therapy, 2021, .	0.3	0
985	Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International Journal of Infectious Diseases, 2021, 105, 598-605.	1.5	27
987	The role of autophagy in controlling SARS-CoV-2 infection: An overview on virophagy-mediated molecular drug targets. Cell Biology International, 2021, 45, 1599-1612.	1.4	33
988	Research and Management of Rare Diseases in the COVID-19 Pandemic Era: Challenges and Countermeasures. Frontiers in Public Health, 2021, 9, 640282.	1.3	28
989	Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies. Journal of Molecular Structure, 2021, 1230, 129891.	1.8	18
990	COVID-19 pneumonia successfully managed with high-flow nasal cannula in a 15-year-old boy. BMJ Case Reports, 2021, 14, e239682.	0.2	0
991	Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. Current Pharmaceutical Design, 2021, 27, 1323-1329.	0.9	0
992	Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of Tj ETQq1 1 0.784314 rgBT /Overlook 2021, 42, 5-18.	0.2	2
993	Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?. European Journal of Pharmacology, 2021, 897, 173928.	1.7	17
994	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. International Journal of Environmental Research and Public Health, 2021, 18, 3919.	1.2	25
995	Coronavirus Disease 2019: An Overview of the Complications and Management. , 0, , 1-28.		1
996	Liver injury, SARS-CoV-2 infection and COVID-19: What physicians should really know?. GastroHep, 2021, 3, 121-130.	0.3	11

#	ARTICLE	IF	CITATIONS
998	Dynamical characterization of antiviral effects in COVID-19. <i>Annual Reviews in Control</i> , 2021, 52, 587-601.	4.4	7
999	Old drugs for a new indication: a review of chloroquine and analogue in COVID-19 treatment. <i>Porto Biomedical Journal</i> , 2021, 6, e132.	0.4	2
1000	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. <i>Rheumatology and Therapy</i> , 2021, 8, 681-691.	1.1	4
1001	Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2021, 24, 716-728.	0.6	39
1002	5-((1H-imidazol-1-yl)methyl)quinolin-8-ol as potential antiviral SARS-CoV-2 candidate: Synthesis, crystal structure, Hirshfeld surface analysis, DFT and molecular docking studies. <i>Journal of Molecular Structure</i> , 2021, 1232, 130005.	1.8	62
1003	Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines. <i>Nano Express</i> , 2021, 2, 022007.	1.2	6
1004	Spatio-temporal analysis of COVID-19 incidence rate using GIS: a case studyâ€”Tehran metropolitan, Iran. <i>Geo Journal</i> , 2022, 87, 3291-3305.	1.7	17
1005	A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
1006	Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement. <i>Biomolecules</i> , 2021, 11, 787.	1.8	14
1007	Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection. <i>Frontiers in Microbiology</i> , 2021, 12, 675419.	1.5	25
1008	Explaining the reasons for not maintaining the health guidelines to prevent COVID-19 in high-risk jobs: a qualitative study in Iran. <i>BMC Public Health</i> , 2021, 21, 848.	1.2	38
1009	The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection. <i>Current Rheumatology Reviews</i> , 2021, 17, 141-152.	0.4	3
1011	COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development. <i>Archives of Pharmacal Research</i> , 2021, 44, 499-513.	2.7	18
1012	Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 349.	0.7	1
1013	Existing Drugs Considered as Promising in COVID-19 Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5434.	1.8	24
1014	Potential medicinal plant remedies and their possible mechanisms against COVID-19: A review. <i>Ife Journal of Science</i> , 2021, 23, 161-194.	0.1	4
1015	HiperpigmentaÃ§Ã£o em mucosa oral de pacientes usuÃ¡rios de cloroquina e hidroxicloroquina: RevisÃ£o de literatura. <i>Research, Society and Development</i> , 2021, 10, e30010514528.	0.0	1
1016	Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. <i>European Journal of Pharmacology</i> , 2021, 898, 173977.	1.7	29

#	ARTICLE	IF	CITATIONS
1017	Identification of SARS-CoV-2 Main Protease Inhibitors Using Structure Based Virtual Screening and Molecular Dynamics Simulation of DrugBank Database. <i>ChemistrySelect</i> , 2021, 6, 4991-5013.	0.7	14
1018	Pharmacotherapy for COVID-19: A Ray of Hope. , 0, , .		0
1019	The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic. <i>Current Medicinal Chemistry</i> , 2021, 28, 2852-2886.	1.2	20
1020	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. <i>Antioxidants</i> , 2021, 10, 881.	2.2	20
1021	Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. <i>Nutrients</i> , 2021, 13, 1550.	1.7	26
1022	SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. <i>Biomedicines</i> , 2021, 9, 611.	1.4	10
1023	COVID-19 and Diabetes Mellitus: A Complex Interplay. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 512-523.	0.3	1
1024	Therapeutic Agents Against COVID-19 with Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1608-1617.	0.9	4
1025	A Study on Novel Corona Virus Disease (COVID-19). <i>Asian Journal of Engineering and Applied Technology</i> , 2021, 10, 29-37.	0.3	4
1026	SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111352.	2.5	23
1027	Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical and Translational Science</i> , 2021, 14, 1101-1112.	1.5	7
1028	Evaluation of COVID-19 Disease Awareness and Its Relation to Mental Health, Dietary Habits, and Physical Activity: A Cross-Sectional Study from Pakistan. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1687-1693.	0.6	13
1029	In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel—A Drug Antitarget. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 645172.	1.1	4
1030	Current Overviews on COVID-19 Management Strategies. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, .	0.9	9
1031	Kawasaki like illness due to COVID-19: a review of the literature. <i>Journal of Infection in Developing Countries</i> , 2021, 15, 630-638.	0.5	9
1032	FunCoup 5: Functional Association Networks in All Domains of Life, Supporting Directed Links and Tissue-Specificity. <i>Journal of Molecular Biology</i> , 2021, 433, 166835.	2.0	25
1033	The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 584940.	1.6	28
1034	Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. <i>Journal of Chemotherapy</i> , 2021, 33, 499-508.	0.7	6

#	ARTICLE	IF	CITATIONS
1035	An Insight into Pandemic COVID-19: Structure, Epidemiology and Therapeutics. <i>Current Biotechnology</i> , 2021, 10, 13-17.	0.2	0
1036	Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 8100-8111.	2.0	3
1037	PHARMACOVIGILANCE IN THE ERA OF COVID-19: A CONCISE REVIEW OF THE CURRENT SCENARIO, IMPLICATIONS, AND CHALLENGES. <i>International Journal of Applied Pharmaceutics</i> , 0, , 1-4.	0.3	2
1038	Evaluation of potency of the selected bioactive molecules from Indian medicinal plants with MPro of SARS-CoV-2 through in silico analysis. <i>Journal of Ayurveda and Integrative Medicine</i> , 2022, 13, 100449.	0.9	21
1039	Current Pharmaceutical Aspects of Synthetic Quinoline Derivatives. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 1152-1172.	1.1	25
1040	Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 1004-1016.	1.1	2
1041	Cyclodextrin-based molecules as hosts in the formation of supramolecular complexes and their practical applicationsâ€”A review. <i>Journal of Carbohydrate Chemistry</i> , 2021, 40, 135-155.	0.4	8
1042	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. <i>Food and Chemical Toxicology</i> , 2021, 151, 112106.	1.8	6
1043	Polymeric surfaces with biocidal action: challenges imposed by the SARS-CoV-2, technologies employed, and future perspectives. <i>Journal of Polymer Research</i> , 2021, 28, 1.	1.2	7
1044	Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. <i>Reviews on Recent Clinical Trials</i> , 2021, 16, 138-145.	0.4	18
1045	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. <i>Pharmaceutics</i> , 2021, 14, 520.	1.7	24
1046	Nigerian polyherbal-based hydrotherapy: a panacea to infectious diseases. <i>Herba Polonica</i> , 2021, 67, 65-79.	0.2	4
1047	Opinion and uptake of chloroquine for treatment of COVID-19 during the mandatory lockdown in the sub-Saharan African region. <i>African Journal of Primary Health Care and Family Medicine</i> , 2021, 13, e1-e8.	0.3	2
1048	Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19â€”The Role of RAGE-RAS Crosstalk. <i>Biomolecules</i> , 2021, 11, 876.	1.8	25
1049	In silico approach for identification of natural compounds as potential COVID 19 main protease (Mpro) inhibitors. <i>VirusDisease</i> , 2021, 32, 325-329.	1.0	8
1050	Chloroquine as Chemoprophylaxis for COVID-19: Will This Work. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, 473-474.	0.4	11
1051	Immuno-Informatics Quest against COVID-19/SARS-COV-2: Determining Putative T-Cell Epitopes for Vaccine Prediction. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, 541-552.	0.4	18
1052	The COVID-19 pandemic face mask waste: A blooming threat to the marine environment. <i>Chemosphere</i> , 2021, 272, 129601.	4.2	187

#	ARTICLE	IF	CITATIONS
1053	A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2. Briefings in Bioinformatics, 2021, 22, .	3.2	29
1054	COVID-19 and ophthalmology- Challenges and mitigation of disease. Indian Journal of Clinical and Experimental Ophthalmology, 2021, 7, 284-288.	0.1	0
1055	Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know?. Cancers, 2021, 13, 3193.	1.7	31
1056	The Plausible Role of Indian Traditional Medicine in Combating Corona Virus (SARS-CoV 2): A Mini-Review. Current Pharmaceutical Biotechnology, 2021, 22, 906-919.	0.9	21
1057	The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy. Infectious Disorders - Drug Targets, 2021, 21, 514-526.	0.4	14
1058	The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. Medicine in Drug Discovery, 2021, 10, 100085.	2.3	19
1059	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. Frontiers in Pharmacology, 2021, 12, 659577.	1.6	31
1060	Coronavirus Disease 2019 (COVID-19): Origin, Impact, and Drug Development. , 0, , .		2
1061	Coronavirus Disease 2019 (COVID-19): Current Situation and Therapeutic Options. Coronaviruses, 2021, 2, 481-491.	0.2	17
1062	MANAGEMENT CHALLENGES IN IMPLEMENTING SCIENTIFIC PROJECTS DURING COVID-19 PANDEMIC. Polish Journal of Management Studies, 2021, 23, 136-150.	0.3	5
1063	Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy. Biomedicine and Pharmacotherapy, 2021, 138, 111518.	2.5	50
1064	Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey. Turkish Journal of Medical Sciences, 2021, 51, 912-920.	0.4	15
1065	Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID). International Journal of Molecular Sciences, 2021, 22, 6937.	1.8	20
1066	Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications. Cardiovascular Diagnosis and Therapy, 2021, 11, 939-953.	0.7	0
1067	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. PLoS ONE, 2021, 16, e0251731.	1.1	9
1068	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduction and Targeted Therapy, 2021, 6, 233.	7.1	203
1069	COVID-19 rhapsody: Rage towards advanced diagnostics and therapeutic strategy. Journal of Pharmaceutical Analysis, 2021, 11, 529-540.	2.4	5
1070	Autophagy, Unfolded Protein Response, and Neuropilin-1 Cross-Talk in SARS-CoV-2 Infection: What Can Be Learned from Other Coronaviruses. International Journal of Molecular Sciences, 2021, 22, 5992.	1.8	25

#	ARTICLE	IF	CITATIONS
1071	The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19. <i>Chinese Medicine</i> , 2021, 16, 44.	1.6	16
1072	Emergence of a New Zoonotic COVID-19 that Creates a Pandemic: Update on Current Pharmacotherapeutics and Future Prospective of Plasma Therapy. <i>Coronaviruses</i> , 2021, 2, 422-430.	0.2	0
1073	Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. <i>Drug Metabolism Reviews</i> , 2021, 53, 508-541.	1.5	0
1074	Mechanism of Action of Chloroquine/Hydroxychloroquine for Covid-19 Infection. <i>Coronaviruses</i> , 2021, 2, .	0.2	3
1075	A review on role of nitrous oxide nanoparticles, potential vaccine targets, drug, health care and artificial intelligence to combat COVID-19. <i>Applied Nanoscience (Switzerland)</i> , 2023, 13, 111-118.	1.6	6
1076	An inclusive review on virology, transmission, and clinical management of COVID-19 resulting from SARS-CoV-2. <i>GSC Biological and Pharmaceutical Sciences</i> , 2021, 15, 080-092.	0.1	0
1077	The scientific community in COVID-19 global pandemic: A systematic update on recent progress and challenges. <i>European Journal of Chemistry</i> , 2021, 12, 222-234.	0.3	0
1078	Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	27
1079	Coronavirus and its terrifying inning around the globe: The pharmaceutical cares at the main frontline. <i>Chemosphere</i> , 2021, 275, 129968.	4.2	7
1080	Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 609-632.	1.3	65
1081	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111642.	2.5	50
1082	COVID-19 Severity: Lung-Heart Interplay. <i>Current Cardiology Reviews</i> , 2021, 17, e230421189016.	0.6	11
1083	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1591-1623.	5.7	57
1084	Recent developments and opportunities in fighting COVID-19. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
1085	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1219-1244.	2.0	6
1086	A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients. <i>Toxicological Research</i> , 2022, 38, 137-148.	1.1	5
1087	Informing selection of drugs for COVID-19 treatment through adverse events analysis. <i>Scientific Reports</i> , 2021, 11, 14022.	1.6	5
1088	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 50.	1.0	22

#	ARTICLE	IF	CITATIONS
1089	Association of anemia and COVID-19 in hospitalized patients. <i>Future Virology</i> , 2021, 16, 459-466.	0.9	8
1090	ORF3a-Mediated Incomplete Autophagy Facilitates Severe Acute Respiratory Syndrome Coronavirus-2 Replication. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 716208.	1.8	74
1091	Boswellic acids/ <i>Boswellia serrata</i> extract as a potential COVID-19 therapeutic agent in the elderly. <i>Inflammopharmacology</i> , 2021, 29, 1033-1048.	1.9	24
1092	Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 599-602.	1.3	1
1093	Antimalarial drugs—are they beneficial in rheumatic and viral diseases?—considerations in COVID-19 pandemic. <i>Clinical Rheumatology</i> , 2022, 41, 1-18.	1.0	7
1094	Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients. <i>Russian Journal of Bioorganic Chemistry</i> , 2021, 47, 789-804.	0.3	1
1095	A dossier on COVID-19 chronicle. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 45-54.	0.7	3
1096	Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 700502.	1.8	18
1097	Kidney involvement in COVID-19 and potential treatment opportunities. <i>Journal of Preventive Medicine and Holistic Health</i> , 2021, 7, 12-18.	0.2	0
1098	Inflammatory effect on the gastrointestinal system associated with COVID-19. <i>World Journal of Gastroenterology</i> , 2021, 27, 4160-4171.	1.4	11
1099	COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now—“New Hopes?”. <i>Pharmaceuticals</i> , 2021, 14, 664.	1.7	3
1100	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3771-3788.	2.5	17
1101	Molecular Insights into COVID-19 Pathophysiology, Immune Pathogenesis, Detection, and Treatment. <i>DNA and Cell Biology</i> , 2021, 40, 858-868.	0.9	0
1103	Novel Coronavirus Disease (COVID-19): An extensive study on evolution, global health, drug targets and vaccines. <i>International Journal of Clinical Virology</i> , 2021, 5, 054-069.	0.1	2
1104	Environmentally Friendly Nafion-Catalyzed Synthesis of Substituted 2-Ethyl-3-Methylquinolines from Aniline and Propionaldehyde under Microwave Irradiation. <i>Catalysts</i> , 2021, 11, 877.	1.6	3
1106	SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies—a narrative review. <i>Journal of Infection and Public Health</i> , 2021, 14, 863-875.	1.9	43
1107	Saving critically ill COVID-19 patients with mechanical circulatory support. <i>Annals of Translational Medicine</i> , 2021, 9, 1221-1221.	0.7	3
1108	A critical review on environmental presence of pharmaceutical drugs tested for the covid-19 treatment. <i>Chemical Engineering Research and Design</i> , 2021, 152, 568-582.	2.7	49

#	ARTICLE	IF	CITATIONS
1109	Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. <i>Epilepsy Research</i> , 2021, 174, 106675.	0.8	18
1110	Rational optimization of a human neutralizing antibody of SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2021, 135, 104550.	3.9	7
1111	Sociodemographic, laboratory, image data and predictors of gravity risk in patients with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0256331.	1.1	3
1112	Theory and reality of antivirals against SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 6663-6673.	0.3	1
1113	Cyclodextrins in the antiviral therapy. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 64, 102589.	1.4	26
1114	Binding of Chloroquine to Whey Protein Relieves Its Cytotoxicity while Enhancing Its Uptake by Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 10669-10677.	2.4	7
1115	Is the Covid-19 pandemic strong enough to change the online order delivery methods? Changes in the relationship between attitude and behavior towards order delivery by drone. <i>Technological Forecasting and Social Change</i> , 2021, 169, 120829.	6.2	54
1116	No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not. <i>PLoS ONE</i> , 2021, 16, e0256035.	1.1	1
1117	A Large-Scale COVID-19 Twitter Chatter Dataset for Open Scientific Research – An International Collaboration. <i>Epidemiologia</i> , 2021, 2, 315-324.	1.1	163
1118	Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies. <i>Microbial Pathogenesis</i> , 2021, 157, 104933.	1.3	6
1119	Combating the progression of novel coronavirus SARS-CoV-2 infectious Disease: Current state and future prospects in molecular diagnostic and drug discovery. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	6
1120	New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE) Tj ETQq1 1 0.784314rgBT /@verlock 10	1.4	10
1121	A computational analysis of molecular evolution for virulence genes of zoonotic novel coronavirus (COVID-19). <i>Computational Biology and Chemistry</i> , 2021, 93, 107532.	1.1	1
1122	Viscometric and FTIR studies of chloroquine phosphate, acefylline piperazine and gentamicin sulfate in aqueous-polyethylene glycol and aqueous-polyvinyl pyrrolidone at different temperatures. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103265.	2.3	2
1123	Computational study for identifying promising therapeutic agents of hydroxychloroquine analogues against SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 11822-11836.	2.0	4
1125	COVID-19 pneumonia with ARDS and secondary haemophagocytic lymphohistiocytosis: a case report. <i>The European Research Journal</i> , 0, , .	0.1	0
1126	An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks. <i>Pathogens</i> , 2021, 10, 1108.	1.2	14
1127	COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges. <i>World Journal of Clinical Cases</i> , 2021, 9, 6178-6200.	0.3	24

#	ARTICLE	IF	CITATIONS
1128	The Impact of Deranged Glucose Metabolism and Diabetes in The Pathogenesis and Prognosis of The Novel Sars-Cov-2: A Systematic Review of Literature. <i>Current Diabetes Reviews</i> , 2021, 17, .	0.6	1
1129	The Promising Enzymes for Inhibitors Development against COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, .	1.1	0
1130	A Comprehensive Review of the Management of Pregnant Women with COVID-19: Useful Information for Obstetricians. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3363-3378.	1.1	8
1131	Does compliance with the preventive health behaviours against COVID-19 mitigate the effects of depression, anxiety and stress? (<i>¿Cumplir con los comportamientos preventivos de salud contra el</i> <i>Tj ETQq1 10,784314,rgBT /O</i> <i>42, 652-676.</i>	0,1	5
1132	Detecting Novel Ototoxins and Potentiation of Ototoxicity by Disease Settings. <i>Frontiers in Neurology</i> , 2021, 12, 725566.	1.1	14
1133	Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications. <i>Precision Clinical Medicine</i> , 2021, 4, 215-230.	1.3	3
1134	New chalcone derivatives as effective against SARS-CoV-2 agent. <i>International Journal of Clinical Practice</i> , 2021, 75, e14846.	0.8	20
1135	Medical education and COVID-19 pandemic: a crisis management model towards an evolutionary pathway. <i>Education and Information Technologies</i> , 2022, 27, 3299-3320.	3.5	17
1136	Greek population's perceptions of nonpharmacological interventions towards the first wave of COVID-19 pandemic mitigation: A regressionbased association analysis. <i>Pneumon</i> , 2021, , .	0.6	1
1137	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A meta-review of systematic reviews and an updated meta-analysis. <i>Travel Medicine and Infectious Disease</i> , 2021, 43, 102135.	1.5	16
1138	Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103315.	2.3	48
1139	COVID-19 epidemiological, sociological and anthropological investigation: study protocol for a multidisciplinary mixed methods research in Burkina Faso. <i>BMC Infectious Diseases</i> , 2021, 21, 896.	1.3	5
1140	Study of Post-COVID-19 Syndrome in Saudi Arabia. <i>Cureus</i> , 2021, 13, e17787.	0.2	11
1141	Coronavirus disease 2019 (COVID-19): Biophysical and biochemical aspects of SARS-CoV-2 and general characteristics. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 164, 3-18.	1.4	8
1142	Curcumin Extraction, Isolation, Quantification and Its Application in Functional Foods: A Review With a Focus on Immune Enhancement Activities and COVID-19. <i>Frontiers in Nutrition</i> , 2021, 8, 747956.	1.6	26
1144	A Nonclinical Spectroscopic Approach for Diagnosing Covid-19: A Concise Perspective. <i>Journal of Applied Spectroscopy</i> , 2021, 88, 765-771.	0.3	3
1145	Coevolution of COVID-19 research and China's policies. <i>Health Research Policy and Systems</i> , 2021, 19, 121.	1.1	7
1146	Drug repurposing against coronavirus disease 2019 (COVID-19): A review. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 683-690.	2.4	14

#	ARTICLE	IF	CITATIONS
1147	New \pm -Hydrazinophosphonic acid: Synthesis, characterization, DFT study and in silico prediction of its potential inhibition of SARS-CoV-2 main protease. <i>Journal of Molecular Structure</i> , 2021, 1239, 130480.	1.8	45
1148	Potential association of COVID-19 and ABO blood group: An Indian study. <i>Microbial Pathogenesis</i> , 2021, 158, 105008.	1.3	9
1149	ANFIS for prediction of epidemic peak and infected cases for COVID-19 in India. <i>Neural Computing and Applications</i> , 2023, 35, 7207-7220.	3.2	10
1150	Innate immunity, inflammation activation and heat-shock protein in COVID-19 pathogenesis. <i>Journal of Neuroimmunology</i> , 2021, 358, 577632.	1.1	13
1151	The Role of Nanotechnology in Antiviral Regime: An Overview. <i>Nano LIFE</i> , 0, , 2130011.	0.6	1
1152	<i>In Vitro</i> Evaluation of Anti-Lung Cancer and Anti-COVID-19 Effects using Fermented Black Color Ginseng Extract. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110343.	0.2	3
1153	Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-18.	2.0	6
1154	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. <i>Animal Diseases</i> , 2021, 1, 15.	0.6	4
1155	Computational approach towards the design of artemisinin-thymoquinone hybrids against main protease of SARS-COV-2. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 185.	1.1	8
1156	Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19. <i>Current Stem Cell Research and Therapy</i> , 2022, 17, 166-185.	0.6	5
1158	Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19. <i>Clinical Pharmacology: Advances and Applications</i> , 2021, Volume 13, 185-195.	0.8	3
1159	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 708848.	2.2	7
1160	Inhibition of Autophagy Suppresses SARS-CoV-2 Replication and Ameliorates Pneumonia in hACE2 Transgenic Mice and Xenografted Human Lung Tissues. <i>Journal of Virology</i> , 2021, 95, e0153721.	1.5	38
1161	Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5597-5606.	0.8	10
1162	A review on the COVID-19, its history, diagnostic approaches, role of herbs and current world scenario. <i>Biomedicine (India)</i> , 2021, 41, .	0.1	2
1163	Docking, Binding Free Energy Estimation, and MD Simulation of Newly Designed CQ and HCQ Analogues Against the Spike-ACE2 Complex of SARS-CoV-2. <i>International Journal of Quantitative Structure-Property Relationships</i> , 2021, 6, 77-89.	1.1	0
1164	Endocytosis of abiotic nanomaterials and nanobiovectors: Inhibition of membrane trafficking. <i>Nano Today</i> , 2021, 40, 101279.	6.2	69
1165	Scoping insight on antiviral drugs against COVID-19. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103385.	2.3	5

#	ARTICLE	IF	CITATIONS
1166	COVID-19 challenges and its therapeutics. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112015.	2.5	59
1167	A Combined Molecular Docking and Density Functional Theory Nuclear Magnetic Resonance Study of Trans-Dehydrocrotonin Interacting with COVID-19 Main Protease and Severe Acute Respiratory Syndrome Coronavirus 2 3C-Like Protease. <i>Journal of Nanoscience and Nanotechnology</i> , 2021, 21, 5399-5407.	0.9	1
1168	Synthesis, crystal structure, computational study and anti-virus effect of mixed ligand copper (II) complex with ONS donor Schiff base and 1, 10-phenanthroline. <i>Journal of Molecular Structure</i> , 2021, 1246, 131246.	1.8	31
1169	Encapsulated hydroxychloroquine and chloroquine into cyclic oligosaccharides are the potential therapeutics for COVID-19: insights from first-principles calculations. <i>Journal of Molecular Structure</i> , 2022, 1247, 131371.	1.8	12
1170	Reflections on COVID-19, Insurance, Business Interruption, Systemic Risk, and the Future. <i>Revista Icade Revista De Las Facultades De Derecho Y Ciencias Económicas Y Empresariales</i> , 2021, , .	0.2	4
1171	Potential Nanospray Inhalation of Remdesivir and Hydroxychloroquine using Poly (lactic-co-glycolic) Acid as Fast Delivery for Covid-19 Treatment.. <i>Journal of Pharmacy</i> , 2021, 1, 34-44.	0.5	4
1172	Computational Modeling of Chloroquine Analogues for Development of Drugs Against Novel Coronavirus (nCoV). <i>Methods in Pharmacology and Toxicology</i> , 2021, , 579-614.	0.1	1
1173	Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications. <i>Frontiers in Pharmacology</i> , 2020, 11, 582154.	1.6	23
1174	Mechanistic modeling of the SARS-CoV-2 disease map. <i>BioData Mining</i> , 2021, 14, 5.	2.2	11
1175	Normalizing images is good to improve computer-assisted COVID-19 diagnosis. , 2021, , 51-62.		4
1176	Experimental Pharmacotherapy for COVID-19: The Latest Advances. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 1-13.	1.5	22
1177	Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection. <i>Asian Journal of Chemistry</i> , 2021, 33, 1718-1722.	0.1	2
1178	COVID-19 Pandemic, Part II: What to Do and Who Is to Blame? Viruses as Part of a Necessary Ecosystem, Possible Prophylactic Medication, Immunity. <i>Voice of the Publisher</i> , 2021, 07, 98-116.	0.0	2
1179	Aspects of epidemiology, pathology, virology, immunology, transmission, prevention, prognosis, diagnosis, and treatment of COVID-19 Pandemic: A narrative review. <i>International Journal of Preventive Medicine</i> , 2021, 12, 38.	0.2	7
1180	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. <i>Internal and Emergency Medicine</i> , 2021, 16, 281-308.	1.0	46
1181	COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. <i>Molecular Pharmaceutics</i> , 2021, 18, 754-771.	2.3	193
1182	Stress of COVID-19 and mental health outcomes in Palestine: the mediating role of well-being and resilience. <i>Health Psychology Report</i> , 2021, 9, 398-410.	0.5	31
1183	Synthesis of Copper(II) Coordination Complex, Its Molecular Docking and Computational Exploration for Novel Functional Properties: A Dual Approach. <i>ChemistrySelect</i> , 2021, 6, 738-745.	0.7	15

#	ARTICLE	IF	CITATIONS
1185	Flavonoids of <i>Salvadora persica</i> L. (meswak) and its liposomal formulation as a potential inhibitor of SARS-CoV-2. RSC Advances, 2021, 11, 13537-13544.	1.7	13
1186	Review and Commentary on: 'Deploying an Artificial Intelligence System for COVID-19 Testing at the Greek Border'. SSRN Electronic Journal, 0, , .	0.4	0
1187	Research Progress on the Mechanism of COVID-19 Complicated with Renal Injury. Advances in Clinical Medicine, 2021, 11, 1585-1591.	0.0	0
1188	SARS-COV-2: IMMUNE RESPONSE, STRUCTURAL CHANGES, TREATMENT STRATEGIES. Ekologiya Cheloveka (Human Ecology), 2021, 28, 4-10.	0.2	4
1189	Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. Biomolecules, 2021, 11, 196.	1.8	4
1190	Hydroxychloroquine and chloroquine in prophylaxis and treatment of COVID-19: What is known?. Journal of Pharmacy and Bioallied Sciences, 2021, 13, 4.	0.2	1
1191	COVID-19 preventive behaviors and influencing factors in the Iranian population; a web-based survey. BMC Public Health, 2021, 21, 143.	1.2	38
1192	High SARS-CoV-2 load in the nasopharynx of patients with a mild form of COVID-19 is associated with clinical deterioration regardless of the hydroxychloroquine administration. PLoS ONE, 2021, 16, e0246396.	1.1	4
1193	Spectroscopic Investigations, Computational Analysis and Molecular Docking to SAR-Cov-2 Targets Studies of 5,8-Quinolinedione Attached to Betulin Derivatives. Crystals, 2021, 11, 76.	1.0	5
1194	Image analysis and data processing for COVID-19. , 2021, , 413-427.		2
1195	Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?. Tuberculosis and Respiratory Diseases, 2021, 84, 22-34.	0.7	14
1196	Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets. Molecules, 2021, 26, 632.	1.7	22
1197	Recent progress in the development of potential drugs against SARS-CoV-2. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100057.	1.7	7
1198	COVID-19: Virology, Epidemiology, Diagnostics and Predictive Modeling. Algorithms for Intelligent Systems, 2021, , 163-205.	0.5	0
1199	Emerging insights on the role of V‑ATPase in human diseases: Therapeutic challenges and opportunities. Medicinal Research Reviews, 2021, 41, 1927-1964.	5.0	16
1200	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Molecular Biomedicine, 2021, 2, 1.	1.7	20
1201	Exploring synthetic and therapeutic prospects of new thiazoline derivatives as aldose reductase (ALR2) inhibitors. RSC Advances, 2021, 11, 17259-17282.	1.7	7
1202	Emerging Technologies for the Treatment of COVID-19. Advances in Experimental Medicine and Biology, 2021, 1321, 81-96.	0.8	3

#	ARTICLE	IF	CITATIONS
1203	Flattening the curves: on-off lock-down strategies for COVID-19 with an application to Brazil. <i>Journal of Mathematics in Industry</i> , 2021, 11, 2.	0.7	18
1204	Metal-free synthesis of quinoline-2,4-dicarboxylate derivatives using aryl amines and acetylenedicarboxylates through a pseudo three-component reaction. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 7041-7050.	1.5	5
1205	Indicator Regularized Non-Negative Matrix Factorization Method-Based Drug Repurposing for COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 603615.	2.2	45
1206	Advancements in research and development to combat COVID-19 using nanotechnology. <i>Nanotechnology for Environmental Engineering</i> , 2021, 6, 1.	2.0	58
1207	The journey of antimalarial drugs against SARS-CoV-2: Review article. <i>Informatics in Medicine Unlocked</i> , 2021, 24, 100604.	1.9	25
1208	MEMS Sensors for Diagnostics and Treatment in the Fight Against COVID-19 and Other Pandemics. <i>IEEE Access</i> , 2021, 9, 61123-61149.	2.6	18
1209	Pneumonia Classification Using Deep Learning from Chest X-ray Images During COVID-19. <i>Cognitive Computation</i> , 2021, , 1-13.	3.6	160
1210	Potential Shortages of Hydroxychloroquine for Patients with Lupus During the Coronavirus Disease 2019 Pandemic. <i>JAMA Health Forum</i> , 2020, 1, e200438.	1.0	37
1211	Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?. <i>International Journal of Health Planning and Management</i> , 2020, 35, 1311-1313.	0.7	2
1212	COVID-19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019-nCoV disease. <i>Journal of Cellular Physiology</i> , 2020, 235, 8873-8924.	2.0	51
1213	Severe SARS-CoV-2 pneumonia in a 58-year-old patient with HIV: a clinical case report from the Republic of Cyprus. <i>Journal of Medical Virology</i> , 2020, 92, 2361-2365.	2.5	14
1214	Therapeutic approaches against coronaviruses acute respiratory syndrome. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00691.	1.1	7
1215	Differential Diagnosis and Possible Therapeutics for Coronavirus Disease 2019. <i>Medical Virology</i> , 2020, , 51-71.	2.1	3
1216	Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. <i>Bioorganic Chemistry</i> , 2020, 104, 104269.	2.0	74
1217	Review of trials currently testing treatment and prevention of COVID-19. <i>Clinical Microbiology and Infection</i> , 2020, 26, 988-998.	2.8	83
1218	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 641-648.	1.8	142
1219	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 105949.	1.1	3,955
1220	A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106028.	1.1	88

#	ARTICLE	IF	CITATIONS
1221	Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2020, 101, 283-289.	1.5	33
1222	Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 579-586.	0.6	30
1223	Hydroxychloroquine as antiviral prophylaxis for exposed caregivers to Covid-19: An urgent appraisal is needed. <i>Journal of Infection and Public Health</i> , 2020, 13, 865-867.	1.9	10
1224	A new approach for COVID-19 treatment by micro-RNA. <i>Medical Hypotheses</i> , 2020, 143, 110203.	0.8	36
1225	Diagnostic approaches and potential therapeutic options for coronavirus disease 2019. <i>New Microbes and New Infections</i> , 2020, 38, 100770.	0.8	12
1226	Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. <i>Therapie</i> , 2020, 75, 363-370.	0.6	37
1227	Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19. <i>Virus Research</i> , 2020, 289, 198146.	1.1	37
1229	Chloroquine hype is derailing the search for coronavirus treatments. <i>Nature</i> , 2020, 580, 573-573.	13.7	31
1230	SARS-CoV-2/COVID-19: Evidence-Based Recommendations on Diagnosis and Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 491-498.	0.8	13
1231	In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 3747-3759.	2.0	50
1232	Treatments in the COVID-19 pandemic: an update on clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 81-88.	1.0	11
1233	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1009-1027.	2.0	23
1234	Natural history of COVID-19 and therapeutic options. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1159-1184.	1.3	101
1235	Plant Cell and Callus Cultures as an Alternative Source of Bioactive Compounds with Therapeutic Potential against Coronavirus Disease (COVID-19). <i>IOP Conference Series: Earth and Environmental Science</i> , 2020, 596, 012099.	0.2	7
1236	Coronavirus disease 2019 in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 297-306.	1.4	59
1237	Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. <i>Rheumatology</i> , 2021, 60, 3222-3234.	0.9	20
1238	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). <i>Critical Care Medicine</i> , 2020, 48, e440-e469.	0.4	816
1239	Hydroxychloroquine and COVID-19: Lack of Efficacy and the Social Construction of Plausibility. <i>American Journal of Therapeutics</i> , 2020, 27, e573-e583.	0.5	4

#	ARTICLE	IF	CITATIONS
1240	Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?. Journal of Pediatric Hematology/Oncology, 2021, 43, 35-36.	0.3	3
1241	Current drugs with potential for coronavirus disease 2019 therapy: a literature review. Reviews in Medical Microbiology, 2022, 33, e148-e160.	0.4	3
1291	Repositioning PARP inhibitors for SARS-CoV-2 infection(COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?. British Journal of Pharmacology, 2020, 177, 3635-3645.	2.7	52
1292	Coronavirus disease (COVID -19): An updated review based on current knowledge and existing literature for dermatologists. Dermatologic Therapy, 2020, 33, e13677.	0.8	18
1293	A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS Journal, 2020, 287, 3633-3650.	2.2	192
1294	<scp>COVID-SAFER</scp>: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. Journal of the American Geriatrics Society, 2020, 68, 1636-1646.	1.3	29
1295	COVID-19 and lung cancer: risks, mechanisms and treatment interactions. , 2020, 8, e000892.		43
1296	Manipulation of ACE2 expression in COVID-19. Open Heart, 2020, 7, e001424.	0.9	55
1297	COVID-19 infection during autoimmune disease: study of 2 cases in Republic of Guinea. Pan African Medical Journal, 2020, 35, 96.	0.3	3
1298	Therapeutic interventions for COVID-19: a living overview of reviews. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662097602.	1.0	8
1299	Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an<i>in silico</i>perspective. Antiviral Chemistry and Chemotherapy, 2020, 28, 204020662098407.	0.3	26
1300	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Research and Therapy, 2020, 22, 290.	1.6	37
1301	Therapeutic strategies for critically ill patients with COVID-19. Annals of Intensive Care, 2020, 10, 45.	2.2	100
1302	Battling COVID-19: using old weapons for a new enemy. Tropical Diseases, Travel Medicine and Vaccines, 2020, 6, 6.	0.9	20
1303	Third Cranial Nerve Palsy Presenting with Unilateral Diplopia and Strabismus in a 24-Year-Old Woman with COVID-19. American Journal of Case Reports, 2020, 21, e925897.	0.3	48
1304	Over view for the truth of COVID -19 pandemic: A guide for the Pathologists, Health care workers and communityâ€™. Pakistan Journal of Medical Sciences, 2020, 36, S111-S114.	0.3	8
1305	Case Report: Use of hydroxychloroquine and N-acetylcysteine for treatment of a COVID-19 patient. F1000Research, 0, 9, 491.	0.8	5
1306	Medical research during the COVID-19 pandemic. World Journal of Clinical Cases, 2020, 8, 3156-3163.	0.3	14

#	ARTICLE	IF	CITATIONS
1307	Special features of SARS-CoV-2 in daily practice. <i>World Journal of Clinical Cases</i> , 2020, 8, 3920-3933.	0.3	48
1308	Virus load and virus shedding of SARS-CoV-2 and their impact on patient outcomes. <i>World Journal of Clinical Cases</i> , 2020, 8, 6252-6263.	0.3	6
1309	Antiviral treatment of COVID-19: a clinical pharmacology narrative review. <i>Medical Journal of Indonesia</i> , 2020, 29, 332-45.	0.2	8
1310	The first wave of COVID-19 in Malta; a national cross-sectional study. <i>PLoS ONE</i> , 2020, 15, e0239389.	1.1	13
1311	Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking. <i>PLoS ONE</i> , 2020, 15, e0241543.	1.1	52
1312	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). <i>PLoS ONE</i> , 2020, 15, e0242763.	1.1	65
1313	The transcriptomic profiling of SARS-CoV-2 compared to SARS, MERS, EBOV, and H1N1. <i>PLoS ONE</i> , 2020, 15, e0243270.	1.1	27
1314	Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients. <i>PLoS ONE</i> , 2020, 15, e0243598.	1.1	1
1315	Manufacturing of convalescent plasma of COVID-19 patients: Aspects of quality. <i>PLoS ONE</i> , 2020, 15, e0243967.	1.1	11
1316	The hallmarks of COVID-19 disease. <i>PLoS Pathogens</i> , 2020, 16, e1008536.	2.1	342
1317	CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST'S THOUGHTS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2020, 58, 123-132.	0.2	43
1318	COVID-19: the new challenge for rheumatologists. <i>Sovremennaya Revmatologiya</i> , 2020, 14, 110-116.	0.1	2
1319	Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor- κ B pathways in non-pregnant and pregnant populations. <i>Cellular and Molecular Biology</i> , 2020, 66, 221-229.	0.3	4
1320	COVID-19, Modern Pandemic: A Systematic Review From Front-Line Health Care Providers' Perspective. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 215-229.	0.6	36
1321	COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 352-361.	0.6	86
1322	Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 483-491.	0.6	11
1323	Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 463-471.	0.6	5
1324	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 604-611.	0.6	7

#	ARTICLE	IF	CITATIONS
1325	An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2020, 31, .	0.7	12
1326	Dynamic analysis of the mathematical model of COVID-19 with demographic effects. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2020, 75, 389-396.	0.6	23
1327	COVID-19 therapy and prevention. <i>Discoveries</i> , 2020, 8, e113.	1.5	4
1328	COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. <i>Discoveries</i> , 2020, 8, e108.	1.5	34
1329	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. <i>EMBO Molecular Medicine</i> , 2021, 13, e13105.	3.3	62
1330	Sustainable Post Covid19 Lockdown Strategy Through Evidence-Based Policy. <i>Integrative Journal of Medical Sciences</i> , 0, 7, .	0.0	6
1331	Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19. <i>International Heart Journal</i> , 2020, 61, 1056-1058.	0.5	9
1332	Saudi Society of Maternal-Fetal Medicine guidance on pregnancy and coronavirus disease 2019. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2020, 41, 779-790.	0.5	8
1334	The comparison of the effectiveness of lincocin® and azitro® in the treatment of covid-19-associated pneumonia: A prospective study. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2020, 27, e5-e10.	1.9	11
1335	Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2020, 27, e14-e25.	1.9	5
1336	COVID-19: etiology, clinical picture, treatment. <i>Russian Journal of Infection and Immunity</i> , 2020, 10, 421-445.	0.2	36
1337	Innate immunity in coronavirus infection. <i>Russian Journal of Infection and Immunity</i> , 2020, 10, 259-268.	0.2	20
1338	Some opportunities for immunotherapy in coronavirus infection. <i>Russian Journal of Infection and Immunity</i> , 2020, 10, 446-458.	0.2	13
1339	COVID-19: therapeutic approaches description and discussion. <i>Anais Da Academia Brasileira De Ciencias</i> , 2020, 92, e20200466.	0.3	9
1340	COVID-19 in Brazil: advantages of a socialized unified health system and preparation to contain cases. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2020, 53, e20200167.	0.4	145
1341	COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2020, 115, e200254.	0.8	26
1342	Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática. <i>Ciencia E Saude Coletiva</i> , 2020, 25, 3517-3554.	0.1	2
1343	Fighting COVID-19. <i>Brazilian Journal of Biology</i> , 2020, 80, 698-701.	0.4	11

#	ARTICLE	IF	CITATIONS
1344	What do we know about COVID-19? A review article. Revista Da Associação Médica Brasileira, 2020, 66, 534-540.	0.3	17
1345	Sars-CoV-2: A clinical update - II. Revista Da Associação Médica Brasileira, 2020, 66, 547-557.	0.3	23
1346	Biological and social aspects of Coronavirus Disease 2019 (COVID-19) related to oral health. Brazilian Oral Research, 2020, 34, e041.	0.6	67
1348	COVID-19: Critical discussion on the applications and implications of chemicals in sanitizers and disinfectants. EXCLI Journal, 2020, 19, 785-799.	0.5	28
1349	Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020. EXCLI Journal, 2020, 19, 992-1016.	0.5	25
1350	Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome – Clearing Safety Issues and Good Clinical Practice. European Endocrinology, 2020, 16, 109.	0.8	4
1351	Chloroquine and Hydroxychloroquine in SARS-Cov-2. Repurposing the old drugs against today's deadly disease. Journal of Pharmaceutical and Biological Sciences, 2020, 8, 1-6.	0.2	2
1352	COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biology and Medicine, 2020, 17, 519-527.	1.4	135
1357	A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19. Annals of Translational Medicine, 2020, 8, 1686-1686.	0.7	6
1363	Need for Abundant Caution in Prophylactic Application of Chloroquine and Hydroxychloroquine for Viral Infections Including COVID-19: Possibility of Increased Susceptibility. SSRN Electronic Journal, 0, , .	0.4	2
1364	COVID-19: Potential of Microalgae Derived Natural Astaxanthin As Adjunctive Supplement in Alleviating Cytokine Storm. SSRN Electronic Journal, 0, , .	0.4	27
1366	<p>>An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease</p>>. Clinical Pharmacology: Advances and Applications, 2020, Volume 12, 203-212.	0.8	7
1367	Volumetric Absorptive Microsampling as a Sampling Alternative in Clinical Trials and Therapeutic Drug Monitoring During the COVID-19 Pandemic: A Review. Drug Design, Development and Therapy, 2020, Volume 14, 5757-5771.	2.0	21
1368	Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment. Anadolu Kliniği Tıp Bilimleri Dergisi, 0, , 204-215.	0.1	4
1369	Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed. Current Medicinal Chemistry, 2021, 28, 2392-2408.	1.2	13
1370	The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. Current Pharmaceutical Design, 2020, 26, 4467-4485.	0.9	34
1371	Recent Advances in Transition Metal Free Synthetic Protocols for Quinoline Derivatives. Current Organic Chemistry, 2020, 24, 1815-1852.	0.9	8
1372	Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19. Current Drug Targets, 2020, 21, 1703-1721.	1.0	9

#	ARTICLE	IF	CITATIONS
1373	COVID-19 Pandemic and the Impact on the Cardiovascular Disease Patient Care. <i>Current Cardiology Reviews</i> , 2020, 16, 173-177.	0.6	10
1374	Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19199.	1.2	36
1375	No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19. <i>Jmirx Med</i> , 2020, 1, e19583.	0.2	6
1376	Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. <i>Journal of Medical Internet Research</i> , 2020, 22, e21758.	2.1	14
1378	SARS-CoV-2 / COVID-19 and its Transmission, Prevention, Treatment and Control - An Update. <i>Journal of Pure and Applied Microbiology</i> , 2020, 14, 945-956.	0.3	2
1379	Current Clinical Trials and Vaccine Development Strategies for Corona Virus Disease (COVID-19). <i>Journal of Pure and Applied Microbiology</i> , 2020, 14, 979-988.	0.3	1
1380	In silico Study of Pharmacological Treatments against SARS-CoV2 Main Protease. <i>Journal of Pure and Applied Microbiology</i> , 2020, 14, 1065-1071.	0.3	4
1381	Repurposing of drugs for COVID-19: a systematic review and meta-analysis. <i>Panminerva Medica</i> , 2022, 64, .	0.2	8
1382	Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications. <i>Acta Biomedica</i> , 2020, 91, 150-168.	0.2	18
1383	Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report. <i>Acta Biomedica</i> , 2020, 91, e2020123.	0.2	4
1384	Cardiovascular impact of COVID-19: an array of presentations. <i>Acta Biomedica</i> , 2021, 92, e2021021.	0.2	3
1386	COVID-19 Pandemisine Pediatrik Yaklaşım. <i>Turkish Journal of Diabetes and Obesity</i> , 2020, 4, 170-176.	0.0	3
1387	Drug Repositioning for COVID-19. <i>Colombia Medica</i> , 2020, 51, e4279.	0.7	5
1388	Chloroquine and Hydroxychloroquine Toxicity. <i>American Journal of Ophthalmic Clinical Trials</i> , 0, 2, 8.	0.0	4
1389	Coronavirus: Hotspot on coronavirus disease 2019 in India. <i>Indian Journal of Medical Sciences</i> , 0, 72, 29-34.	0.1	16
1393	Novel Coronavirus Disease 2019 (COVID-19): An Emerging Infectious Disease in the 21st Century. <i>Iranian South Medical Journal</i> , 2020, 22, 432-450.	0.2	64
1394	COVID-19 Outbreak and Perspective in Morocco. <i>Electronic Journal of General Medicine</i> , 2020, 17, em204.	0.3	32
1395	Chloroquine and COVID-19: A Light at the End of the Tunnel, or is it Another Train?. <i>Electronic Journal of General Medicine</i> , 2020, 17, em207.	0.3	8

#	ARTICLE	IF	CITATIONS
1396	A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?. <i>Electronic Journal of General Medicine</i> , 2020, 17, em251.	0.3	12
1397	Pharmacological treatment of COVID-19: an update. <i>Journal of Global Health Reports</i> , 0, , .	1.0	2
1398	The Battle Against COVID-19: Where Do We Stand Now?. <i>Iranian Journal of Medical Sciences</i> , 2020, 45, 81-82.	0.3	31
1399	Idiosyncrasies of COVID-19; A Review. <i>Iranian Journal of Medical Microbiology</i> , 2020, 14, 290-296.	0.1	2
1400	COVID-19 Tragic Pandemic: Concerns over Unintentional "Directed Accelerated Evolution" of Novel Coronavirus (SARS-CoV-2) and Introducing a Modified Treatment Method for ARDS. <i>Journal of Biomedical Physics and Engineering</i> , 2020, 10, 241-246.	0.5	45
1401	COVID-19 and Substance Use Disorders as Brain Diseases: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper. <i>Basic and Clinical Neuroscience</i> , 2020, 11, 133-150.	0.3	74
1402	Potential Inhibitory Effect of Vitamins Against COVID-19. <i>Computers, Materials and Continua</i> , 2020, 66, 707-714.	1.5	8
1403	The third coronavirus epidemic in the third millennium: what's next?. <i>Croatian Medical Journal</i> , 2020, 61, 1-4.	0.2	36
1404	Molecular Docking Evaluation of Some Indonesian's Popular Herbals for a Possible COVID-19 Treatment. <i>Biointerface Research in Applied Chemistry</i> , 2020, 11, 9827-9835.	1.0	7
1405	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <i>Frontiers in Pharmacology</i> , 2020, 11, 597985.	1.6	25
1406	Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System. <i>Biomedicines</i> , 2021, 9, 11.	1.4	8
1407	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9775.	1.8	40
1408	Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101069.	0.9	86
1409	Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community. <i>Research</i> , 2020, 2020, 6925296.	2.8	26
1411	Acute kidney injury in COVID-19; a review on current knowledge. <i>Journal of Nephropathology</i> , 2020, 9, e31-e31.	0.1	13
1412	Novel Coronavirus (COVID-19): A New Emerging Pandemic Threat. <i>Journal of Research in Clinical Medicine</i> , 2020, 8, 5-5.	0.3	18
1415	Coronavirus disease 2019 (COVID-19): research progress and clinical practice. <i>Global Health & Medicine</i> , 2020, 2, 78-88.	0.6	16
1416	O Efeito da Doena de Coronavrus 2019 nas Doenas Cardiovasculares. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 114, 817-822.	0.3	29

#	ARTICLE	IF	CITATIONS
1417	C�ncncr e Doen�sas Cardiovasculares na Pandemia de COVID-19. Arquivos Brasileiros De Cardiologia, 2020, 115, 547-557.	0.3	5
1419	COVID-19 in a liver transplant recipient: Could iatrogenic immunosuppression have prevented severe pneumonia? A case report. World Journal of Gastroenterology, 2020, 26, 7076-7084.	1.4	11
1420	Hydroxychloroquine And Azithromycin As A Treatment Of Covid- 19: Electrocardiogram Variability. Journal of the Saudi Heart Association, 2020, 32, 350-357.	0.2	4
1421	Knowledge, attitude, and perception of University students toward COVID-19 Pandemic. Pakistan Journal of Surgery and Medicine, 2020, 1, e148.	0.4	3
1422	Cov�d-19 Salg�n�nda Ya�yanan Haftal�k Duygusal De�yi�imler: T�rkiye �rne�i. Ekonomi ��letme Ve Maliye Ara�t�rma Dergisi, 0, , 280-304.	0.5	7
1423	The novel zoonotic COVID-19 pandemic: An expected global health concern. Journal of Infection in Developing Countries, 2020, 14, 254-264.	0.5	180
1424	Knowledge, behavior and precautionary measures related to COVID-19 pandemic among the general public of Punjab province, Pakistan. Journal of Infection in Developing Countries, 2020, 14, 823-835.	0.5	31
1425	Repurposing current therapeutic regimens against SARS-CoV-2 (Review). Experimental and Therapeutic Medicine, 2020, 20, 1845-1855.	0.8	8
1426	Towards a more effective strategy for COVID�19 prevention (Review). Experimental and Therapeutic Medicine, 2020, 21, 1-1.	0.8	4
1427	Comprehensive analysis of drugs to treat SARS�CoV�2 infection: Mechanistic insights into current COVID�19 therapies (Review). International Journal of Molecular Medicine, 2020, 46, 467-488.	1.8	116
1428	Clinical and Epidemiological Characteristics of Coronavirus Disease 2019 in the Early Stage of Outbreak. Korean Journal of Medicine, 2020, 95, 67-73.	0.1	24
1429	Insights of Novel Coronavirus (SARS-CoV-2) disease outbreak, management and treatment. AIMS Microbiology, 2020, 7, 183-203.	1.0	6
1430	Interim Guidelines on Antiviral Therapy for COVID-19. Infection and Chemotherapy, 2020, 52, 281.	1.0	29
1431	COVID-19 and the kidney. Cleveland Clinic Journal of Medicine, 2020, 87, 619-631.	0.6	52
1432	Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). Journal of Microbiology and Biotechnology, 2020, 30, 313-324.	0.9	709
1433	COVID-19: general overview, pharmacological options and ventilatory support strategies. Multidisciplinary Respiratory Medicine, 2020, 15, 708.	0.6	2
1434	COVID-19 pneumonia in an Iraqi pregnant woman with preterm delivery. Asian Pacific Journal of Reproduction, 2020, 9, 156.	0.2	27
1435	Novel coronavirus pandemic: A global health threat. Turkish Journal of Emergency Medicine, 2020, 20, 55.	0.3	30

#	ARTICLE	IF	CITATIONS
1436	Hospital preparedness and management of pediatric population during COVID-19 outbreak. <i>Annals of Thoracic Medicine</i> , 2020, 15, 107.	0.7	12
1437	Chloroquine: Can it be a Novel Drug for COVID-19. <i>International Journal of Applied & Basic Medical Research</i> , 2020, 10, 128-130.	0.2	11
1438	Clinical management of COVID-19. <i>Indian Journal of Medical Research</i> , 2020, 151, 401.	0.4	68
1439	COVID 19 and acute kidney injury. <i>Indian Journal of Nephrology</i> , 2020, 30, 161.	0.2	14
1440	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. <i>Indian Journal of Ophthalmology</i> , 2020, 68, 693.	0.5	78
1441	The 2019-2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: A joint american college of academic international medicine-world academic council of emergency medicine multidisciplinary COVID-19 working group consensus paper. <i>Journal of Global Infectious Diseases</i> , 2020, 12, 47.	0.2	270
1442	Therapeutic status of hydroxychloroquine in COVID-19: A review. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2020, 36, 160.	0.2	5
1443	The COVID-19 hydroxychloroquine prophylaxis perception of Indian anesthesiologists: A survey-based original article. <i>Journal of Anaesthesiology Clinical Pharmacology</i> , 2020, 36, 471.	0.2	3
1444	The saudi critical care society clinical practice guidelines on the management of COVID-19 patients in the intensive care unit. <i>Saudi Critical Care Journal</i> , 2020, 4, 27.	0.4	18
1445	Combating 2019-nCoV Amidst the Pandemic Scare. <i>Open Journal of Regenerative Medicine</i> , 2020, 09, 15-19.	0.5	3
1446	Perspectives on mesenchymal stem/progenitor cells and their derivatives as potential therapies for lung damage caused by COVID-19. <i>World Journal of Stem Cells</i> , 2020, 12, 1013-1022.	1.3	15
1447	A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19). <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 932-933.	0.6	23
1448	An Urgent Need for "Common Cold Units" to Study COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1152-1153.	0.6	2
1449	Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1184-1188.	0.6	109
1450	Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 73-76.	0.6	22
1451	Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies. <i>Medical Journal of the Islamic Republic of Iran</i> , 2020, 34, 171.	0.9	1
1452	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 1106-1113.	0.3	1
1453	A fragilidade do sistema de saúde brasileiro e a vulnerabilidade social diante da COVID-19. <i>Revista Brasileira Em Promoção Da Saúde</i> , 0, 33, 1-12.	0.1	4

#	ARTICLE	IF	CITATIONS
1454	Tratamento precoce para COVID-19 baseado em evidência científica. Revista Brasileira Em Promoção Da Saúde, 0, 33, 1-11.	0.1	2
1455	THE EPIDEMIOLOGICAL AND CLINICAL FEATURES OF COVID-19 AND LESSONS FROM THIS GLOBAL INFECTIOUS PUBLIC. , 2020, 01, 01-24.		7
1456	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. European Journal of Rheumatology, 2020, 7, S110-S116.	1.3	4
1457	COVID-19: An International Public Health Concern. Central Asian Journal of Global Health, 2020, 9, e466.	0.6	16
1458	COVID-19 compared to other epidemic coronavirus diseases and the flu. World Journal of Clinical Infectious Diseases, 2020, 10, 1-13.	0.5	8
1459	Post-transplant immunosuppression and COVID-19: From a double whammy to a mixed blessing. World Journal of Transplantation, 2020, 10, 267-276.	0.6	6
1460	COVID-19 and acute kidney injury. Tuberkuloz Ve Toraks, 2020, 68, 407-418.	0.2	30
1461	An overview of potential therapeutic agents to treat COVID-19. BioScience Trends, 2020, 14, 318-327.	1.1	5
1462	The Current Clinically Relevant Findings on COVID-19 Pandemic. Anesthesiology and Pain Medicine, 2020, 10, e103819.	0.5	45
1463	Is Coronavirus Disease 2019 (COVID-19) Associated with Renal Involvement? A Review of Century Infection. Jundishapur Journal of Microbiology, 2020, 13, .	0.2	14
1464	The Role of Autophagy in Respiratory Complications of COVID-19. Shiraz E Medical Journal, 2020, 21, .	0.1	5
1465	Evidence synthesis relevant to COVID-19: a protocol for multiple systematic reviews and overviews of systematic reviews. Medwave, 2020, 20, e7867-e7867.	0.2	33
1466	Recommendations from the Sociedade Portuguesa de Cuidados Intensivos and Infection & Sepsis Group for intensive care approach to COVID-19. Revista Brasileira De Terapia Intensiva, 2020, 32, 2-10.	0.1	12
1467	Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations. Journal of Medical Biochemistry, 2020, 39, 488-499.	0.7	6
1468	Pharmacologist's view of the new corona virus. Scripta Medica, 2020, 51, 6-8.	0.0	4
1469	COVID-19 Diagnostic and Management Protocol for Pediatric Patients. Clinics, 2020, 75, e1894.	0.6	64
1470	Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. Drugs in Context, 2020, 9, 1-14.	1.0	14
1471	Chloroquine and hydroxychloroquine in the context of COVID-19. Drugs in Context, 2020, 9, 1-8.	1.0	35

#	ARTICLE	IF	CITATIONS
1472	Pharmacological treatment of COVID-19: lights and shadows. <i>Drugs in Context</i> , 2020, 9, 1-11.	1.0	13
1473	Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2. <i>Cureus</i> , 2020, 12, e7386.	0.2	117
1474	Coronavirus Disease 2019 (COVID-19) in Children: Vulnerable or Spared? A Systematic Review. <i>Cureus</i> , 2020, 12, e8207.	0.2	26
1475	Acute Respiratory Failure Secondary to COVID-19 Viral Pneumonia Managed With Hydroxychloroquine/Azithromycin Treatment. <i>Cureus</i> , 2020, 12, e8268.	0.2	3
1476	Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications. <i>Cureus</i> , 2020, 12, e8750.	0.2	13
1477	Chloroquine and COVID-19 – a potential game changer?. <i>Clinical Medicine</i> , 2020, 20, 278-281.	0.8	19
1478	Optimizing the Use of Hydroxychloroquine in the Management of COVID-19 Given Its Pharmacological Profile. <i>Journal of Pharmaceutical Research International</i> , 0, , 29-43.	1.0	8
1479	An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100063.	1.7	7
1480	Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 103.	0.4	3
1481	Coronavirus Disease 2019 (COVID-19) and Pregnancy. <i>Biomedical and Pharmacology Journal</i> , 2021, 14, 1161-1174.	0.2	2
1482	A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. <i>Saudi Journal of Biological Sciences</i> , 2021, 29, 860-860.	1.8	5
1483	Potential Novel Thioether-Amide or Guanidine-Linker Class of SARS-CoV-2 Virus RNA-Dependent RNA Polymerase Inhibitors Identified by High-Throughput Virtual Screening Coupled to Free-Energy Calculations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11143.	1.8	11
1484	Impact of SARS-CoV-2 on pregnancy outcomes (Review). <i>Medicine International</i> , 2021, 1, .	0.2	0
1485	PABPC4 Broadly Inhibits Coronavirus Replication by Degrading Nucleocapsid Protein through Selective Autophagy. <i>Microbiology Spectrum</i> , 2021, 9, e0090821.	1.2	26
1486	Update on the COVID-19 Vaccine Research Trends: A Bibliometric Analysis. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 4237-4247.	1.1	17
1487	A Comprehensive Overview of the Newly Emerged COVID-19 Pandemic: Features, Origin, Genomics, Epidemiology, Treatment, and Prevention. <i>Biologics</i> , 2021, 1, 357-383.	2.3	8
1488	Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 155-160.	1.2	5
1489	Current treatment strategies for COVID-19 (Review). <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	19

#	ARTICLE	IF	CITATIONS
1490	Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. <i>Environmental Science and Pollution Research</i> , 2021, 28, 68071-68089.	2.7	15
1491	COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. <i>Open Rheumatology Journal</i> , 2021, 15, 69-76.	0.1	1
1492	COVID-19 Therapy: the Role of Antirheumatic Drugs. <i>Antibiotiki I Khimioterapiya</i> , 2021, 66, 83-89.	0.1	0
1493	Evaluation of Hospitalized Patient Outcomes in COVID-19 Infection for Continued versus Discontinued Use of Preadmission Antiplatelet Regimen. <i>Journal of Pharmacy Practice</i> , 2023, 36, 508-513.	0.5	0
1494	Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. <i>Advances in Rheumatology</i> , 2021, 61, 60.	0.8	5
1495	Deep Transfer Learning-Based COVID-19 Prediction Using Chest X-Rays. <i>Journal of Health Management</i> , 2021, 23, 730-746.	0.4	8
1496	Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment. <i>European Journal of Medicinal Chemistry Reports</i> , 2021, 3, 100013.	0.6	25
1497	The Potential Effectiveness of Acetazolamide in the Prevention of Acute Kidney Injury in COVID-19 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1498	COVID-19: Older drugs for a novel disease—Chloroquine, hydroxychloroquine, and possible Pentoxifylline—set to start the second innings?. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 2172.	0.3	2
1499	Anti-corona Drugs: Current scenario. <i>Indian Journal of Nephrology</i> , 2020, 30, 179.	0.2	0
1502	The Chemical Sciences' Advances on Coronavirus Disease 2019 (COVID-19). <i>Asian Journal of Organic & Medicinal Chemistry</i> , 2020, 5, 179-184.	0.1	0
1503	The COVID-19: Current understanding. <i>Veterinary World</i> , 2020, 13, 1998-2005.	0.7	0
1504	HYDROXYCHLOROQUINE IS NO MIRACLE CURE FOR COVID-19 INFECTION —IMAGING AND CLINICAL COURSE IN AN ELDERLY FEMALE. <i>Wiadomości Lekarskie</i> , 2020, 73, 1583-1585.	0.1	1
1505	Hydroxychloroquine and chloroquine for COVID-19 infection. Rapid systematic review. <i>Journal of Evidence-Based Healthcare</i> , 2020, 2, 74-92.	0.3	5
1507	Coronavirus Disease 2019 (COVID-19): Morocco Interrupting the Transmission by Ethics, Logistics, and Therapeutics Efforts. <i>Journal of Clinical and Experimental Investigations</i> , 2020, 11, em00743.	0.1	2
1510	Pathological Findings and Management of COVID-19 Patients: A Brief Overview of Modern-day Pandemic. <i>Cureus</i> , 2020, 12, e8136.	0.2	5
1514	Exploring pathophysiology of COVID-19 infection: Faux espoir and dormant therapeutic options. <i>International Journal of Clinical Virology</i> , 2020, 4, 034-040.	0.1	1
1517	Pharmacy and Therapeutics Committee Preparedness Plan for COVID-19. <i>Global Journal on Quality and Safety in Healthcare</i> , 2020, 3, 55-64.	0.1	3

#	ARTICLE	IF	CITATIONS
1519	A Silent Attacker SARS-CoV-2 - A Review. European Journal of Medical and Health Sciences, 2020, 2, .	0.1	0
1520	Janela de Oportunidade para a Imunomodulaç�o na COVID-19. Revista De Medicina Intern�f, Neurologie, Psiquiatria, Neurocirurgia, Dermato-venerologie Medicina Intern�f, 2020, 27, .	0.0	0
1525	Current Status of Treatment Options, Clinical Trials, and Vaccine Development for SARS-CoV-2 Infection. Journal of Pure and Applied Microbiology, 2020, 14, 733-740.	0.3	2
1527	COVID-19 in pregnancy: What do we really know?. F1000Research, 0, 9, 362.	0.8	6
1528	Hindistan'ın Coronavirus Salg�n� ile M�cadele Yolu. Online T�rk Saėil�k Bilimleri Dergisi, 0, , .	0.1	0
1534	A pandemic associated with novel coronavirus of probable animal origin. Research in Pharmacy and Health Sciences, 2020, 06, 121-125.	0.1	0
1535	Profil clinique, biologique et radiologique des patients Alg�riens hospitalis�s pour COVID-19: donn�es pr�liminaires. Pan African Medical Journal, 2020, 35, 77.	0.3	15
1536	Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. Drug Discoveries and Therapeutics, 2020, 14, 109-116.	0.6	4
1537	COVID-19 PANDEMIC â€“ A REVIEW WITH A DENTAL PERSPECTIVE. Cumhuriyet Dental Journal, 2020, 23, 240-247.	0.1	1
1539	As Drugs Assemble to Treat SARS-COV-2, Which Drug will Prove Efficacious : A Search for Suitable Drug or Vaccine to Manage COVID-19 Pandemic. Western Journal of Medical and Biomedical Sciences, 2020, 1, 1-18.	0.2	0
1540	A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. Wellcome Open Research, 2020, 5, 141.	0.9	1
1542	Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. BioScience Trends, 2020, 14, 161-167.	1.1	8
1543	A Perspective Approach Of Hydroxychloroquine In The Treatment for Covid-19. American Journal of Pharmacy and Health Research, 2020, 08, 32-37.	0.1	0
1545	Az �j t�pus� koronavirus okozta megbeteged�s (COVID�19): �sszefoglal� hematol�gusoknak II. â€“ a diagnosztika, ter�pia �s prevenci� lehet�s�gei. Transfusio, 2020, 53, 81-95.	0.0	0
1546	Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus. Drugs in Context, 2020, 9, 1-4.	1.0	3
1547	Perspectives on COVID-19 therapies: conflicts and consensus. Research, Society and Development, 2020, 9, e85997019.	0.0	1
1548	CHLOROQUINE AND HYDROXYCHLOROQUINE: A MAJOR BREAKTHROUGH FOR COVID-19. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 1-5.	0.3	0
1549	Features of the course and approaches to the treatment of coronavirus infection COVID- 19 patients with cardiovascular diseases. Kardiologicheskii Vestnik, 2020, , 64-71.	0.1	0

#	ARTICLE	IF	CITATIONS
1550	Chloroquine and Hydroxychloroquine in Treatment of Coronavirus Disease-19. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 203-207.	0.1	0
1552	Short-Term Corticosteroid Therapy for Early Exacerbation of COVID-19 Pneumonia: A Case Report. American Journal of Case Reports, 2020, 21, e924476.	0.3	1
1554	Cytokine storm is the cryptic killer behind coronavirus disease-2019 infections, review of the current evidence to identify therapeutic options. Reviews in Medical Microbiology, 2021, 32, 57-65.	0.4	1
1555	Effects of Aminoquinolines in COVID-19 Treatment: Hydroxychloroquine and Chloroquine. Annals of Military and Health Sciences Research, 2020, 18, .	0.1	0
1556	Coronavirus (COVID-19) Pandemic: Concern about Misuse of Antibiotics. Journal of Biomedical Analytics, 2020, 3, 19-23.	2.3	5
1557	Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations. World Journal of Stem Cells, 2020, 12, 721-730.	1.3	3
1558	Revealing Potential Binding Affinity of FDA Approved Therapeutics Targeting Main Protease (3CLpro) in Impairing Novel Coronavirus (SARSCoV- 2) Replication that Causes COVID-19. Coronaviruses, 2020, 1, 98-107.	0.2	4
1559	COVID-19: risk factors for severe cases of the Delta variant. Aging, 2021, 13, 23459-23470.	1.4	24
1560	SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. International Journal of Biological Macromolecules, 2021, 193, 1249-1273.	3.6	19
1561	Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19. Cardiac Electrophysiology Clinics, 2022, 14, 95-104.	0.7	5
1562	The impact of the hypoxiaâ€VEGFâ€Vvascular permeability on COVIDâ€V19â€Vinfected patients. Exploration, 2021, 1, 20210051.	5.4	20
1563	COVID-19 Drug Repositioning: Present Status and Prospects. Studies in Systems, Decision and Control, 2022, , 645-671.	0.8	1
1564	Immunosuppression for liver transplant recipients during the COVID-19 pandemic. Annals of Liver Transplantation, 2021, , .	0.4	0
1565	Covid-19 Pandemic and Coronaviruses from Discovery to Treatment: A Tale of Two Decades of 21st Century. Studies in Systems, Decision and Control, 2022, , 1065-1095.	0.8	0
1566	Drug repurposing in COVID-19: A review with past, present and future. Metabolism Open, 2021, 12, 100121.	1.4	25
1567	Cardiovascular complications related to COVID-19 disease. Anesthesia: Essays and Researches, 2020, 14, 359.	0.2	2
1568	Corona virus disease bring a new challenge for the dentistry: A review. Journal of Family Medicine and Primary Care, 2020, 9, 3883.	0.3	2
1569	COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. Postepy Mikrobiologii, 2020, 59, 207-225.	0.1	2

#	ARTICLE	IF	CITATIONS
1570	Alterations in Peripheral Lymphocyte Subsets in Early Stage of Novel Coronavirus Pneumonia. SSRN Electronic Journal, 0, , .	0.4	0
1571	Coronavirus disease of 2019 (COVID-19) facts and figures: What every dermatologist should know in this hour of need. Indian Journal of Dermatology, 2020, 65, 251.	0.1	4
1572	Treatment of COVID-19 disease in older people with cognitive impairment: a challenge into the challenge. Journal of Gerontology and Geriatrics, 2020, 68, 224-230.	0.2	2
1573	Protein Domain Annotations of the SARS-CoV-2 Proteomics as a Blue-Print for Mapping the Features for Drug and Vaccine Designs. Jurnal Matematika Dan Sains, 2020, 25, 26-32.	0.1	0
1574	Complications of Coronavirus Disease-19 in a Hospitalized Patient: A Case Report. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 613-618.	0.1	0
1576	Drug-Nutrition Interactions in Infectious Diseases. , 2021, , 367-410.		2
1577	Would the interference phenomenon be applied as an alternative option for prophylaxis against COVID-19?. BiolImpacts, 2020, 11, 169-172.	0.7	1
1578	COVID-19 Treatment at a Glance. Turkish Thoracic Journal, 2020, 21, 438-445.	0.2	2
1579	Ionizing Radiation as a Non-invasive Treatment for COVID-19 Patients-A Perspective Review. IOP Conference Series: Earth and Environmental Science, 0, 596, 012036.	0.2	2
1580	Chloroquine Phosphate is not Proved to be an Effective Treatment for Coronavirus: A Meta-analysis of Clinical Trials. Open Microbiology Journal, 2020, 14, 310-311.	0.2	0
1581	COVID-19: A Critical Review on Viral Biochemistry, Environmental Transmission, Therapeutics and Safety Measures. European Journal of Biology and Biotechnology, 2020, 1, .	0.2	0
1582	Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. Journal of Tropical Pediatrics, 2021, 67, .	0.7	1
1583	The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19. SeÅenovskij Vestnik, 2020, 11, 29-39.	0.3	0
1584	Strategies for search of pharmacological drugs against SARS-CoV-2 on the base of studying the structural-genetic features of coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. Reviews on Clinical Pharmacology and Drug Therapy, 2020, 18, 269-296.	0.2	2
1585	Investigating Side Effects of Existing Drugs Used in Covid-19 Treatment. , 2020, , .		0
1586	Therapy of patients with COVID-19: clinical studies and recommendations in different countries. Infusion & Chemotherapy, 2020, , 5-12.	0.0	2
1587	Coronavirus Disease 2019 (COVID-19): A Simplified Assessment of its Origin, Epidemiology and Physiological Manifestations. Asian Journal of Scientific Research, 2020, 14, 13-23.	0.3	0
1588	COVID-19: Update on Pathogenesis and Treatment Strategies. Current Immunology Reviews, 2020, 16, 1-5.	1.2	0

#	ARTICLE	IF	CITATIONS
1589	Melatonin mitigates Chloroquine-induced defects in porcine immature Sertoli cells. <i>Theriogenology</i> , 2022, 177, 1-10.	0.9	2
1590	Theoretical Prediction of Possible Drug Treatment of COVID-19 using Coumarins Containing Chloroquine Moeity. <i>Asian Journal of Chemistry</i> , 2020, 32, 3120-3126.	0.1	2
1591	COVID-19 management: who needs electrocardiographic monitoring and why. <i>Profilakticheskaya Meditsina</i> , 2020, 123, 45.	0.2	0
1592	Therapeutic options in SARS-CoV-2 infection. <i>Farmacist Ro</i> , 2020, 4, 14.	0.0	1
1593	Managing prosthodontic (geriatric) patients during the SARS-CoV-2 pandemic. <i>Journal of International Oral Health</i> , 2020, 12, 69.	0.0	3
1595	Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. <i>Sudanese Journal of Paediatrics</i> , 2020, 20, 4-9.	0.6	4
1596	Challenges in the management of corona virus in pregnancy in low resource countries. <i>Sahel Medical Journal</i> , 2020, 23, 73.	0.2	0
1597	COVID-19 – mTORC1-centric Paradigm. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1598	Management of COVID-19: A brief overview of the various treatment strategies. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 233.	0.1	4
1599	The Macroeconomic Determinants of COVID19 Mortality Rate and the Role of Post Subprime Crisis Decisions. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
1601	Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. <i>Profilakticheskaya Meditsina</i> , 2020, 123, 74.	0.2	0
1602	Pregnancy in Coronavirus Disease (COVID-19) Pandemic: Clinical Opinion. <i>Open Journal of Obstetrics and Gynecology</i> , 2020, 10, 708-713.	0.1	0
1603	Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown. <i>Indian Journal of Pharmacology</i> , 2020, 52, 75.	0.4	2
1604	Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel?. <i>Cureus</i> , 2020, 12, e7415.	0.2	2
1605	OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19. <i>Journal of Hearing Science</i> , 2020, 10, 9-20.	0.1	2
1606	Understanding the Mosaic of COVID-19: A Review of the Ongoing Crisis. <i>Cureus</i> , 2020, 12, e7366.	0.2	3
1607	Coronavirus Disease 2019 (COVID-19): review study. <i>Jorjani Biomedicine Journal</i> , 2020, 8, 4-10.	0.1	2
1608	COVID 19 opciones terapeuticas desde la viro-patogenesis a la evidencia clinica. <i>Revista Colombiana De NefrologÃa</i> , 2020, 7, 5-6.	0.1	0

#	ARTICLE	IF	CITATIONS
1612	Patogenez e perspectivas de tratamento da Covid-19: uma revisão. Research, Society and Development, 2020, 9, e05973730.	0.0	9
1613	COVID-19'un Tanı ve Tedavi Recinde Hematolojik Parametreler. Journal of Biotechnology and Strategic Health Research, 0, , .	0.8	1
1614	NOVEL APPROACH TO ENHANCE THE ANTI VIRAL ACTIVITY OF EXISTING DRUG/DEVELOPING VACCINE AGAINST PANEDMIC COVID-19. , 2020, 04, 474-477.		0
1616	Beyond ventilatory support: challenges in general practice and in the treatment of critically ill children and adolescents with SARS-CoV-2 infection. Revista Da Associação Médica Brasileira, 2020, 66, 521-527.	0.3	3
1617	THERAPEUTIC MANAGEMENT OF PATIENTS INFECTED WITH SARS-CoV-2 VIRUS - A REVIEW. Proceedings of CBU in Medicine and Pharmacy, 0, 2, 9-16.	0.0	0
1618	An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity. ChemistrySelect, 2021, 6, 11502-11527.	0.7	8
1619	Clinical features and mechanistic insights into drug repurposing for combating COVID-19. International Journal of Biochemistry and Cell Biology, 2022, 142, 106114.	1.2	12
1621	Identification and Development of Therapeutics for COVID-19. MSystems, 2021, 6, e0023321.	1.7	20
1622	Recent scientific research progress and challenges of COVID-19 pandemic: a global public health event. Proceedings of the Indian National Science Academy, 0, , .	0.5	0
1624	COVID-19'DA SAKITLIK SALINIM SENDROMU VE TEDAVI YAKLAŞIMLARI. Turkish Journal of Pediatric Disease, 0, , 55-59.	0.0	0
1625	The First Few Hundred Cases for Coronavirus Disease 2019 (COVID-19) in Colombia. Iranian Journal of Public Health, 2020, 49, 48-56.	0.3	0
1626	How to manage rheumatic patients during the coronavirus pandemic. Panminerva Medica, 2020, 62, 176-177.	0.2	1
1627	What ophthalmologists need to know about pandemic of Corona Virus 19. Journal of Clinical Research and Ophthalmology, 2020, , 050-053.	0.1	0
1628	Çocuklarda COVID-19 Tedavisi. Turkish Journal of Pediatric Disease, 0, , 9-14.	0.0	0
1629	Discussing Evidence in the Fog of the Pandemic. American Journal of Critical Care, 2020, 29, 246-248.	0.8	1
1630	Managing Spontaneous Bacterial Peritonitis (SBP) Patients During The Coronavirus Disease (COVID-19) Pandemic. Sohag Medical Journal (SMJ), 2020, 24, 1-5.	0.1	0
1631	COVID 19 opciones terapeuticas desde la viro-patogenesis a la evidencia clinica. Revista Colombiana De Nefrología, 2020, 7, 17-18.	0.1	0
1632	A Patient with COVID-19 Pneumonia Who Developed Ventricular Fibrillation during Treatment with Hydroxychloroquine, Azithromycin and Favipiravir. Journal of the Japanese Association for Infectious Diseases, 2020, 94, 600-603.	0.0	0

#	ARTICLE	IF	CITATIONS
1634	COVID-19 and Rheumatology: so far, so close. Meditsinskiy Sovet, 2020, , 135-143.	0.1	2
1635	Challenges in the setting of coronavirus 2019: A review of disease and experience from delta state university teaching hospital. Annals of Medical Research and Practice, 0, 1, 9.	0.0	0
1636	A Hemodialysis Patient with COVID-19 Who Received Treatment with Hydroxychloroquine. Journal of the Japanese Association for Infectious Diseases, 2020, 94, 596-599.	0.0	0
1640	Eficacia y seguridad de cloroquina, hidroxicloroquina y azitromicina en pacientes con COVID-19: Resumen de evidencia. Revista Colombiana De Nefrología, 2020, 7, 5-6.	0.1	1
1641	Current trends and possible therapeutic options against COVID-19. Journal of Microbiology and Infectious Diseases, 0, , 110-120.	0.1	2
1642	Caring for patients in a new pandemic: the necessity and challenges of observational research. Journal of Clinical Investigation, 2020, 130, 6225-6227.	3.9	5
1643	COVID-19: A review of the pandemic with emphasis on the role of imaging. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 640-651.	0.1	0
1644	The COVID-19 pandemic: a systematic review of the current evidence. Russian Journal of Infection and Immunity, 2020, 10, 655-663.	0.2	8
1645	Immunomodulatory drug therapy for the disease caused by SARS-CoV-2 infection (COVID-19). AlĖmanah KliniĖeskoj Mediciny, 0, 48, 51-67.	0.2	1
1646	Potential Drugs for Treating COVID-19 Infection. International Journal of Infection, 2020, 7, .	0.4	0
1648	Should We Rely on Screening Tests for Further Management Alone in Polymerase Chain Reaction Negative COVID-19 Patients? A Case Series. Cureus, 2020, 12, e10555.	0.2	1
1649	Worldwide Crude Death Rate, Case Fatality Rate, and Attack Rate from COVID-19: with up to date Comprehensive Review. , 2020, , .		0
1650	Pediatric Hematopoietic Stem Cell Transplant in the COVID-19 Pandemic: The Problems We Faced and The Strategies We Adopted. Archives of Pediatric Infectious Diseases, 2020, 8, .	0.1	0
1651	The COVID-19 era: the view from Nigeria. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 13-15.	0.2	2
1654	Therapeutic agents currently employed against Covid-19: an effort to control the pandemic. Turkish Journal of Biochemistry, 2020, 45, 651-658.	0.3	0
1655	Diabetes mellitus and COVID-19: current issues of pathogenesis, clinic and therapy. Literature review. Reproductive Endocrinology, 2020, .	0.0	1
1656	Critical Insight into the Attributes of Emerging Novel Coronavirus (COVID-19) in India and Across the World. Coronaviruses, 2020, 1, 49-56.	0.2	2
1657	The Comprehensive Appraisal of COVID-19: Its™ Clinical Panorama from Virology till Management and Beyond. Coronaviruses, 2020, 1, 57-72.	0.2	2

#	ARTICLE	IF	CITATIONS
1658	COVID-19: Understanding the Pandemic Emergence, Impact and Infection Prevalence Worldwide. <i>Journal of Pure and Applied Microbiology</i> , 2020, 14, 2235-2251.	0.3	1
1660	New psychopharmacotherapy dilemmas associated with COVID-19 – case report. <i>Pharmacotherapy in Psychiatry and Neurology</i> , 2020, 36, 149-153.	0.1	0
1661	COVID-19: Clinical Characteristics and Molecular Levels of Candidate Compounds of Prospective Herbal and Modern Drugs in Indonesia. <i>Pharmaceutical Sciences</i> , 2020, 26, S12-S23.	0.1	2
1662	A Summary of Coronavirus Disease 2019: What We Should Know?. <i>Pharmaceutical Sciences</i> , 2020, 26, S24-S35.	0.1	0
1663	Gastrointestinal symptoms in the course of COVID-19. <i>Postepy Higieny I Medycyny Doswiadczonej</i> , 2020, 74, 498-503.	0.1	3
1664	Therapeutic Options and Treatment Strategies Against COVID-19 in China. <i>Current Organic Synthesis</i> , 2020, 17, 413-414.	0.7	1
1665	Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population. <i>Current Drug Metabolism</i> , 2020, 21, 534-540.	0.7	3
1666	In-silico identification of natural antiviral drug against SARS-CoV-2 and comparison with potential FDA approved drug targets. <i>Journal of Science</i> , 2020, 3, 1-11.	0.0	1
1667	Treatment of People with Evans Syndrome in the Setting of COVID-19 Pandemic. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2020, 1, 160-162.	0.1	0
1671	Treatments for COVID-19: emerging drugs against the coronavirus. <i>Acta Biomedica</i> , 2020, 91, 118-136.	0.2	18
1672	Current therapeutic options for coronavirus disease 2019 (COVID-19) – lessons learned from severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) therapy: a systematic review protocol. <i>Annals of Translational Medicine</i> , 2020, 8, 1527-1527.	0.7	4
1673	Potential Treatments for COVID-19; a Narrative Literature Review. <i>Archives of Academic Emergency Medicine</i> , 2020, 8, e29.	0.2	70
1674	Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. <i>Archives of Academic Emergency Medicine</i> , 2020, 8, e41.	0.2	82
1676	Clinical interventions for severe and critical COVID-19: what are the options. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 2110-2117.	0.0	2
1677	What We Learned about COVID-19 So Far? Notes from Underground. <i>Turkish Thoracic Journal</i> , 2020, 21, 185-192.	0.2	2
1678	Aplastic anemia and COVID-19: how to break the vicious circuit?. <i>American Journal of Blood Research</i> , 2020, 10, 60-67.	0.6	4
1679	Legal Considerations of COVID-19 Patients' Disposition in Emergency Department; Report of 10 Cases. <i>Archives of Academic Emergency Medicine</i> , 2020, 8, e64.	0.2	0
1681	Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review. <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 258-281.	0.3	1

#	ARTICLE	IF	CITATIONS
1682	Medication use during COVID-19: Review of recent evidence. Canadian Family Physician, 2021, 67, 171-179.	0.1	1
1684	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. American Journal of Cardiovascular Disease, 2021, 11, 93-107.	0.5	13
1685	Pharmacological and Nonpharmacological Studies on Coronavirus Disease 2019: A Mini-review of the Recent Evidence. Journal of Research in Pharmacy Practice, 2020, 9, 175-180.	0.2	0
1686	Covid-19: Face Mask Protection in the Pediatric Setting. Mã dica, 2021, 16, 149-151.	0.4	1
1687	Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Research, 2022, 197, 105212.	1.9	9
1688	Treatment and therapeutic agents. , 2022, , 121-176.		0
1689	Introduction to COVID-19. , 2022, , 3-16.		2
1690	The potential of drug delivery nanosystems to treat COVID-19. , 2022, , 307-337.		0
1691	Molecular docking and dynamics studies on propolis sulabiroin-A as a potential inhibitor of SARS-CoV-2. Journal of King Saud University - Science, 2022, 34, 101707.	1.6	28
1692	Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. Journal of Molecular and Cellular Cardiology, 2022, 164, 69-82.	0.9	34
1693	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. Emerging Microbes and Infections, 2022, 11, 18-29.	3.0	25
1694	Herb-Drug Interaction Between Xiyanning Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy. Frontiers in Pharmacology, 2021, 12, 773126.	1.6	7
1695	Insights into the Role of Graphene/Graphene-hybrid Nanocomposites in Antiviral Therapy. ChemBioEng Reviews, 2021, 8, 549.	2.6	1
1696	Roles of host mitochondria in the development of COVID-19 pathology: Could mitochondria be a potential therapeutic target?. Molecular Biomedicine, 2021, 2, 38.	1.7	19
1697	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. Respiratory Research, 2021, 22, 304.	1.4	7
1698	Current status of therapeutic approaches and vaccines for SARS-CoV-2. Future Microbiology, 2021, 16, 1319-1326.	1.0	2
1699	Demographic and Clinical Features Associated with in-Hospital Mortality in Egyptian COVID-19 Patients: A Retrospective Cohort Study. Open Access Macedonian Journal of Medical Sciences, 2021, 9, 1068-1075.	0.1	2
1700	Systematic Review of Sensorineural Hearing Loss Associated With COVID-19 Infection. Cureus, 2021, 13, e19757.	0.2	10

#	ARTICLE	IF	CITATIONS
1701	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 732403.	1.6	13
1702	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <i>Advances in Virology</i> , 2021, 2021, 1-13.	0.5	0
1703	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. <i>Future Microbiology</i> , 2021, 16, 1341-1370.	1.0	25
1704	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. <i>Future Virology</i> , 2022, 17, 95-118.	0.9	17
1705	Diabetes in COVID-19 patients: challenges and possible management strategies. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	2
1706	Effectiveness and Controversy of Convalescent Plasma Therapy for Coronavirus Disease 2019 Patients. <i>Infectious Diseases & Immunity</i> , 2021, Publish Ahead of Print, .	0.2	2
1707	A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 869.	0.7	3
1708	Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept. <i>European Journal of Pharmacology</i> , 2021, 913, 174632.	1.7	12
1710	COVID-19, An early investigation from exposure to treatment outcomes in Tehran, Iran. <i>Journal of Research in Medical Sciences</i> , 2021, 26, 114.	0.4	3
1711	Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. <i>E3S Web of Conferences</i> , 2021, 319, 01035.	0.2	1
1712	Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications. <i>Phytomedicine</i> , 2022, 98, 153930.	2.3	25
1713	Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2. <i>Molecular Diversity</i> , 2022, 26, 2613-2629.	2.1	4
1714	Ammonium iodide-catalyzed radical-mediated tandem cyclization of aromatic aldehydes, arylamines and 1,4-dioxane. <i>New Journal of Chemistry</i> , 2022, 46, 959-965.	1.4	1
1715	Anthranilamides with quinoline and β -carboline scaffolds: design, synthesis, and biological activity. <i>Molecular Diversity</i> , 2022, 26, 2595-2612.	2.1	3
1716	Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study. <i>Computers in Biology and Medicine</i> , 2022, 141, 105155.	3.9	17
1717	In silico evidence of beauvericin antiviral activity against SARS-CoV-2. <i>Computers in Biology and Medicine</i> , 2022, 141, 105171.	3.9	9
1718	A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112550.	2.5	26
1720	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm. <i>Journal of Pharmaceutical Research International</i> , 0, , 119-134.	1.0	0

#	ARTICLE	IF	CITATIONS
1721	Potential Antiviral Effect of Chloroquine Therapy against SARS-CoV-2 Infection. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 184-191.	0.1	1
1723	Efficacy and safety of Hydroxychloroquine in treating COVID-19 pneumonia: uncertainty of data and changing treatment protocols. Journal of Lung, Pulmonary & Respiratory Research, 2020, 7, 51-54.	0.3	1
1724	Severe Acute Respiratory Syndrome-coronavirus 2 Interstitial Bilateral Pneumonia: A Case Report and Review of Literature. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 229-232.	0.1	0
1725	Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Vicious Circle. , 0, , .		6
1726	Phytoconstituents of Zingiber officinale Targeting Host viral Protein Interaction at Entry Point of SARS CoV 2 A Molecular Docking Study. Defence Life Science Journal, 2020, 5, 268-277.	0.1	7
1727	A Review on the Novel Coronavirus and Its Effects on Children. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 233-239.	0.1	0
1728	A Review on Novel Coronavirus Outbreak: Current Scenario of Bangladesh. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 314-324.	0.1	1
1729	An overview of treatment options for COVID-19. International Journal of Basic and Clinical Pharmacology, 2020, 9, 1770.	0.0	0
1731	IDENTIFYING A POTENTIAL DRUG FROM ACORUS CALAMUS AND DETERMINING THE SPECIFIC BINDING REGION IN THE HUMAN CORONAVIRUS PROTEIN VIA INSILICO DOCKING METHOD.. Journal of Bio Innovation, 2020, 9, 827-834.	0.0	1
1732	A Review on Corona Virus and Covid-19. International Journal of Pharmaceutical Sciences Review and Research, 2020, 65, 110-115.	0.1	0
1733	Deterioration of heart rhythm during short-term hydroxychloroquine therapy for COVID-19: report of two cases. ACI (Acta Cardiologia Indonesiana), 2021, 7, 54-62.	0.0	1
1735	The use of Tisdale risk score during hydroxychloroquine/chloroquine treatments on COVID-19 patients. ACI (Acta Cardiologia Indonesiana), 2021, 7, 19-23.	0.0	0
1736	Medicinal Plants for Prevention and Treatment of Coronavirus Disease. , 2021, , 74-85.		2
1737	Malaria Endemicity Effect on Incidence and Mortality Rate of COVID-19 in Some Malaria-Endemic Regions of Iran; An Ecological Study (2020-21). Journal of Occupational Health and Epidemiology, 2021, 10, 169-174.	0.1	0
1738	Combatting SARS-CoV-2: Potential Therapeutic Candidates Against COVID-19. European Medical Journal Allergy & Immunology, 0, , 61-70.	0.0	1
1739	Molecular docking, molecular dynamics simulation, and ADMET analysis of levamisole derivatives against the SARS-CoV-2 main protease (M ^{Pro}). BiolImpacts, 2021, 12, 107-113.	0.7	5
1740	The association between QT interval changes and the treatment protocols of COVID-19 patients. Åstanbul Kuzey Klinikleri, 2022, , .	0.1	0
1741	Adverse Effects of COVID-19 Treatments: A Special Focus on Susceptible Populations. Journal of Environmental Pathology, Toxicology and Oncology, 2022, , .	0.6	0

#	ARTICLE	IF	CITATIONS
1742	Potential antiviral therapies for Coronavirus disease 2019 (COVID-19). , 2022, , 729-748.		0
1743	Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases. <i>Scientific Reports</i> , 2022, 12, 1075.	1.6	11
1744	Antiviral Drugs and Their Roles in the Treatment of Coronavirus Infection. , 0, , .		2
1745	Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS CoV-2 main protease (Mpro) and 3C-like protease for COVID-19 treatment. <i>Clinical Nutrition Open Science</i> , 2022, 42, 62-72.	0.5	10
1746	Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro. <i>Biorganic and Medicinal Chemistry</i> , 2022, 53, 116523.	1.4	13
1747	When Music Changes, so Does the Dance. , 2022, , 585-606.		0
1748	Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. <i>Medicina (Lithuania)</i> , 2022, 58, 144.	0.8	126
1749	Plasmapheresis with Convalescent Plasma as a Rescue Therapy for COVID-19 Patients: A Case Series. <i>Archives of Clinical Infectious Diseases</i> , 2022, 16, .	0.1	1
1750	APOA1 Level is Negatively Correlated with the Severity of COVID-19. <i>International Journal of General Medicine</i> , 2022, Volume 15, 689-698.	0.8	5
1751	Hydroxychloroquine pre-exposure prophylaxis provides no protection against COVID-19 among health care workers: a cross-sectional study in a tertiary care hospital in North India. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 103-107.	0.7	2
1752	Phytoconstituents in the Management of Covid-19: Demystifying the Fact. <i>Drug Research</i> , 2022, 72, .	0.7	0
1755	Stem cells or their exosomes: which is preferred in COVID-19 treatment?. <i>Biotechnology Letters</i> , 2022, 44, 159-177.	1.1	5
1756	Identification of potential edible mushroom as SARS-CoV-2 main protease inhibitor using rational drug designing approach. <i>Scientific Reports</i> , 2022, 12, 1503.	1.6	15
1757	Leveraging electron-deficient iminium intermediates in a general synthesis of valuable amines. <i>Angewandte Chemie - International Edition</i> , 2022, , .	7.2	5
1758	Leveraging electron-deficient iminium intermediates in a general synthesis of valuable amines. <i>Angewandte Chemie</i> , 0, , .	1.6	0
1759	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa. <i>IScience</i> , 2022, 25, 103880.	1.9	6
1760	Human SARS-CoV-2 has evolved to increase U content and reduce genome size. <i>International Journal of Biological Macromolecules</i> , 2022, 204, 356-363.	3.6	12
1763	Clinical Features, Diagnostic Evaluation, and Management of COVID-19 Patients. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1353, 1-22.	0.8	0

#	ARTICLE	IF	CITATIONS
1764	Current Challenges for the Effective Management of the COVID-19 Pandemic. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1353, 131-149.	0.8	1
1765	Treatment of Myasthenia Gravis Patients with COVID-19: Review of the Literature. <i>Acta Clinica Croatica</i> , 2021, 60, 496-509.	0.1	6
1766	Cardiometabolic Morbidity and Other Prognostic Factors for Mortality in Adult Hospitalized COVID-19 Patients in North Jakarta, Indonesia. <i>Global Heart</i> , 2022, 17, 9.	0.9	2
1767	Pharmacological repurposed agents for COVID-19. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 441-446.	0.2	5
1768	Use of chloroquine and hydroxychloroquine in COVID-19 patients: A dilemma. <i>Journal of Primary Care Specialties</i> , 2022, 3, 3.	0.0	0
1769	Synthesis and characterization of novel copper(II) complexes as potential drug candidates against SARS-CoV-2 main protease. <i>New Journal of Chemistry</i> , 2022, 46, 4911-4926.	1.4	16
1770	Targeting Angiotensin-Converting Enzyme 2 (ACE2) for the Discovery of Anticoronaviral Drugs. <i>Coronaviruses</i> , 2022, 03, .	0.2	0
1771	Osteoarthritis, Corticosteroids and Role of CYP Genes in COVID-19 Patients: A Mini Review. <i>Journal of Pure and Applied Microbiology</i> , 2022, 16, 18-25.	0.3	1
1772	SARS-CoV-2: una revisión rápida de algunas de las opciones de tratamiento disponibles.. , 2022, 25, 39-43.		0
1773	Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect. <i>Journal of Nanostructure in Chemistry</i> , 2023, 13, 263-281.	5.3	13
1774	The relevant information about the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the five-question approach (when, where, what, why, and how) and its impact on the environment. <i>Environmental Science and Pollution Research</i> , 2023, 30, 61430-61454.	2.7	6
1775	Potential Roles of Phytochemicals in Combating Severe Acute Respiratory Syndrome Coronavirus Infection. <i>Plant Science Today</i> , 0, , .	0.4	0
1776	Functional food: complementary to fight against COVID-19. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2022, 11, 33.	0.8	24
1777	Linking genomic and epidemiologic information to advance the study of COVID-19. <i>Scientific Data</i> , 2022, 9, 121.	2.4	3
1778	Can anti-parasitic drugs help control COVID-19?. <i>Future Virology</i> , 2022, 17, 315-339.	0.9	5
1779	Systematic optimization of host-directed therapeutic targets and preclinical validation of repositioned antiviral drugs. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	3
1780	Identification of the Hub Genes and the Signaling Pathways in Human iPSC-Cardiomyocytes Infected by SARS-CoV-2. <i>Biochemical Genetics</i> , 2022, 60, 2052-2068.	0.8	5
1781	Bioactive Compounds from Plants and their Immune Potential against Corona Virus. <i>Current Nutrition and Food Science</i> , 2022, 18, .	0.3	0

#	ARTICLE	IF	CITATIONS
1782	A network biology approach to identify crucial host targets for COVID-19. <i>Methods</i> , 2022, 203, 108-115.	1.9	6
1783	Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis. , 2022, 1, .		7
1784	Targeting natural products against SARS-CoV-2. <i>Environmental Science and Pollution Research</i> , 2022, 29, 42404-42432.	2.7	9
1785	Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge. <i>Frontiers in Pharmacology</i> , 2022, 13, 848676.	1.6	6
1786	Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2. <i>Microbial Pathogenesis</i> , 2022, , 105512.	1.3	6
1787	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105254.	1.0	21
1789	Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210903.	0.4	4
1790	Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 71, 126954.	1.5	8
1791	Inhibitory effect of compounds extracted from <i>Monochoria hastata</i> (L.) Solms on SARS-CoV-2 main protease: An insight from molecular docking and MD-simulation studies. <i>Journal of Molecular Structure</i> , 2022, 1257, 132644.	1.8	2
1792	KNOWLEDGE REGARDING COVID- 19 AMONG THE ADOLESCENT STUDENTS. , 2021, , 51-52.		0
1793	Interplay of Nutrition and Psychoneuroendocrine-immune Modulation: Relevance for COVID-19 in BRICS Nations. <i>Frontiers in Microbiology</i> , 2021, 12, 769884.	1.5	3
1794	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. <i>World Journal of Hepatology</i> , 2021, 13, 1850-1874.	0.8	10
1795	A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	56
1796	COVID-19 pandemisinin ilk yÄ±lÄ±nda Å¶ÄŸrendiklerimiz. <i>Hitit Medical Journal</i> ; 0, , .	0.4	0
1797	Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets. <i>Molecules</i> , 2021, 26, 7459.	1.7	30
1798	Knowledge, perception, and protective measures of Turkish pregnant women towards COVID-19 pandemic and their effects on anxiety levels. <i>Journal of Obstetrics and Gynaecology</i> , 2022, 42, 1018-1022.	0.4	2
1799	Nanoscience versus Viruses: The SARS-CoV-2 Case. <i>Advanced Functional Materials</i> , 2022, 32, 2107826.	7.8	8
1800	A systematic review on the therapeutic relevance of hydroxychloroquine/chloroquine in the management of COVID-19. <i>Indian Journal of Community Medicine</i> , 2021, 46, 380.	0.2	2

#	ARTICLE	IF	CITATIONS
1802	Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, 850583.	1.6	4
1803	A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus. <i>Endocrinology and Metabolism</i> , 2022, 37, 195-207.	1.3	1
1804	Relevance of Akerloff's theory of information asymmetry for the prevention and control of zoonotic infectious diseases in Sub-Saharan Africa: Perspective of Library and Information Services Provision. , 2022, , .		6
1805	Current Research Trends in Cytokine Storm: A Scientometric Study. <i>Current Drug Targets</i> , 2022, 23, .	1.0	0
1806	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. <i>Process Biochemistry</i> , 2022, 118, 154-170.	1.8	4
1807	Systematic Review of the Common Pathophysiological Mechanisms in COVID-19 and Neurodegeneration: The Role of Bioactive Compounds and Natural Antioxidants. <i>Cells</i> , 2022, 11, 1298.	1.8	18
1822	Progress in the study on COVID19related renal injury. <i>Journal of Central South University (Medical)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	0
1825	SARS-COV-2 " the pandemic of the XXI century, clinical manifestations " neurological implications. <i>Journal of Medicine and Life</i> , 2022, 15, 319-327.	0.4	2
1831	Medication use during COVID-19. <i>Canadian Family Physician</i> , 2021, 67, 171-179.	0.1	6
1832	MÃ©dicaments utilisÃ©s durant la COVID-19. <i>Canadian Family Physician</i> , 2021, 67, e69-e78.	0.1	0
1833	What We Learned about COVID-19 So Far? Notes from Underground. , 2023, 21, 185-192.		3
1835	Adversarial Training for Predicting the Trend of the COVID-19 Pandemic. <i>Journal of Database Management</i> , 2022, 33, 1-16.	1.0	1
1836	Research on COVID-19 Prevention and Control Model Based on Evolutionary Games. <i>Journal of Global Information Management</i> , 2022, 30, 1-17.	1.4	5
1837	Epidemiology and Clinical Characteristics of People with Confirmed SARS-CoV-2 Infection during the Early COVID-19 Pandemic in Saudi Arabia. <i>Medicines (Basel, Switzerland)</i> , 2022, 9, 32.	0.7	1
1838	Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates. <i>Molecules</i> , 2022, 27, 2723.	1.7	29
1839	Telenursing use in promoting pediatric nurses' knowledge regarding COVID-19 and delta variant pandemic. <i>International Journal of Health Sciences</i> , 0, , 4374-4393.	0.0	0
1840	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. <i>Frontiers in Immunology</i> , 2022, 13, 804945.	2.2	12
1841	Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. <i>Osong Public Health and Research Perspectives</i> , 2022, 13, 84-100.	0.7	0

#	ARTICLE	IF	CITATIONS
1842	A Bibliometric Analysis of Personal Protective Equipment and COVID-19 Researches. <i>Frontiers in Public Health</i> , 2022, 10, 855633.	1.3	8
1843	Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 1099-1105.	1.0	7
1844	Frequently Used Allopathic and Traditional Medicine for COVID-19 Treatment and Feasibility of Their Integration. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 1040-1047.	0.7	3
1847	Epidemiología y nuevos métodos de estimación del riesgo, en casos de pandemias: COVID-19. <i>Revista De Salud Publica</i> , 2021, 23, 1-7.	0.0	0
1848	An overview of possible solutions putting an end to the COVID-19 pandemic.. <i>Acta Biomedica</i> , 2022, 93, e2022202.	0.2	0
1849	Forecasting the spread of Covid-19 pandemic outbreak in India using ARIMA time series modelling. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
1850	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022, 15, 634.	1.7	7
1851	Pharmaceutics Informatics: Bio/Chemoinformatics in Drug Delivery. , 2022, , 705-724.		1
1852	Journey of Chloroquine/ Hydroxychloroquine in the management of COVID-19. <i>Research Journal of Pharmacology and Pharmacodynamics</i> , 2022, , 110-116.	0.1	0
1853	Epidemiology, Clinico-Pathological Characteristics, and Comorbidities of SARS-CoV-2-Infected Pakistani Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	0
1854	A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 78.	1.5	9
1855	A Social-Ecological Exploration of College and University Students' COVID-19 Infection Preventive Behaviors. <i>American Journal of Health Education</i> , 2022, 53, 256-265.	0.3	2
1856	Recent Updates on Diagnosis and Treatment of SARS-CoV-2: A Review. , 2021, 1, 1-8.		0
1857	The coronavirus global pandemic and its impacts on society. , 2022, , 267-311.		10
1858	Myth surrounding the FDA disapproval of hydroxychloroquine sulfate and chloroquine phosphate as drugs for coronavirus disease 2019. , 2022, , 153-168.		1
1859	Understanding COVID-19 Situation in Nepal and Implications for SARS-CoV-2 Transmission and Management. <i>Environmental Health Insights</i> , 2022, 16, 117863022211043.	0.6	2
1860	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 603-617.	0.9	5
1861	COVID-19 tanımlanmış evde takip edilen hastaların hidroklorokin tedavisine uyumları ve geri bildirimleri. <i>Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi</i> , 0, , .	0.1	0

#	ARTICLE	IF	CITATIONS
1862	Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2652-2661.	1.6	15
1863	Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2652-2661.	1.6	15
1864	Favourable Interfacial Characteristics of A2 Milk Protein Monolayer. <i>Journal of Membrane Biology</i> , 2023, 256, 35-41.	1.0	2
1865	Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1866	Strategies to fight COVID-19: Beyond the difference between SARS-CoV-2 and Influenza virus. <i>International Journal of Sexual and Reproductive Health Care</i> , 2022, 5, 016-029.	0.1	0
1867	Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. <i>Pharmaceuticals</i> , 2022, 15, 739.	1.7	6
1868	Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. , 2022, , 21-63.		0
1869	Virus, Exosome, and MicroRNA: New Insights into Autophagy. <i>Advances in Experimental Medicine and Biology</i> , 2022, , .	0.8	12
1870	Databases, DrugBank, and virtual screening platforms for therapeutic development. , 2022, , 291-334.		0
1871	Mapping the intersection of nanotechnology and SARS-CoV-2/COVID-19: A bibliometric analysis. , 2022, 1, 103-112.		3
1872	Therapeutic role of traditionally used Indian medicinal plants and spices in combating COVID-19 pandemic situation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5894-5913.	2.0	6
1873	Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. <i>Microorganisms</i> , 2022, 10, 1284.	1.6	2
1874	Leveraging Real-World Data in COVID-19 Response. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 582-595.	0.6	0
1875	Analyzing the research trends of COVID-19 using topic modeling approach. <i>Journal of Modelling in Management</i> , 2023, 18, 1204-1227.	1.1	4
1876	Overview of Hydroxychloroquine and Remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Journal of Heterocyclic Chemistry</i> , 2023, 60, 165-182.	1.4	4
1877	Impact of gamma-irradiation on the degradation and mineralization of hydroxychloroquine aqueous solutions. <i>International Journal of Environmental Science and Technology</i> , 2023, 20, 6815-6824.	1.8	6
1878	Hydroxychloroquine Adsorption in Aqueous Medium Using Clinoptilolite Zeolite. <i>Water, Air, and Soil Pollution</i> , 2022, 233, .	1.1	7
1879	Non-iterative learning machine for identifying CoViD19 using chest X-ray images. <i>Scientific Reports</i> , 2022, 12, .	1.6	0

#	ARTICLE	IF	CITATIONS
1880	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 269-297.	0.8	2
1881	COVID-19 Pandemic: Assessment of Current Strategies and Socio-economic Impact. <i>Journal of Health Management</i> , 0, , 097206342211092.	0.4	1
1882	Synthesis and greener pastures biological study of bis-thiadiazoles as potential Covid-19 drug candidates. <i>Arabian Journal of Chemistry</i> , 2022, 15, 104101.	2.3	10
1883	COVID-19 pharmacological research trends: a bibliometric analysis. <i>Intelligent Medicine</i> , 2023, 3, 1-9.	1.6	2
1884	Insight into coronaviruses and natural products-based approach for COVID-19 treatment. <i>Studies in Natural Products Chemistry</i> , 2022, , 443-469.	0.8	0
1885	Impact of COVID-19 on Rheumatic Diseases in India: Determinants of Mortality and Adverse Outcome: A Retrospective, Cross-Sectional Cohort Study. <i>Indian Journal of Rheumatology</i> , 2023, 18, 134-140.	0.2	0
1887	Artesunate Drug-loaded 2D Nano-shuttle Landing on RBCs Infected with Malaria Parasites. <i>Biomaterials Science</i> , 0, , .	2.6	0
1889	Negative impacts of the administration of hydroxychloroquine and anticoagulant in patients with SARS-COV-2 infection: a randomized clinical trial. , 2022, 101, .	0.0	0
1890	Factors associated with the perception of inadequate sanitary control in 12 Latin American countries during the COVID-19 pandemic. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
1891	The effect of coronavirus infection on QT and QTc intervals of hospitalized patients in Qazvin, Iran. <i>Annals of Data Science</i> , 0, , .	1.7	1
1892	A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic. <i>Environmental Science and Pollution Research</i> , 2022, 29, 67685-67703.	2.7	8
1893	Analysis of factors influencing public employees' work cognition under a public health crisis: A survey of China's response to COVID-19. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	4
1894	Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. <i>PLoS ONE</i> , 2022, 17, e0272034.	1.1	9
1895	Audiovestibular and vaccination complications of COVID-19. <i>The Egyptian Journal of Otolaryngology</i> , 2022, 38, .	0.1	4
1896	Demarcating Patriotic Science on Digital Platforms: Covid-19, Chloroquine and the Institutionalisation of Ignorance in Brazil. <i>Science As Culture</i> , 2022, 31, 530-554.	2.4	2
1897	Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	6
1898	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2211-2233.	0.9	1
1899	Impacts of the COVID-19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central Pennsylvania. <i>Journal of Environmental Quality</i> , 2022, 51, 1066-1082.	1.0	11

#	ARTICLE	IF	CITATIONS
1900	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1901	Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	16
1902	Emetine in Combination with Chloroquine Induces Oncolytic Potential of HIV-1-Based Lentiviral Particles. <i>Cells</i> , 2022, 11, 2829.	1.8	1
1903	In silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and nonstructural proteins. , 2022, , 313-333.		8
1904	An Insight into COVID-19 and Traditional Herbs: Bangladesh Perspective. <i>Medicinal Chemistry</i> , 2023, 19, 361-383.	0.7	4
1905	The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
1906	Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: a retrospective, propensity-matched cohort study. <i>American Journal of the Medical Sciences</i> , 2022, , .	0.4	0
1907	Ocular manifestations of recent viral pandemics: A literature review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	10
1908	The Impact of Chest Computed Tomography in A Covid-19 Reference Hospital - First Wave - Distrito Federal - Brazil. <i>International Journal of Coronaviruses</i> , 2022, 4, 28-42.	0.8	0
1909	Transcriptomics, Cheminformatics, and Systems Pharmacology Strategies Unveil the Potential Bioactives to Combat COVID-19. <i>Molecules</i> , 2022, 27, 5955.	1.7	5
1910	Neurological changes post-covid-19 infection. <i>International Journal for Innovation Education and Research</i> , 2022, 10, 336-350.	0.0	0
1911	Current status of coronavirus disease 2019 vaccine research based on bibliometric analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
1912	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0273526.	1.1	4
1913	DPPH and Nitric Oxide Free Radical Scavenging Potential of Phenyl Quinoline Derivatives and Their Transition Metal Complexes. <i>Journal of Molecular Structure</i> , 2022, , 134058.	1.8	5
1914	Tetraspanin-enriched Microdomain Containing CD151, CD9, and TSPAN 8 “ Potential Mediators of Entry and Exit Mechanisms in Respiratory Viruses Including SARS-CoV-2. <i>Current Pharmaceutical Design</i> , 2022, 28, 3649-3657.	0.9	5
1915	Screening Active Phytochemicals of Some Ayurvedic Medicinal Plants to Identify Potential Inhibitors against SARS-CoV-2 Mpro by Computational Investigation. <i>Letters in Drug Design and Discovery</i> , 2023, 20, 1380-1392.	0.4	0
1916	Transmission, Medical Consequences, and Prevention/Treatment of COVID-19 Infection. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 45-67.	0.1	0
1917	Candidate Drugs for the Potential Treatment of Coronavirus Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 85-114.	0.1	0

#	ARTICLE	IF	CITATIONS
1918	Homology Modeling and Molecular Dynamics-Driven Search for Natural Inhibitors That Universally Target Receptor-Binding Domain of Spike Glycoprotein in SARS-CoV-2 Variants. <i>Molecules</i> , 2022, 27, 7336.	1.7	1
1919	COVID-19 and hepatorenal syndrome. <i>World Journal of Gastroenterology</i> , 0, 28, 5666-5678.	1.4	1
1920	Antidepressant Drug Sertraline against Human Cancer Cells. <i>Biomolecules</i> , 2022, 12, 1513.	1.8	7
1921	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. <i>History and Philosophy of the Life Sciences</i> , 2022, 44, .	0.6	4
1922	Postoperative Management During the Pandemic Coronavirus Disease 2019 (COVID-19) Era. <i>European Journal of Medical and Health Sciences</i> , 2022, 4, 26-29.	0.1	0
1923	ABO blood group relationship with COVID-19 occurrence and severity. <i>Indian Journal of Clinical Anatomy and Physiology</i> , 2022, 9, 192-196.	0.1	1
1924	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 1-12.	0.3	0
1925	Nitrogen-rich based conjugated microporous polymers for highly efficient adsorption and removal of COVID-19 antiviral drug chloroquine phosphate from environmental waters. <i>Separation and Purification Technology</i> , 2023, 305, 122517.	3.9	14
1926	Novel Î±-aminophosphonate derivatives synthesis, theoretical calculation, Molecular docking, and in silico prediction of potential inhibition of SARS-CoV-2. <i>Journal of Molecular Structure</i> , 2023, 1272, 134196.	1.8	25
1927	A STUDY OF POST COVID SYNDROME IN PATIENTS ADMITTED IN A TERTIARY HOSPITAL IN CENTRAL INDIA.. , 2022, , 38-39.		0
1928	Insight into the role of clathrinâ€mediated endocytosis inhibitors in SARSâ€CoVâ€2 infection. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	14
1929	Attitudes and beliefs regarding the use of herbs and supplementary medications with COVID-19: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2023, 19, 343-355.	1.5	0
1930	Arzneimittelnutzung unter Pandemiebedingungen. , 2022, , 171-187.		0
1931	Chloroquine chaos and COVID-19: Smart delivery perspectives through pH sensitive polymers/micelles and ZnO nanoparticles. <i>Arabian Journal of Chemistry</i> , 2023, 16, 104468.	2.3	2
1932	IFITM3 is a host restriction factor that inhibits porcine transmissible gastroenteritis virus infection. <i>Veterinary Microbiology</i> , 2023, 277, 109622.	0.8	1
1933	SARS-CoV-2: Recent Past and Present: An Unusual Review. , 2022, 2, 1-33.		0
1934	On-Admission Anemia and Survival Rate in COVID-19 Patients. <i>Iranian Biomedical Journal</i> , 2022, 26, 389-397.	0.4	3
1935	PROPHYLACTIC USE OF ALLOPATHIC, COMPLEMENTARY & ALTERNATIVE MEDICINE (CAM) FOR COVID-19: A CROSS SECTIONAL SURVEY AMONG MEDICAL POST-GRADUATES OF TERTIARY CARE TEACHING HOSPITALS, GUJARAT. , 2022, , 6-8.		0

#	ARTICLE	IF	CITATIONS
1936	Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. <i>Pharmaceuticals</i> , 2022, 15, 1456.	1.7	0
1937	Changes in drug demand when a pandemic coincides with other outbreaks in a war zone country: a cross-sectional pilot study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022, 15, .	1.1	5
1938	Characterization of SARS-CoV-2 Isolate (MZ558159) Reported from India for in Silico Drug Designing. , 2022, 8, 175-188.		0
1939	COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 6865.	1.0	0
1940	Bibliometric and visual analysis of cardiovascular diseases and COVID-19 research. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	11
1941	Small molecules in the treatment of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	42
1942	Metal- and solvent-free synthesis of 2-benzyl-3-arylquinoline using a pseudo-three-component reaction. <i>Tetrahedron Letters</i> , 2023, 115, 154283.	0.7	2
1943	Clinical Overview in Pregnancy with COVID-19 at prof. Dr. I.G.N.G. Ngoerah Hospital Period of April 2020-March 2021. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 2513-2519.	0.1	0
1944	Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein. <i>Journal of Virology</i> , 2022, 96, .	1.5	10
1945	Flavonoids from the roots and rhizomes of <i>Sophora tonkinensis</i> and their in vitro anti-SARS-CoV-2 activity. <i>Chinese Journal of Natural Medicines</i> , 2023, 21, 65-80.	0.7	1
1946	A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics. , 0, , .		0
1947	Knowledge, beliefs, and practices about COVID-19 among students and the general public in Tamil Nadu: A cross-sectional study. <i>Apollo Medicine</i> , 2023, 20, 18.	0.0	0
1948	Applications of mathematical modeling and simulation in COVID-19. , 2023, , 275-290.		0
1949	Cu(II)(PhOMe-Salophen) Complex: Greener Pasture Biological Study, XRD/HAS Interactions, and MEP. <i>Russian Journal of Inorganic Chemistry</i> , 2022, 67, S114-S127.	0.3	4
1950	Emerging Novel Therapies for COVID-19: Implications for the Use of Nitric Oxide as an Anti-COVID-19 Therapy. , 2023, , 259-278.		0
1951	Antimalarial drugs. , 2023, , 363-396.		0
1952	Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 59, .	1.2	0
1953	A quinoline-benzotriazole derivative: Synthesis, crystal structure and characterization by using spectroscopic, DFT and molecular docking methods. <i>Results in Chemistry</i> , 2023, 5, 100916.	0.9	5

#	ARTICLE	IF	CITATIONS
1954	Quaternary Ammonium Salt Strategy and Molecular Docking Studies of Novel 5-Acyl-8-(Arylamino)-Quinolines by Acetyl and Methanesulfonyl Chloride for Dual Evaluation Bioactivity. <i>Russian Journal of Bioorganic Chemistry</i> , 0, , .	0.3	0
1955	Quinoline analogue as a potential inhibitor of SARS-CoV-2 main protease: ADMET prediction, molecular docking and dynamics simulation analysis. <i>European Journal of Chemistry</i> , 2023, 14, 30-38.	0.3	0
1956	In silico study of novel niclosamide derivatives, SARS-CoV-2 nonstructural proteins catalytic residue-targeting small molecules drug candidates. <i>Arabian Journal of Chemistry</i> , 2023, 16, 104654.	2.3	2
1957	Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. <i>Journal of Pharmacological Sciences</i> , 2023, 152, 1-21.	1.1	7
1958	Medicinal Plants used Traditionally in Sudan to Treat Viral Infections Related to the Signs and Symptoms of COVID-19: A Systematic Review. <i>Current Traditional Medicine</i> , 2023, 9, .	0.1	0
1959	Lysosomal dysfunction induced cytosolic vacuolation and increased intracellular amyloid-beta 42 (A β 42) in human brain endothelial cells (HBEC-5i). <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114501.	2.5	2
1960	A three-dimensional terbium metal-organic framework fluorescent sensor for efficient detection of chloroquine phosphate in serum. <i>Microchemical Journal</i> , 2023, 190, 108743.	2.3	1
1961	Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M ^{pro}) by using STD-NMR spectroscopy, in silico studies and antiviral assays. <i>International Journal of Biological Macromolecules</i> , 2023, 234, 123540.	3.6	2
1962	An overview on the treatments and prevention against COVID-19. <i>Virology Journal</i> , 2023, 20, .	1.4	19
1963	COVID-19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats. <i>Physiological Reports</i> , 2023, 11, .	0.7	1
1964	Comparative Study of Molecular Docking, Structural, Electronic, and Fukui Function Studies on Favipiravir and its Newly Designed Derivatives (Potential Inhibitors) for COVID-19 Protease. <i>Macromolecular Symposia</i> , 2023, 407, .	0.4	1
1965	The next generation of malaria treatments: the great expectations. <i>Future Science OA</i> , 2023, 9, .	0.9	2
1966	Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. <i>Medicina (Lithuania)</i> , 2023, 59, 541.	0.8	1
1967	New bi-phosphonate derivative: Synthesis, characterization, antioxidant activity in vitro and via cyclic voltammetry mode and evaluation of its inhibition of SARS-CoV-2 main protease. <i>Journal of Molecular Structure</i> , 2023, 1284, 135356.	1.8	2
1968	Current Strategies to Combat COVID-19. , 2023, , 361-374.		0
1969	Exploring the Link Between Malaria and COVID-19. , 2023, , 311-338.		0
1970	Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. <i>European Journal of Clinical Pharmacology</i> , 2023, 79, 723-751.	0.8	7
1971	The importance of outpatient etiotropic therapy in patients hospitalized with COVID-19. <i>Jurnal Infektologii</i> , 2023, 15, 48-54.	0.1	0

#	ARTICLE	IF	CITATIONS
1978	Medical Perspective on COVID-19. Contributions To Economics, 2023, , 15-103.	0.2	0
1980	Methods in Drug Repurposing: Emphasis on COVID-19. , 2023, , 111-126.		0
1986	Therapeutic Interventions for COVID-19. , 0, , .		0
1998	Nanotechnological strategies for drug delivery and treatment of COVID-19. , 2023, , 301-333.		0
2005	Investigation of FAD and porphyrin bands and correlation of change in porphyrin content of head and neck cancer patients with COVID-19 using biomaterials and fluorescence spectroscopy. AIP Conference Proceedings, 2023, , .	0.3	0
2006	COVID-19 Combating Strategies and Associated Variables for Its Transmission: An Approach with Multi-Criteria Decision-Making Techniques in the Indian Context. Springer Optimization and Its Applications, 2023, , 233-257.	0.6	0
2015	COVID-19 in Children and Hearing Loss. , 2023, , 857-869.		0
2016	Proposed Sentiment Analysis of COVID-19 Tweets using Machine Learning Algorithm. , 2023, , .		0
2020	Drug Therapies against Acute Respiratory Distress: A Critical Endpoint of COVID-19. , 2023, , 110-149.		0
2031	Potential therapeutic landscape of COVID-19: molecular targets, repurposed drugs, and nano- and cell-based intervention. , 2024, , 139-157.		0
2035	Immunological Interventions for the Management of Coronavirus Disease 2019 (COVID-19). , 2024, , 453-482.		0